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1 Introduction 
1.1 Background 
The New South Wales drug and alcohol withdrawal clinical 
practice guidelines provide the most up to date knowledge 
and current level of best practice for the treatment of 
withdrawal, also called detoxification, from alcohol and 
other drugs such as benzodiazepines, heroin and other 
opioids, cannabis, and psychostimulants. The specific 
problems of polydrug use are addressed.  
Specialist withdrawal services, hospitals, psychiatric units, 
and community health services in the NSW public health 
system (including non-government agencies funded by 
theNSW Department of Health) are required to adopt these 
guidelines.  
These clinical practice guidelines update and supersede:  
! NSW Department of Health (1999). NSW 
detoxification clinical practice guidelines. Sydney: State 
Health Publication Number (DTPU) 990049. 
The new guidelines have been cross-referenced with:  
! NSW Department of Health (2007). Clinical guidelines 
for nursing and midwifery practice in NSW: identifying 
and responding to drug and alcohol issues. Sydney: 
State Health Publication Number (MHDAO) 060187. 
Drug withdrawal may occur in a predictable way in a 
withdrawal unit or it may occur unexpectedly in an acute 
care setting following an unplanned admission. The aim of 
this document is to assist three broad groups of clinicians 
to manage drug-dependent people experiencing 
withdrawal:  
! Specialist withdrawal services that treat individuals on 
an outpatient and inpatient basis for drug withdrawal 
(see Appendix A). 
! Hospitals, nursing homes, and other acute facilities 
that admit patients for primary medical problems and 
then are faced with an unexpected withdrawal 
syndrome. 
! Primary care clinicians such as general practitioners, 
non-government agencies and community and welfare 
services that deal with people who may experience 
drug problems including withdrawal. 
 
 
 
 
This document includes developments since the previous 
NSW detoxification clinical practice guidelines were 
published in 1999. The main changes and additions are:  
! The term “detoxification” is no longer scientifically 
acceptable and the term “withdrawal management” 
has been adopted. 
! Buprenorphine has been approved in Australia for the 
treatment of opioid (heroin) withdrawal and 
maintenance and this is now included. 
! Cannabis dependence and cannabis withdrawal have 
been documented in recent literature, and are 
discussed in these guidelines. 
! The chapter on psychostimulant use and withdrawal is 
also expanded in these guidelines, in accordance with 
a recent National Drug Strategy publication (Jenner 
and Saunders 2004). 
The key concept in the management of withdrawal is 
patient safety. These guidelines are designed to allow 
clinicians to offer safe withdrawal management to 
dependent individuals. 
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1.2 Dependence, tolerance and 
withdrawal 
Withdrawal occurs in drug-dependent people who stop or 
considerably reduce their drug use. The diagnosis of 
dependence is generally required to understand and 
manage drug withdrawal. 
1.2.1 ICD-10 definitions 
The International classification of diseases (ICD-10) 
contains the following definitions: 
Dependence syndrome 
A cluster of behavioural, cognitive, and physiological 
phenomena that develop after repeated substance use and 
that typically include a strong desire to take the drug, 
difficulties in controlling its use, persisting in its use despite 
harmful consequences, a higher priority given to drug use 
than to other activities and obligations, increased 
tolerance, and sometimes a physical withdrawal state.  
The dependence syndrome may be present for a specific 
psychoactive substance (eg, tobacco, alcohol, or 
diazepam), for a class of substances (eg, opioid drugs), or 
for a wider range of pharmacologically different 
psychoactive substances. 
Withdrawal state 
A group of symptoms of variable clustering and severity 
occurring on absolute or relative withdrawal of a 
psychoactive substance after persistent use of that 
substance. The onset and course of the withdrawal state 
are time-limited and are related to the type of psychoactive 
substance and dose being used immediately before 
cessation or reduction of use.  
 
 
 
 
 
 
 
 
1.2.2 DSM-IV definitions 
The Diagnostic and statistical manual of mental disorders, 
fourth edition (DSM-IV) contains the following definitions: 
Substance dependence 
A maladaptive pattern of substance use, leading to 
clinically significant impairment or distress, as manifested 
by three (or more) of the following, occurring at any time 
in the same 12-month period: 
(1)  tolerance, as defined by either of the following: 
 (a) a need for markedly increased amounts of the 
substance to achieve intoxication or desired effect 
 (b)  markedly diminished effect with continued use of 
the same amount of the substance 
(2)  withdrawal, as manifested by either of the following: 
 (a)  the characteristic withdrawal syndrome for the 
substance 
 (b)  the same (or a closely related) substance is taken 
to relieve or avoid withdrawal symptoms 
(3)  the substance is often taken in larger amounts or over 
a longer period than was intended 
(4)  there is a persistent desire or unsuccessful efforts to 
cut down or control substance use 
(5)  a great deal of time is spent in activities necessary to 
obtain the substance, use the substance, or recover 
from its effects 
(6)  important social, occupational, or recreational activities 
are given up or reduced because of substance use 
(7)  the substance use is continued despite knowledge of 
having a persistent or recurrent physical or 
psychological problem that is likely to have been 
caused or exacerbated by the substance. 
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2 General principles of withdrawal management 
Chapter summary 
! Withdrawal management provides an opportunity for engagement, planning and coordination of 
post-withdrawal care. 
! Patients may present for elective withdrawal, present when already in withdrawal (crisis presentation), 
or commence withdrawal incidentally when in treatment for another condition. 
! A comprehensive assessment is the first step in managing the withdrawal process. It will define the 
risks that will confront the patient by identifying drug use and health issues for the patient and it will 
also identify specific needs that may interfere with successfully completing withdrawal. See section 
2.3. 
! An accurate consumption history should record for each drug (whether prescribed or not) the 
quantity, frequency, duration and pattern of use; time and amount of last use; route of administration; 
recent pattern leading up to this presentation; and average daily consumption. For prescribed 
medications, also record prescribed dose and prescribing doctor. 
! Try to match the patient with the withdrawal treatment approach that maximises patient safety and 
provides the most effective and most economical options for their management. 
! If possible, formalise a treatment agreement with the patient. The agreement may be verbal or 
written, and should not be used against the patient in a punitive manner.  
! Frequent observations of the patient are the mainstay of management. Assessment of clinical features, 
explanation, reassurance and repeated encouragement are provided at these times. 
! Medication is used in withdrawal to provide symptomatic relief, to treat complications and coexisting 
conditions, and to reduce the intensity of withdrawal. 
! The aim of supportive care is to minimise environmental stimuli that may exacerbate withdrawal 
symptoms and to enhance the patient’s ability to complete withdrawal successfully. 
! Develop strategies to help the patient cope with the period after withdrawal, particularly if the patient 
required withdrawal management in hospital. Strategies for discharge should encourage harm 
reduction and referral to appropriate agencies. 
! The withdrawal state from some drugs may be complicated by convulsions, which may be life 
threatening. 
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2.1 Rationale and underlying 
principles for withdrawal 
management  
 
The rationale of withdrawal management is to provide 
the appropriate level of support for withdrawal to be 
completed safely, which then allows the individual to 
determine his or her optimal ongoing management 
strategy. An understanding of the pharmacology and 
physiology of withdrawal allows the use of appropriate 
medications to modify the withdrawal process, making it 
more tolerable and safe. 
Underlying principles: 
! Withdrawal management may be an opportunity to 
initiate lasting abstinence, but the primary goal is 
patient safety, not long-term abstinence. 
! Withdrawal management services should not be 
withheld from people because of doubts about their 
commitment to long-term abstinence. 
! Supportive care and patient choice are crucial to 
success. Supportive care should include attention to 
the patient’s environment, the transfer of information, 
reassurance, attention to anxiety and assistance with 
the development of coping skills. 
! The syndrome of withdrawal is monitored clinically 
and appropriate care is provided, which may range 
from counselling and support to the use of specific 
medications to ameliorate symptoms of withdrawal. 
! Planning and coordinating post-withdrawal care is an 
integral part of treatment. 
 
 
2.2 Presentation for withdrawal 
management 
Patients present for withdrawal management with a 
mixture of attitudes and emotions. Some present in crisis. 
They may be suspicious of people in positions of authority 
as a result of previous experiences in a variety of settings, 
including the healthcare system. The initial assessment is 
an important opportunity to begin building an effective 
therapeutic relationship with the patient. 
! Be non-judgemental, empathic and respectful. 
! Listen and clearly elucidate the patient’s needs.  
! Encourage the patient to participate actively in 
treatment decisions from the outset.  
! Communicate clearly, and allow time for the patient to 
gain an understanding of what assistance is being 
offered and the reasoning behind it. 
 
2.2.1 Elective presentations 
The objective in managing those seeking elective 
withdrawal management is to balance the need for safety 
with patient choice and desirable outcomes. 
In order of priority, this requires: 
! identifying withdrawal risks 
! assessing psychosocial factors 
! matching safety requirements and psychosocial factors 
to treatment setting. 
 
   When a person is dependent on a drug, 
withdrawal of the drug carries risks of physical 
harm, psychological trauma and (rarely) death. 
The aim of withdrawal management is to 
minimise the risks associated with withdrawal. 
 
 
It is common for drug-dependent people to 
present in a state of intoxication (which can 
complicate assessment and management of 
withdrawal) or overdose (which can be life-
threatening). Both intoxication and overdose 
may require acute medical care. 
See Appendix B for guidelines on assessment 
and management of intoxication and overdose. 
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2.2.2 Crisis presentations  
(presenting in withdrawal) 
Crisis presentations generally involve people who are 
already in withdrawal. The patient may present to a variety 
of settings (eg, emergency department, drug and alcohol 
unit, psychiatric service, correctional service, emergency 
accommodation centre, general practitioner, hospital 
ward). 
The critical issues are: 
! prompt identification of the withdrawal 
! minimising the risk of complications 
! managing withdrawal symptoms 
! stabilising medical and psychiatric conditions. 
2.2.3 Unplanned withdrawal 
Some people in the care of a clinician for reasons other 
than withdrawal management may begin to undergo 
withdrawal. These people may be receiving acute care in a 
hospital or being assisted with psychiatric, medical or 
surgical problems in other settings.  
Assessment for unplanned withdrawal is similar to that for 
crisis presentations.  
Early detection of withdrawal and preventing the risks 
associated with withdrawal are the key considerations. 
The key to effective management is coordinating 
withdrawal and other clinical care. Withdrawal may 
increase the expected hospital length of stay of the patient 
or require transfer to a more suitable setting. 
2.2.4 Referral to withdrawal services 
Alcohol Drug Information Service (ADIS) 
ADIS is a 24-hour, 7-day phone service for people seeking 
information or assistance with drug or alcohol related 
issues.  The telephone line also provides assessment, 
referral and brief counselling.    
 
Centralised intake lines 
Each Area Health Service in NSW has a centralised intake 
telephone number which acts as the first point of contact 
for people seeking assistance for drug or alcohol problems. 
Callers may be assessed by telephone and referred to 
relevant services within the Area.  Centralised intake lines 
operate Monday to Friday during business hours.  
Individual Area Health Service centralised intake lines are 
listed in Appendix C.   
2.3 Assessment for withdrawal 
management 
2.3.1 Primary aims of assessment 
Assessment is the first step in managing drug and alcohol 
withdrawal. The primary aims are to: 
! predict the risks that will confront the patient because 
of withdrawal  
! identify the specific needs of the patient to enhance 
the likelihood of completing withdrawal (ie, to match 
treatment to patient needs) 
! begin building a therapeutic relationship with the 
patient. 
Clinicians should: 
! take care to ensure that personal values and 
stereotypes do not interfere with effective assessment 
of the patient 
! explain the purpose of each element of the assessment 
process to the patient 
! seek the active involvement of the patient in planning 
treatment. 
2.3.2 Key elements in assessment 
Components of a comprehensive assessment are: 
! full drug consumption history 
! identifying risks associated with polydrug use 
! identifying past history of withdrawal and any 
associated complications 
! medical and psychiatric history 
! physical examination 
! mental state examination 
! appropriate laboratory investigations 
 
 
  Alcohol Drug Information Service (ADIS) 
9361 8000 
1800 422 599 (outside Sydney) 
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! psychosocial assessment to identify expectations, 
supports, barriers and preferences that may influence 
withdrawal management  
! formulating a management plan. 
Psychosocial assessment may be deferred if the patient is 
unwell, but it will serve to assist in planning future care 
and in determining treatment options. 
 
2.3.3 Full consumption history 
Obtain a description of consumption over a typical week 
(or month). This may easily be recorded on a “consumption 
calendar” (see Appendix D). There is a degree of 
correlation between quantity consumed and the severity of 
withdrawal. 
Obtain a general history of alcohol and drug use first, then 
attempt to identify daily patterns of alcohol and drug 
consumption from a retrospective consumption history.   
Most people, with or without drug problems, are likely to 
underestimate or estimate inaccurately how much they use 
if asked the question: “On average how much do you use 
a day or a week?” 
Recording consumption history 
An accurate consumption history should record, for each 
drug (whether prescribed or not prescribed): 
! quantity, frequency, duration of use, pattern of use 
! time and amount of last use 
! route of administration 
! recent pattern leading up to this presentation 
! average daily consumption. 
For prescribed medications, also record prescribed dose 
and prescribing doctor. 
2.3.4 Brief consumption history 
If documenting a full consumption history is not practical:  
! obtain whatever substance use history is available from 
the patient, family, friends, or other sources, especially 
details of the last episode of use 
! consider the possibility of polydrug use and record this 
possibility if concerned 
! identify any signs of drug consumption and effects 
during physical examination 
! consider urine or blood testing in most patients 
! take a further consumption history when the patient is 
stable or when others are able to provide information. 
   Note: In some circumstances the advice or 
assistance of a drug and alcohol specialist, or 
other specialist, may be required. 
   How to take a retrospective consumption history 
! Always ask about each drug group (eg, tobacco, alcohol, opioids, benzodiazepines, cannabis, 
amphetamines, cocaine, “club drugs”). 
! Start with most recent use. Ask “When did you last have anything to drink/use?” 
! Ascertain how much was consumed at that time. 
! Inquire back through that day: “What about during the day?” 
! Link consumption to activities. “What were you doing during the day?” Then, for example, “How much 
did you drink/use when you went to your friends’ house?” 
! Examine consumption through each day for the past week. 
! Then ask if that was a typical week’s pattern. If not, ask specifically how it differed (ie, how much more 
or less of each drug than usual). 
! Recording a complete consumption history is not always practical because of the context of the 
presentation, including the physical and mental state of the person in withdrawal. 
! A common drug combination that should be noted is alcohol and benzodiazepines. These drugs produce 
cross-tolerance, and regular use of both can make withdrawal more severe and/or protracted. 
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2.3.5 Street names and prices of drugs 
Drugs, their street names and prices vary across the country. This table should be used as a rough guide only.  
 
Drug Street names Approximate street price 
Alcohol grog, piss, cans, six pack, long necks, slabs, 
casks 
N/A 
Benzodiazepines benzos, pills, jack & jills, downers, seras, 
rowies 
Depends on type and dose ( mg) 
Heroin smack, hammer, h, gear $50 a cap 
$300 gram/weight 
Methadone syrup 
Physeptone tablets 
‘done 50 cents per mL 
Morphine  
Oxycodone 
Oxycontin 
oxy $25 per 100 mg 
$10–$40 
Buprenorphine bupe N/A 
GHB (gamma-hydroxybutyrate) fantasy, grievous bodily harm, liquid ecstasy, 
liquid e 
$5 for 1ml 
$25 for a vial 
Cannabis/marijuana  
Bush: medium strength  
Hydro: high strength  
grass, pot, gunja, reefer, joint, yarndi 
Implements:  bong, cone 
Bush: $20 gram, $300 ounce 
Hydro: $20 gram, $200 ounce 
Amphetamines   
Amphetamine/methamphetamine powder speed, gooey, uppers, whiz, velocity $50–$90 gram 
Methamphetamine base  
(stronger than powder) 
base, paste, wax, pure, point, 
red liquid speed, liquid red, ox blood 
$50 a point (0.1gm)  
$160 per gram 
Methamphetamine ice 
(stronger than base) 
crystal, crystal meth, shabu, yaabaa, point $50 a point (0.1gm)  
$360 gram 
Cocaine coke, c, snow, nose candy, okey-doke 
crack, free base 
$50 a cap, $280 a gram 
 
N/A 
Ecstacy/MDMA 
(methylenedioxymethamphetamine) 
xtc, eccy, E, pills $30 a tablet 
LSD (lysergic acid diethylamide) trips, acid $20 a tablet 
Magic mushrooms golden top mushrooms, magic mushies  
Ketamine special k, k, vitamin k $100 a gram 
PCP (phencyclidine)  angel dust, super weed, killer weed N/A 
Sources:  
Sunjic S, Mabbutt J. Street Drug Tables 1995-2005; NDARC Drug Fact sheets; NSW Department of Health Drug Fact Sheets; ADF 
Drug Fact Sheets; Psychostimulants information for health care workers (QLD Health 2006); NDARC NSW Drug Trends 2005; NSW 
Ecstasy and Related Drug Trends 2005; NUAA. 
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2.3.6 Consumption calculations 
Alcohol 
Record average daily consumption in grams of alcohol. 
Amount of alcohol in common drink measures and containers 
 Container size Type of container Alcohol content 
Beer  285 mL  
427 mL  
375 mL  
750 mL  
1 carton  
Middy  
Schooner  
Can/stubby (6 = six pack) 
Large bottles (long neck) 
24 cans/stubbies(slab) or 12 large bottles  
10 g 
15 g 
14 g 
28 g 
336 g 
Table wine 100 mL  
750 mL  
1 L  
4 L  
Standard glass  
Bottle  
Cask  
Cask  
10 g 
60–80 g 
100 g 
400 g 
Fortified wine (eg, port, sherry) 60 mL  
750 mL  
Standard glass  
Bottle  
10 g 
120 g 
Spirits (eg, whisky, brandy, vodka) 30 mL  
750 mL 
Nip  
Bottle  
10 g 
240 g 
Note: Light beer usually has about half the alcohol content of normal beer. 
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Benzodiazepines 
Note the dose (in milligrams) and the type of each benzodiazepine product used. 
Absorption rates, half-life, and equivalent daily doses of common benzodiazepines* 
Generic name Trade name 
Time to peak 
concentration Elimination half life† Equivalent dose‡ 
Diazepam Antenex 
Ducene 
Valium 
Valpam 
30–90 min Biphasic:  
rapid phase half-life, 3 hours; 
elimination half-life, 20–48 hours 
5 mg 
Alprazolam Alprax 
Xanax 
Kalma 
1 hour 6–25 hours 0.5–1.0 mg 
Bromazepam Lexotan 0.5–4 hours 20 hours 3–6 mg 
Clobazam Frisium 1 – 4 hours 17–49 hours 10 mg 
Clonazepam Paxam 
Rivotril 
2–3 hours 22–54 hours 0.5 mg 
Flunitrazepam Hypnodorm 1–2 hours 20–30 hours 1–2 mg 
Lorazepam Ativan 2 hours 12–16 hours 1 mg 
Nitrazepam Alodorm 
Mogadon 
2 hours 16–48 hours 2.5–5 mg 
Oxazepam Alepam 
Murelax 
Serepax 
2–3 hours 4–15 hours 15–30 mg 
Temazepam Euhypnos 
Normison 
Temaze 
Temtabs 
30–60 minutes after tablets, 
2 hours after capsules 
5–15 hours 10–20 mg 
Triazolam Halcion 1–3 hours Biphasic:  
rapid phase half-life, 2.5–3.5 hours; 
elimination half-life, 6–9 hours 
0.25 mg 
Zolpidem Stilnox 0.5–3 hours 2.5 hours Not known 
*Based on manufacturer’s product information.  
†Elimination half-life: time for the plasma drug concentration to decrease by 50%.  
‡Equivalent dose: approximate dose equivalent to diazepam 5 mg. 
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Opioids 
There are a range of opioid drugs that may be used by intravenous, oral or inhalational routes. 
Opioid drugs, with details of approximately equivalent doses 
Generic name Trade name 
Approximately 
equivalent doses (mg) 
Duration of 
analgesia (hours) Half life (hours) 
Buprenorphine hydrochloride Subutex/ Suboxone 0.3 4-8 20-73  
Codeine phosphate 
 
Codeine, 
Panadeine forte 
30-60 3-4 2-4 
Diacetylmorphine Heroin (converts to morphine) 3–4 2 
Fentanyl citrate Fentanyl  0.1 1-1.5 3-4 
Methadone 4–5hydrochloride Biodone forte 
Methadone syrup 
Physeptone 
10 4-6 15-60 
Morphine sulfate Morphine 
Kapanol 
MS Contin 
10 
10 
4-5 
4-5 
2 
2-4 
Oxycodone hydrochloride OxyContin 
Endone 
4.5 3-4 6.5 
Sources: Katzung BG (2006) Basic and Clinical Pharmacology, 9th Edition, The McGraw-Hill Companies [CIAP]; MIMS on-line (2006) 
[CIAP]. 
 
Heroin 
Heroin dosage estimates are difficult because of wide 
variations in the concentration and purity of (illicit) heroin. 
Consumption may be recorded as: 
! the number of injections per day 
! the number of grams ingested 
! dollars spent. 
Note that “street” usage patterns alter frequently. 
Approximate guide to a patient’s level of heroin use 
Low end: 
! one to two injections per day, or 
! 0.5 g or less per day 
High end: 
! four or more injections per day, or 
! 1–2 g or more per day. 
 
Cannabis  
Identify as accurately as possible: 
! the way in which the drug is consumed 
! the frequency of use 
! the amount spent per day on cannabis. 
Users will usually be able to report how many grams (10-
15 cones/gram, more if “mulled” or “spun” with tobacco) 
they smoke per day. Smoking marijuana cigarettes (rolled 
with or without tobacco) commonly known as “joints” or 
“spliffs” is another common mode of use. Heavy users can 
smoke more than 1 ounce / 28 grams) a week. 
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Psychostimulants  
Amphetamines are the most frequently used group of 
drugs in this category.  
Define the route of administration, the specific agents 
used, and the frequency and pattern of use. 
Many street products will not be pure, and urine drug 
screening is appropriate to document what has been 
consumed. 
Consumption may be recorded as frequency of 
administration or as dollars spent.  
 
Summary of different forms of psychostimulants available on the illicit market in Australia  
 Speed Base Ice Cocaine Ecstasy 
Drug Methamphetamine 
or amphetamine 
Methamphetamine Methamphetamine Cocaine 
hydrochloride 
MDMA, or 
methamphetamine, 
often with other 
drugs added to mimic 
the effects of MDMA 
Street names Goey, whiz, velocity Paste, point, pure, 
wax 
Shabu, crystal, 
crystal meth, 
yaabaa 
Coke, okey-doke E, eckie, XTC, pills 
Appearance Fine or coarse 
powder 
Sticky, gluggy, waxy 
or oily form of damp 
powder, paste or 
crystal 
Crystal or coarse 
crystalline powder 
Crystalline powder Tablets, powder 
Colour White, pink, yellow, 
orange, brown 
Often has a yellow or 
brown tinge 
Translucent or 
white; may have 
green, blue or pink 
tinge 
White Various 
Method of 
administration 
Usually snorted or 
injected, sometimes 
swallowed 
Swallowed, smoked, 
snorted, injected 
Swallowed, 
smoked, snorted, 
injected 
Swallowed, 
snorted, injected 
Swallowed, 
sometimes injected 
Place of origin Most is produced in 
clandestine 
laboratories in 
Australia, some 
imported 
Most is produced in 
clandestine 
laboratories in 
Australia. 
Most imported 
from East and 
South-East Asia 
Imported from 
South America 
Mostly imported; 
some domestic 
manufacture in 
clandestine 
laboratories 
Purchase 
quantity 
Point (0.1 gram), 
half gram, gram 
Point (0.1 gram); also 
gram, half gram 
Point, gram Gram Pill 
Availability Most widely 
available form 
Widely available 
(varies between 
states and territories) 
Less available but 
availability is 
increasing 
Not very available Availability is 
increasing 
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2.3.7 Identifying risks associated with 
polydrug use 
The most frequent comorbid diagnosis among those with 
dependence on a substance is another substance use 
disorder (other than nicotine), commonly another 
dependence. Episodic use of alcohol, opioids and 
benzodiazepines is more common than consistent and 
heavy use of more than one drug (and less likely to lead to 
dependence). 
Where polydrug use is likely, obtain advice from, or 
consider referral to, a specialist drug and alcohol service to 
assist with assessment. 
Managing withdrawal in a person with multiple 
dependencies requires extra clinical vigilance and 
consideration of the order in which the withdrawals should 
be managed. Although many patients seeking treatment 
may wish to withdraw immediately from all drugs, in some 
instances a stepped approach is preferable, addressing 
withdrawal from one drug at a time. The driving principle 
in determining the order of withdrawal is to begin with the 
substance with the potential for the most problematic 
withdrawal. In most instances this will be alcohol.  
2.3.8 Selective withdrawal 
In some cases, selective withdrawal is required in people 
who have stable dependence on a prescribed treatment 
such as methadone, but who are using other substances in 
a harmful fashion (eg, amphetamine or alcohol). For 
further information on withdrawal from a specific drug or 
alcohol, see the relevant chapter in these guidelines. 
Selective withdrawal while on an opioid treatment 
program 
Patients in an opioid treatment program who are 
dependent upon other drugs, in particular 
benzodiazepines, alcohol or psychostimulants, may require 
assistance to withdraw from those drugs while continuing 
methadone or buprenorphine treatment.  
Unless the patient requires admission to a hospital for 
withdrawal, the patient’s prescriber should take 
responsibility for coordinating selective withdrawal. 
The prescriber should:  
! review the patient frequently 
! monitor the patient closely for evidence of intoxication 
with sedative drugs in combination with methadone or 
buprenorphine 
! provide only small quantities of withdrawal medication 
at a time (preferably daily pick-up of withdrawal 
medication). 
Often the prescriber will personally manage the 
withdrawal. If this is not practical (eg, heavy alcohol use 
and withdrawal), the prescriber will need to work with 
withdrawal management services in their area. 
2.3.9 Identifying past history of withdrawal 
The likely course of withdrawal may be anticipated from 
past experiences.  
Determine whether there is any past history of withdrawal, 
including complications (seizures, delirium or psychosis), 
treatments used, and where and when previous 
withdrawals occurred. Obtain a medical history from the 
patient, previous medical records, relatives or friends. 
2.3.10 Assessing current withdrawal status 
In patients who are in withdrawal at the time of 
assessment, assess the type and severity of withdrawal 
symptoms. 
Alcohol 
Onset: As blood alcohol level falls; depends on rate of fall 
and hours after last drink. 
Duration: 3–7 days (up to 14 days in severe withdrawal). 
Features: anxiety, agitation, sweating, tremor, nausea, 
vomiting, abdominal cramps, diarrhoea, anorexia, craving, 
insomnia, elevated blood pressure, pulse and temperature, 
headache, confusion, perceptual distortions, disorientation, 
hallucinations. Seizures may occur and may be life 
threatening. 
Benzodiazepines 
Onset: 1–10 days (depending on half-life of drug). 
Duration: 3–6 weeks (may be longer). 
Features: anxiety, headache, insomnia, muscle aching and 
twitching, perceptual changes, feelings of unreality, 
depersonalisation, seizures (these can be life threatening). 
Opioids 
Onset: 6–24 hours (may be later with longer-acting 
opioids). 
Duration: peaks 2–4 days, ceases 5–10 days (more 
prolonged for longer-acting opioids). 
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Features: anxiety, craving, muscle tension, muscle and 
bone ache, muscle cramps and sustained contractions, 
sleep disturbance, sweating, hot and cold flushes, 
piloerection, yawning, lacrimation and rhinorrhea, 
abdominal cramps, nausea, vomiting, diarrhoea, 
palpitations, elevated blood pressure and pulse, dilated 
pupils. 
Cannabis 
Onset: Within 24 hours. 
Duration: 1–2 weeks. 
Features: insomnia, shakiness; irritability, restlessness, 
anxiety; anger, aggression. 
Psychostimulants 
Onset: 6–12 hours (cocaine); 12–24 hours (amphetamines). 
Duration: Several weeks for withdrawal phase, then 
months for extinction. 
Features: 3 phases. Crash: fatigue, flat affect, increased 
sleep, reduced cravings. Withdrawal: fluctuating mood and 
energy levels, cravings, disturbed sleep, poor 
concentration. Extinction: persistence of withdrawal 
features, gradually subsiding. 
Nicotine 
Onset: within several hours of the last cigarette. 
Duration: Peak within the first 24–72 hours and resolves in 
2–4 weeks. 
Features: craving; irritability, restlessness, mood swings; 
increased appetite and hunger; sleep disturbances with 
resulting insomnia and fatigue; anxiety and depression and 
difficulty concentrating. 
2.3.11 Physical examination for withdrawal 
management 
The extent of the physical examination will depend on the 
setting and the assessor. 
! Assessment by a medical practitioner should include a 
full physical examination. 
! A nursing examination in a medical setting should 
include assessment of respiration and evaluation of the 
general appearance of the patient. Record pulse, 
temperature and blood pressure on an appropriate 
chart or scale to allow monitoring over time. 
! Examination by a non-medical professional should 
include observation of physical appearance —
 sweating, tremor, agitation, coordination, gait. Rate 
these appearances and reassess them at regular 
intervals to monitor the progress of symptoms. If 
symptoms are increasing in severity, notify a senior 
staff member, or if available, a doctor. 
2.3.12 Mental health and suicide risk 
assessment 
NSW Department of Health Policy Directive PD2005_121 
(previously Circular 98/31), Policy guidelines for the 
management of patients with possible suicidal behaviour 
for NSW Health staff and staff in private hospital facilities, 
outlines the mandatory requirement that all patients with 
possible suicidal behaviour having contact with health 
services, require a psychosocial, suicide risk and psychiatric 
assessment. All patients must have a preliminary screening 
of suicide risk and be referred to specialist mental health 
services as appropriate. 
The framework for suicide risk assessment and 
management for NSW Health staff (NSW Department of 
Health, 2004) links the Mental Health – Outcomes 
Assessment Tools (MH – OAT) to the above policy and 
provides more detailed information on suicide risk 
assessment. 
The goal of suicide risk assessment is to determine the level 
of risk at a given time and to provide appropriate clinical 
care and management. Possible suicidal behaviour includes 
thinking about suicide, harming oneself or attempting 
suicide. There is no current rating scale that has a proven 
predictive value in clinical assessment of suicide. A 
comprehensive assessment of the person is the only valid 
method.  
Drug and alcohol staff should at least conduct these steps 
in the assessment of suicide risk: 
! Engagement 
! Detection (of risk factors) 
! Preliminary suicide risk assessment 
! Immediate management 
Detection 
Intoxication with drugs or alcohol precludes a valid 
immediate assessment. If suicide risk is identified in an 
intoxicated person, he or she should be detained in an 
appropriate and safe setting until a full assessment if 
conducted. Enduring risk cannot be judged until the 
person is sober. 
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Preliminary suicide risk assessment 
This assessment determines the severity and nature of an 
individual’s problems, the risk of danger to self and others 
and whether a more detailed risk assessment is indicated.  
A mental state examination should be performed, 
including observations of general appearance and 
behaviour, affect, and thinking (especially with regard to 
risk of harm to self and others), perception (including 
hallucinations and illusions), cognition (level of 
consciousness and orientation) and insight. A mental state 
assessment is required to determine: 
! the need for other psychological therapies 
! concomitant psychiatric conditions which place the 
patient or others at risk 
! the patient’s capacity for informed consent and active 
participation in treatment planning. 
Screening questions of suicide risk: 
! Have things been so bad lately that you have thought 
you would rather not be here? 
! Have you had any thoughts of harming yourself? 
! Are you thinking of suicide? 
! Have you ever tried to harm yourself? 
! Have you made any current plans? 
! Do you have access to a firearm? Access to other 
lethal means? 
! Concern about the safety of the patient should lead to 
appropriate referrals with the local Area Health Service 
with the withdrawal management taking less of a 
priority. 
! For further information see Appendix E. 
2.3.13 Screening for domestic violence 
The domestic violence screening tool is to be used with 
women aged 16 and over in accordance with NSW 
Department of Health policy and procedures for identifying 
and responding to domestic violence (see Appendix F). 
2.3.14 Psychosocial assessment 
Identify and consider the patient’s social situation, support 
systems, preference for treatment, capacity to undertake 
withdrawal and the likely success of treatment. 
This assessment helps in developing an agreed treatment 
plan with the patient. Discussing these issues and seeking 
the participation of patients in developing treatment plans 
will improve their compliance with treatment and increase 
the chances of successful withdrawal. 
Psychosocial factors affecting withdrawal 
Ask about expectations of withdrawal: 
! reasons for presenting for withdrawal management at 
this time 
! past experiences of withdrawal 
! current knowledge and fears of withdrawal 
! perceived ability to cope with withdrawal and its 
treatment. 
Ask about supports for withdrawal treatment: 
! stability of accommodation 
! the extent and suitability of the patient’s social 
network 
! supportive family and friends 
! the patient’s links with local health professionals. 
Ask about potential barriers to successful withdrawal: 
! distance to nearest clinician 
! access to transport 
! relationship issues 
! care of children 
! drug use of cohabitants 
! current legal issues 
! financial problems 
! work commitments. 
2.3.15 Child protection 
On initial assessment and at treatment and discharge 
review it is important to consider the safety, welfare and 
well-being of any children in the patient’s care. This may 
include a patient’s own children, children living at the same 
residence, or children to whom the patient has access. 
Health care workers have a duty under the NSW Children  
and Young Persons (Care and Protection) Act 1998 to 
notify the Department of Community Services (DOCS)
whenever they suspect that a child or young person may
be at risk of harm through abuse or neglect. This duty 
may be invoked when considering the potential risk of 
harm of a child yet to be born.  
When necessary, the duty to report possible harm through 
abuse or neglect overrides the duty to maintain patient 
confidentiality.  
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Under Section 23 of the Act, a child or young person is at 
risk of harm if current concerns exist for the safety, welfare 
and well-being of the child or young person because of the 
presence of one or more of the following circumstances: 
! the child or young person’s basic physical or 
psychological needs are not being met or are at risk of 
not being met 
! the parents or caregivers have not arranged and are 
unable or unwilling to arrange for the child or young 
person to receive necessary medical care 
! the child or young person has been, or is at risk of 
being, physically or sexually abused or ill-treated 
! the child or young person is living in a household 
where there have been incidents of domestic violence 
and, as a consequence, the child or young person is at 
risk of serious physical or psychological harm 
! a parent or caregiver has behaved in such a way 
towards the child or young person that the child or 
young person has suffered or is at risk of suffering 
serious psychological harm. 
NSW Department of Health Policy PD 2006_109 provides 
the form to be used for reporting a child or young person 
at risk of harm to the DOCS helpline. 
A parent or carer of children wanting to withdraw from an 
alcohol or other drugs program is not itself a reason to 
make a report to the Department of Community Services.  
In relation to newborn infants of mothers on methadone 
maintenance, NSW Department of Health Policy Directive 
PD2005_299 (previously Circular 2003/16), Protecting 
children and young people, recommends that a 
multidisciplinary case conference should be convened in 
accordance with NSW Department of Health Policy 
Directive PD2005_494 (previously circular 2002/101), 
Neonatal abstinence syndrome guidelines (2002), to 
formulate a discharge plan for mother and baby with clear, 
documented responsibilities and timeframes. 
Representation at this meeting should include the parents, 
a health worker with expertise in child protection, and any 
services or supports involved with the family. 
2.3.16 Formulating the management plan 
Summarise the patient’s overall assessment and identify: 
! potential risks to the patient during withdrawal 
! problems and barriers that may prevent the patient 
completing withdrawal 
! interventions that have been indicated by the 
assessment. 
Recording the main issues identified in the assessment 
helps continuity and quality of care when more than one 
clinician is involved. 
Link the assessment to a treatment plan, which addresses: 
! management of withdrawal 
! setting for withdrawal 
! follow-up and communication with other relevant 
service providers and agencies. 
An example of an assessment summary for withdrawal 
management services is provided in Appendix G. 
2.4 Treatment matching for 
withdrawal management 
The overriding priorities for managing withdrawal are: 
! Safety: no treatment can be recommended that is not 
safe for that patient. 
! Outcome: treatments should only be recommended if 
they are likely to succeed. 
! Choice: patients have the right to choose from the 
treatment options that are available and considered 
appropriate by the clinician. They should be advised as 
to the suitability and availability of services. 
Try to match the patient with the treatment intervention 
that maximises patient safety and provides the most 
effective and most economical options for withdrawal 
management. 
 
Ambulatory management is contraindicated if: 
! the safety of the person or others in the household 
would be at risk (see section 2.3.15)  
! the likelihood of a successful outcome is poor  
! the person will not agree. 
The original setting for withdrawal management may 
become inappropriate for the needs of the patient. 
Re-evaluate the setting as part of the ongoing assessment 
of patients in withdrawal. When indicated, transfer 
patients to a more suitable treatment setting (either more 
or less intensive) as soon as possible. 
Only refer the patient to hospital when withdrawal may be 
complicated by its severity or other medical or psychiatric 
problems, or when no more suitable option is available. 
 Always consider ambulatory withdrawal 
management (patient at home, supported by 
visits to the clinic or visits from the clinician and 
telephone) as the first option. 
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2.4.1 Special groups  
Culturally and linguistically diverse populations, young 
people, Aboriginal and Torres Strait Islander people, women 
(especially in pregnancy), mentally ill people, elderly people 
who present to health services involuntarily, people residing 
in rural and remote locations, people living with HIV/AIDS, 
people belonging to particular religious groups, and people 
in custody may have special needs. Withdrawal services must 
consider the needs of these specific groups of patients and 
seek further information from relevant NSW Department of 
Health documents or services.  
Consider the following: 
Pregnancy 
! specialist antenatal and obstetric care 
! specialist drug and alcohol services. 
Psychiatric illness 
! available information on the patient’s mental health 
before withdrawal 
! the possibility of emergence or exacerbation of 
psychological symptoms 
! availability of community psychiatry or consultation 
liaison services 
! possible need for withdrawal management in a 
psychiatric hospital. 
Elderly 
! concomitant illnesses 
! potentially longer period of use/dependence 
! vulnerability if admitted to a unit with predominantly 
younger people 
! difficulties with mobility, increased risk of falls 
! communication issues (eg, decreased hearing) 
! increased risk of delirium. 
Youth 
! need to use the least restrictive setting 
! risk of exposure to other forms of drug use 
(information and other patients) in particular settings 
! availability of appropriate liaison staff 
! vulnerability in residential settings. 
Cultural issues 
! availability of appropriate liaison staff 
! availability and use of interpreters when necessary 
! cultural aspects that may affect setting, expectations, 
importance of family, follow-up and other issues. 
2.5 Treatment agreements 
Encouraging patients to participate in treatment choice 
enables their views to be considered and increases the 
awareness of both the patient’s and the clinician’s 
responsibilities. 
If possible, formalise a treatment agreement with the 
patient. The agreement may be verbal or written. The 
acknowledgement of a verbal agreement should be 
recorded in the notes.  
Make the patient aware of his or her responsibilities and 
those of the service provider. Be specific about 
expectations for feedback and how complaints will be 
managed. 
Address any failure to follow the agreement by re-
evaluating the management plan in consultation with the 
patient.  
Do not set up an agreement so that it can be used against 
the patient in a punitive manner. Failing to follow an 
agreement is not in itself sufficient grounds for discharge 
from care. 
 
 
 Recommended points in a treatment 
agreement 
! Identify the patient and clinic/medical 
practitioner. 
! Specify the date/period of treatment, nature 
of the treatment (eg, ambulatory alcohol 
withdrawal management), special 
requirements (eg, daily attendance at 
outpatient clinic), any prescribed 
medications, and the role of the patient 
and/or carer (eg, completion of withdrawal 
chart). 
! List identified risks to the patient. 
! Identify special steps intended to enhance 
the likelihood of completing withdrawal, 
including transportation arrangements and 
supportive care protocol. 
! Detail conditions under which urgent contact 
should be made with the medical 
practitioner, contact numbers and emergency 
procedures. 
! Indicate agreed strategies for managing the 
period after withdrawal. 
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2.6 Treating withdrawal 
This section outlines the principles of treating withdrawal. 
Details of managing withdrawal from specific drug types 
are given in later chapters. 
2.6.1 Monitoring 
Frequent observations of the patient are the mainstay of 
management. Assessment of clinical features, explanation, 
reassurance and repeated encouragement are provided at 
these times. 
The frequency of observations and evaluation of progress 
will depend on the severity of withdrawal and the setting. 
2.6.2 Pharmacological treatment 
Medication is used in withdrawal to provide symptomatic 
relief, to treat complications and coexisting conditions, and 
to reduce the intensity of withdrawal symptoms. 
The choice of pharmacological treatment in withdrawal is 
guided by the severity of withdrawal and the drug from 
which the patient is withdrawing. Certain regimens should 
only be prescribed when appropriately trained staff are 
available to supervise and monitor the outcome. 
2.6.3 Routine supportive care 
The aim of supportive care is to minimise environmental 
stimuli that may exacerbate withdrawal symptoms and to 
enhance the patient’s ability to complete withdrawal 
successfully. 
Use a protocol for supportive care (Appendix H), 
particularly for managing withdrawal in hospital and 
residential settings. The supportive care routine should go 
hand in hand with monitoring of physical signs. 
Anxiety and depression are commonly associated with 
drug dependence and withdrawal and can be managed 
effectively with supportive care. They may be part of a 
more pervasive disorder, but this cannot be determined 
until the withdrawal syndrome subsides. Usually, the need 
for specific treatments for anxiety and depression is 
reassessed 2–4 weeks after withdrawal. 
Key elements of supportive care 
Information about what to expect can allay fear and 
anxiety. Studies show that patients who are given 
information will have lower withdrawal scale scores than 
those who are not. Information given to the person in 
withdrawal should include: 
! orientation to the setting and primary care giver 
! a description of the likely course of withdrawal 
! the likely length and intensity of withdrawal symptoms 
! the support plan for withdrawal and afterwards 
! the risks associated with withdrawal. 
The environment can have a significant effect on the 
severity of withdrawal. Minimise stress by making sure that 
the environment is quiet, calm, homely, not overly bright, 
without striking colours or patterns, safe and private. 
Attention to the environment also includes considering the 
person’s physical comfort by making adjustments to 
position, pillows and blankets when necessary. Hot packs, 
hot spa bath and massage can also relieve aches and 
increase comfort. 
Reassurance is probably the most effective intervention in 
reducing the severity of withdrawal symptoms. 
Reassurance might be achieved through allaying concerns 
and fears, positive encouragement, feedback on progress, 
regular contact, providing information, and dealing with 
immediate social and family problems. The reassurance of 
family members will help them provide support to the 
person during withdrawal (active participation and support 
of family is likely to be a significant factor in the 
completion of withdrawal). 
Coping skills, such as relaxation techniques, dietary 
guidelines, sleep disturbance management, and methods 
to reduce craving (Appendix I) should be introduced to 
the patient. 
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2.6.4 Managing difficult behaviour 
Difficult behaviour is a significant barrier to successful 
withdrawal. Adherence to appropriate protocols will 
minimise the risk. This is more of a problem in general 
hospital settings where close links between general staff 
and drug and alcohol staff will be required to prevent 
escalation of difficult behaviour. 
Key elements of managing difficult behaviour 
Anxiety/agitation/panic 
! Approach in a calm and confident manner. 
! Reduce stimulation and the number of people 
attending the patient. 
! Explain interventions carefully. 
! Minimise the risk from self-harm. 
Confusion/disorientation//hallucinations 
! Provide frequent reality orientation. 
! Ensure frequent supervision. 
! Explain perceptual errors. 
! Ensure environment is simple and uncluttered and well 
lit. 
! Protect from self-harm and harm to others. 
Anger/aggression 
! Use space to protect yourself. 
! Remain calm and reassuring. 
! Do not challenge the patient. 
! Acknowledge the patient’s feelings. 
! Remove the source of anger, if possible. 
! Be flexible within reason. 
2.6.5 Driving 
Most withdrawal involves some psychomotor impairment, 
psychological disorder or fatigue. Clinicians responsible for 
withdrawal management are responsible for ensuring that 
patients are adequately informed of the symptoms they 
may experience, the effects these may have on driving skills 
and the increased risk of being involved in an accident. 
There is the potential for civil liability if, as a result of 
impaired driving while medically unfit, a person causes a 
road accident. Withdrawal could be considered a condition 
that renders an individual “medically unfit”. 
Special warning: fitness to drive  
It is recommended that patients in an ambulatory or home-
based withdrawal setting or who are leaving an inpatient 
setting receive an information card regarding fitness to 
drive. 
Primary responsibility to assess fitness to drive and to 
inform patients of the potential risk rests with the medical 
officer, but other health professionals involved in care and 
case management are also responsible for advising patients 
not to drive if there is any doubt about their fitness to do 
so at that time. 
In addition to penalties under the legislation, patients may 
be liable at common law if they continue to drive knowing 
that they have a condition likely to adversely affect driving. 
Failure to report may also breach the terms of insurance.  
There may be circumstances, such as a patient’s failure to 
report, under which a medical professional is required to 
report a patient’s unfitness to drive to the Driver Licensing 
Authority if there is a known impairment and a subsequent 
risk to road safety. 
 
2.7 HIV, hepatitis B and hepatitis C 
screening 
The NSW Department of Health now expects all drug and 
alcohol services to take responsibility for discussing blood-
borne viruses and the risk of acquisition with their patients. 
Either at the assessment interview or after treatment has 
commenced, offer all patients screening for HIV, hepatitis B 
and hepatitis C and advise on the availability of hepatitis B 
vaccination.  
! Tests should only be undertaken when patients have 
voluntarily agreed to such testing and at an 
appropriate time in the withdrawal process (not in the 
acute phase). 
! To assist patients to make a decision regarding testing, 
provide sufficient information to allow them to give 
informed consent, and assure them that confidentiality 
will be maintained.  
! If patients elect to undergo these tests, pre-test and 
post-test counselling must be provided as outlined in 
NSW Department of Health Policy Directive 
PD2005_048: Counselling associated with HIV 
antibody testing — guidelines.  
 Assessing fitness to drive  
Assessing fitness to drive for commercial and private 
vehicle drivers. Medical standards for licensing and 
clinical management guidelines. Approved by the 
Australian Transport Council and endorsed by all 
Australian Driver Licensing Authorities (2003). 
<http://www.austroads.com.au/aftd/index.html> 
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2.8 Continuing care 
2.8.1 Discharge planning 
Develop strategies to help the patient cope with the period 
after withdrawal, particularly if the patient required 
withdrawal management in hospital. Discharge planning 
begins with the initial assessment for withdrawal 
management. 
Involve patients in discharge planning, and make them fully 
aware of their options. Part of this participation is 
identifying support that can be called upon by the patient 
after withdrawal. It should be the clinician’s responsibility 
to ensure that patients are aware of options to seek further 
assistance in the future. Where a follow-up option is 
agreed to, make professional contact with that service to 
facilitate the referral process. 
Patients have the right to refuse further follow-up. If this 
occurs, note the refusal in the patient’s record and avoid 
judgmental reactions. 
Document discharge planning in the patient record. 
When planning discharge, consider: 
! stability of accommodation — whether the person 
lives alone or with others who use drugs. 
! the extent of their social network — their existing links 
with health professionals in their local community. 
Key requirements of planning discharge from 
withdrawal management 
! Organise/facilitate follow-up appointments. 
! Link up with further treatment (including 
rehabilitation, outpatient treatment, self-help). 
! Communicate with other relevant service providers. 
! Provide emergency assistance numbers. 
When people complete withdrawal from drugs or alcohol it 
can be frustrating for them, their health care workers, 
partners, family and friends if follow-up help is delayed. 
There is no easy answer to this difficult issue, but good 
information about what to expect can help people prepare 
for the procedures and delays ahead. Effective networking 
between withdrawal management units and other services 
can reduce these delays. Sending people to services 
without informing the service first can be a waste of time. 
Aftercare 
Aftercare services might include skills training (eg, relapse 
prevention, problem solving skills or vocational skills 
training), social support services (eg, self-help groups such 
as Narcotics Anonymous), or booster motivational 
counselling sessions. Supportive care should be offered 
after finishing withdrawal treatment. 
Counselling and group programs 
Counselling is an important option to consider in 
continuing care for someone who has completed 
withdrawal. A range of free or fee-charging services are 
provided by government, non-government and private 
organisations. 
Self help programs 
There are several self help programs modelled on the 12 
step program developed originally by Alcoholics 
Anonymous (AA), such as Narcotic Anonymous (NA), Al 
Anon (for people affected by someone’s use), Gamblers 
Anonymous and so on. They are based on the belief that 
total abstinence is the only way to recovery. People 
interested need to be motivated to attend meetings and 
become part of the program. There is no formal referral 
process to specific AA or NA programs but patients can be 
advised to make contact with a functioning group in their 
area. This free resource to the community should be 
discussed with patients who want to maintain abstinence.  
The SMART recovery program is a new self help 
meeting-style program available in Sydney and in other 
parts of NSW. Family Drug Support (FDS) is a self help 
support service for people affected by someone’s drug or 
alcohol use. NSW Users and AIDS Association (NUAA) is a 
peer based organisation which provides support and 
information for “users”. 
Pharmacotherapies  
There are a range of pharmacotherapies available for 
people completing drug and alcohol withdrawal. Opioid 
treatment pharmacotherapies, including methadone, 
buprenorphine (Subutex), buprenorphine and naloxone 
(Suboxone) and naltrexone, are discussed in New South 
Wales Opioid Treatment Program: clinical guidelines for 
methadone and buprenorphine treatment (NSW 
Department of Health GL2006_019, 2006).  
Alcohol pharmacotherapies include naltrexone, 
acamprosate and disulfiram. The pharmacology of these 
agents needs to be understood before they are 
recommended.  
Rehabilitation programs 
Government and private rehabilitation programs include 
outpatient programs and live-in programs. The length, 
philosophy, cost, assessment procedures, target groups 
(exclusions) and support afterwards all vary. As with most 
service providers, the agencies will want to speak to the 
person being referred before offering a place. Programs 
run for periods ranging from 3 weeks to over a year and 
there are waiting lists (sometimes long) for most services.  
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3 Alcohol  
Chapter summary 
! Patients admitted to hospitals or presenting to the emergency department should undergo screening 
at admission to identify those at risk of alcohol withdrawal. 
! Anyone who reports alcohol consumption in excess of NHMRC recommended levels should be 
considered at risk of withdrawal. They should be asked about features of dependence, particularly 
previous withdrawal, and they should be monitored in hospital with an alcohol withdrawal rating 
scale. 
! About 95% of alcohol-dependent people can stop drinking without major withdrawal (delirium, 
seizures).  
! The risk of major withdrawal is greater in people with acute medical conditions (eg, trauma or sepsis). 
! Onset of alcohol withdrawal is usually 6–24 hours after the last drink. Usually, withdrawal resolves 
after 2–3 days without treatment; occasionally, withdrawal may continue for up to 10 days. 
! Seizures affect about 5% of patients, occurring early (usually 7–24 hours after the last drink). They are 
grand mal in type (ie, generalised, not focal) and usually (though not always) occur as a single episode. 
! Delirium tremens (“the DTs”) is the most severe form of alcohol withdrawal and is a medical 
emergency. It usually develops 2–5 days after stopping or significantly reducing alcohol consumption. 
The usual course is 3 days, but can be up to 14 days. 
! The Clinical Institute withdrawal assessment for alcohol – revised version (CIWA-AR) is a valid, reliable 
and a sensitive instrument for assessing the clinical course of simple alcohol withdrawal. The Alcohol 
withdrawal scale (AWS) is another useful scale. The use of either scale is supported. 
! Supportive care alone is often effective in minor alcohol withdrawal. 
! Diazepam is the pharmacotherapy of choice for alcohol withdrawal. Diazepam treatment is best 
initiated early in the course of alcohol withdrawal, to prevent progression to more severe withdrawal. 
Diazepam loading is recommended for inpatient settings, and tapering diazepam for outpatient 
settings. 
! All people being treated for alcohol withdrawal should routinely receive thiamine for prophylaxis 
against Wernicke’s encephalopathy. Thiamine should initially be given intramuscularly or intravenously. 
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3.1 Use and effects of alcohol 
At low doses, alcohol causes loss of emotional restraint, 
vivaciousness, feeling of warmth, flushing of skin and mild 
impairment of judgment. As blood alcohol levels increase, 
speech becomes slurred and the intoxicated person begins 
losing motor control. At higher levels, memory is affected 
and the person becomes stuporous and unable to be 
aroused. Coma and death can, rarely, ensue. 
3.2 Assessment issues specific to 
alcohol-dependent patients 
 
Record average daily consumption in grams of alcohol (see 
table below). 
The patient may be intoxicated on presentation, and this 
may affect his or her ability to provide and receive 
information. 
 
See Appendix B for a guide to managing intoxication and 
overdose. 
Assessment of intoxicated individuals is difficult but should 
be pursued as far as is possible. Assessment findings may 
be reviewed after signs of intoxication have abated. 
Intoxication may be a contraindication for admission for 
withdrawal management. Some dependent people may 
present for withdrawal management with a high blood 
alcohol level, but without intoxication. This is not a 
contraindication to admission. 
3.2.1 Unplanned withdrawal 
Patients admitted to hospitals or presenting to the 
emergency department should undergo screening at 
admission to identify those at risk of alcohol withdrawal.  
The standard method of screening is to take a drinking 
history. Anyone who reports alcohol consumption in excess 
of NHMRC recommended levels should be considered at 
risk of withdrawal. They should be asked about features of 
dependence, particularly prior withdrawal, and they should 
be monitored in hospital with an alcohol withdrawal rating 
scale. 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
Amount of alcohol in common drink measures and containers 
 Container size Type of container Alcohol content 
Beer  285 mL  
427 mL  
375 mL  
750 mL  
1 carton  
Middy  
Schooner  
Can/stubby (6 = six pack) 
Large bottles (long neck) 
24 cans/stubbies(slab) or 12 large 
bottles  
10 g 
15 g 
14 g 
28 g 
336 g 
Table wine 100 mL  
750 mL  
1 L  
4 L  
Standard glass  
Bottle  
Cask  
Cask  
10 g 
60–80 g 
100 g 
400 g 
Fortified wine (eg, port, sherry) 60 mL  
750 mL  
Standard glass  
Bottle  
10 g 
120 g 
Spirits (eg, whisky, brandy, vodka) 30 mL  
750 mL 
Nip  
Bottle  
10 g 
240 g 
Note: Light beer usually has about half the alcohol content of normal beer. 
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Heavy drinkers are often reluctant to disclose their 
drinking, and will seriously under-report their level of 
consumption. General hospital staff need to maintain an 
index of suspicion, and be alert to the possibility that 
someone who reports only modest or no drinking is in fact 
alcohol dependent.  
Particular issues that should raise the possibility that 
someone is a dependent drinker are: 
! a presenting condition or previous diagnosis of an 
alcohol-related disease (eg, alcoholic hepatitis, 
alcoholic cardiomyopathy, and pancreatitis) 
! stigmata of chronic liver disease (including prominent 
facial capillaries, spider naevi, and palmar erythema) 
! blood tests showing raised serum gamma-glutamyl 
transferase or raised mean corpuscular red cell volume 
! symptoms such as anxiety, agitation or confusion, or 
other clinical features that might be due to an alcohol 
withdrawal syndrome. 
In hospitalised patients, early detection and treatment to 
prevent the development of withdrawal is the optimal 
approach.  
3.3 Alcohol withdrawal 
3.3.1 Onset and duration  
Onset of alcohol withdrawal is usually 6–24 hours after the 
last drink. Consuming benzodiazepines or other sedatives 
may delay the onset of withdrawal. In some severely 
dependent drinkers, simply reducing the level of 
consumption may precipitate withdrawal, even if they have 
consumed alcohol recently. Usually, withdrawal is brief, 
and resolves after 2–3 days without treatment; 
occasionally, withdrawal may continue for up to 10 days.  
Withdrawal can occur when the blood alcohol level is 
decreasing, even if the patient is still intoxicated. 
3.3.2 Signs and symptoms  
The signs and symptoms of alcohol withdrawal may be 
grouped into three major classes. 
 
Adapted from Frank L, Pead J. New concepts in drug withdrawal: a resource 
handbook. ©1995 State of Victoria. Reproduced with permission 
Main signs and symptoms of alcohol withdrawal 
Autonomic 
overactivity Gastrointestinal  
Cognitive and 
perceptual changes 
Sweating Anorexia Anxiety 
Tachycardia Nausea Vivid dreams 
Hypertension Vomiting Illusions 
Insomnia Dyspepsia Hallucinations 
Tremor  Delirium 
Fever   
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Seizures occur in about 5% of people withdrawing from 
alcohol. They occur early (usually 7–24 hours after the last 
drink), are grand mal in type (ie, generalised, not focal) and 
usually (though not always) occur as a single episode.  
Delirium tremens (“the DTs”) is the most severe form of 
alcohol withdrawal syndrome, and a medical emergency. It 
usually develops 2–5 days after stopping or significantly 
reducing alcohol consumption. The usual course is 3 days, 
but can be up to 14 days. Its clinical features are: 
! confusion and disorientation 
! extreme agitation or restlessness—the patient often 
requires restraining 
! gross tremor 
! autonomic instability (eg, fluctuations in blood 
pressure or pulse), disturbance of fluid balance and 
electrolytes, hyperthermia 
! paranoid ideation, typically of delusional intensity 
! distractibility and accentuated response to external 
stimuli 
! hallucinations affecting any of the senses, but typically 
visual (highly coloured, animal form). 
3.4 Monitoring 
Withdrawal scales provide a systematic measure of the 
severity of uncomplicated withdrawal by recording changes 
in the severity of clinical features over time.  
The Clinical Institute withdrawal assessment for alcohol —
revised version (CIWA-AR) has been shown to be a valid, 
reliable and a sensitive instrument for assessing the clinical 
course of simple alcohol withdrawal (see Appendix J). The 
Alcohol withdrawal scale (AWS) is a useful scale (see 
Appendix K), widely used in New South Wales. The use of 
either scale is supported.  
Withdrawal scales do not diagnose withdrawal. They 
are merely guides to the severity of an already diagnosed 
withdrawal syndrome. 
 
3.4.1 Routine observations during 
withdrawal 
If possible, regular and frequent observations are 
recommended, including: 
! temperature, pulse rate and blood pressure 
! CIWA-AR or AWS withdrawal scale 
! level of hydration. 
3.5 Treatment  
3.5.1 Supportive care 
Supportive care alone is often effective in minor alcohol 
withdrawal. 
See section 2.6.3 and Appendix H for more specific 
detail. 
3.5.2 Medication  
A long-acting benzodiazepine (diazepam) is the treatment 
of choice for alcohol withdrawal (Mayo-Smith 1997).  
 
Diazepam treatment is best used early in the course of 
alcohol withdrawal, to prevent progression to more severe 
withdrawal. The three most commonly used approaches 
are: 
! Diazepam loading, which involves giving a large dose 
on day 1, then no further diazepam (recommended for 
inpatient withdrawal) 
! Tapering dose regimens, where a predetermined dose 
of diazepam is administered in tapering doses over 2–
6 days (recommended for outpatient withdrawal) 
! Symptom-triggered sedation, where doses of 
diazepam are administered according to the severity of 
withdrawal symptoms. 
   Re-evaluate the patient regularly to ensure  
that it is alcohol withdrawal and not another 
underlying medical condition that is being 
monitored, particularly if the patient is not 
responding well to treatment. 
 Contraindications to diazepam include 
respiratory failure, significant liver impairment, 
possible head injury or cerebrovascular 
accident. In these situations, specialist 
consultation is essential. 
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Other symptomatic treatments 
For headache, consider paracetamol. 
For nausea or vomiting, consider metoclopramide 
(Maxolon) 10 mg every 4–6 hours or prochlorperazine 
(Stemetil) 5 mg every 4–6 hours orally or intramuscularly. 
Reduce the dose rate to 8 hourly as symptoms abate. 
For diarrhoea consider loperamide or Kaomagma. 
 
Control of medication in the outpatient setting 
It is optimal to supply only 24 hours of medication at a 
time, as self-medication presents a risk during alcohol 
withdrawal, particularly when there is minimal supervision. 
Inform patients of the risks of self-medication (eg, 
overdose, undiagnosed complications, failure to complete 
withdrawal). 
3.5.3 Preventing dehydration 
In some cases dehydration may be serious and require 
aggressive fluid replacement. 
! Assess and record nutritional intake, fluid intake and 
output. 
! Encourage oral rehydration. 
! Monitor carefully for signs of dehydration. 
In severe withdrawal: 
! Intravenous rehydration, 2–5 L per day may be 
required. 
! Monitor urea, electrolytes, liver function and 
creatinine. 
3.5.4 Routine prevention of Wernicke’s 
encephalopathy 
This acute neurological syndrome due to thiamine 
deficiency can complicate withdrawal or present in the 
continuing drinker. It is characterised by ataxia, 
ophthalmoplegia, nystagmus and global memory 
impairment. Untreated, it can progress to Korsakoff’s 
psychosis, which may result in permanent cognitive 
damage. It can be prevented in heavy or dependent 
alcohol users by good nutrition and by the early routine 
use of thiamine in all patients presenting to drug and 
alcohol clinical services.  
All people being treated for alcohol withdrawal should 
routinely receive prophylactic thiamine, 100 mg 
intravenously or intramuscularly on day 1 and then (unless 
contraindicated) a minimum of 100 mg orally daily. In 
suspected Wernicke’s, give 100 mg thiamine daily, 
intramuscularly or intravenously for three days and then 
switch to oral doses. 
 
3.5.5 Ambulatory withdrawal treatment 
Explain to the patient and the carer: 
! expected symptoms and course of withdrawal 
! possible complications, and measures that should be 
taken if complications do arise 
! the medication (diazepam) to be used, its side effects 
(mainly sedation) and the risks of combining it with 
alcohol (ie, incoordination, disinhibition, respiratory 
depression, impaired driving capacity). 
The standard therapeutic regimen involves regular and 
reducing doses of diazepam over 2–6 days. Diazepam 
should not normally continue past the sixth day. 
On the first morning, assess the patient for early 
withdrawal symptoms, intoxication, or alcohol 
consumption in the past 8 hours. Intoxication or alcohol 
consumption within the past 8 hours are contraindications 
to commencing treatment. Prescribe diazepam, to begin 
after the patient arrives home from attending the 
consultation.  
A medical practitioner or drug and alcohol nurse should 
see the patient each day for the first 3 or 4 days. 
Additional telephone contact in the first 1 or 2 days may 
be helpful. Tailor the diazepam dose to the patient’s needs 
— the aim is to control withdrawal symptoms without 
oversedation. 
The medical practitioner or drug and alcohol nurse should 
continue daily or second daily contact with the patient until 
withdrawal is completed. 
 
An example of a diazepam regimen for alcohol 
withdrawal in an ambulatory setting 
Days 1 diazepam 10 mg six hourly  
Day 2–3 diazepam 5–10 mg eight hourly 
Day 4 diazepam 5 mg morning and night 
Tapering doses may be required over the next 2 days. 
   Never give alcohol to relieve withdrawal 
symptoms. It is not a safe medication and its 
use falsely suggests that alcohol has clinical 
benefit for the patient. 
 Administer thiamine before giving glucose in 
any form. A carbohydrate load in the presence 
of thiamine deficiency risks precipitating 
Wernicke’s encephalopathy. 
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3.5.6 Treatment in a hospital or specialist 
residential setting 
Specialist residential settings are indicated when moderate 
or severe withdrawal is predicted, the patient has a past 
history of seizures, or the patient has multiple drug 
dependencies or other significant medical problems. 
Treatment in hospital is indicated when the patient has 
concurrent illness that increases the risks associated with 
withdrawal, or when there is a high risk of severe 
withdrawal complications. 
 
 
3.6 Special issues 
3.6.1 Seizures 
When there is a history of withdrawal seizures, early 
treatment with diazepam is indicated (either diazepam 
loading or 40 mg on day 1). 
Prophylactic treatment with anticonvulsants (eg, phenytoin, 
carbamazepine and sodium valproate) has no benefit in 
preventing alcohol withdrawal seizures. 
If a seizure occurs, medical assessment is required to 
exclude other contributing factors (eg, head injury, 
electrolyte disturbances or other medical conditions). 
3.6.2 Delirium tremens 
 
Delirium tremens is rare and is a diagnosis by exclusion, so 
before commencing treatment, screen for other factors 
contributing to delirium, in particular: 
! subdural haematoma 
! head injury 
! Wernicke’s encephalopathy 
! hepatic encephalopathy 
! hypoxia 
! sepsis 
! metabolic disturbances 
! intoxication with or withdrawal from other drugs. 
Major psychotic disorders can sometimes mimic this state. 
Management of established delirium tremens 
Patients in delirium tremens are mentally disordered, and it 
is not acceptable to allow them to sign themselves out of 
hospital.  
Sedation 
Sedation with benzodiazepines should be initiated, but is 
often insufficient to reverse delirium tremens.  
   Overview of alcohol withdrawal treatment for a 
specialist residential or hospital setting 
Diazepam loading regimen 
On development of withdrawal symptoms, initiate the 
diazepam loading: 20 mg initially, increasing to 80 mg over 
4–6 hours, or until patient is sedated (medical review 
required if dose required exceeds 80 mg). 
 
Symptom-triggered sedation 
Mild withdrawal (CIWA-AR score < 10; AWS score < 4): 
! Supportive care, observations 4-hourly. 
! If sedation necessary: 5–10 mg oral diazepam every 6–8 
hours for first 48 hours. 
Moderate withdrawal (CIWA-AR score 10–20; AWS score 5–
14): 
! Medical officer to assess. 
! If alcohol withdrawal confirmed: hourly observations; 
give 10–20 mg oral diazepam immediately; repeat 10 mg 
diazepam hourly or 10–20 mg every two hours until the 
patient achieves good symptom control (up to a total 
dose of 80 mg).  
! Repeat medical review after 80 mg of diazepam and if 
patient is not settling, consider olanzapine 5–10 mg. 
Severe withdrawal (CIWA-AR score > 20; AWS score > 14): 
! Urgent management. Give a loading dose. 
! Review more frequently until score falls. 
A rising score indicates a need for more aggressive 
management. 
 Delirium tremens is a medical emergency that 
requires hospital treatment (high dependency 
unit). 
PAGE 26 New South Wales drug and alcohol withdrawal clinical practice guidelines 
If patients will not or cannot take diazepam orally (20 mg 
hourly up to 80 mg total dose), use an intravenous 
midazolam infusion (5 mg bolus, then commence infusion 
at 2 mg/h, titrating rate of infusion against response). 
Midazolam infusion must be monitored either by a special 
nurse or in a high dependency unit. Intramuscular 
lorazepam 2 mg is an alternative to midazolam if no high 
dependency unit is available. Aim to have the patient in a 
state resembling light sleep, from which he or she can be 
readily aroused.  
Once loaded with benzodiazepines (either by intravenous 
infusion or oral diazepam), olanzapine 10 mg sublingually 
(wafer) is indicated if patient is not settled.  
Occasionally, patients need doses of diazepam greater than 
80 mg to achieve sedation. However, high doses of 
benzodiazepines can themselves produce a delirium, so 
specialist assessment and review is required.  
Thiamine 
Intravenous thiamine (100 mg) should be administered. 
Supportive management  
Supportive management includes: 
! intravenous fluid and electrolyte replacement, if 
required 
! restraints, if required (in line with local policy) 
! monitoring for infection or other medical problem. 
One-on-one nursing care may be required for a period to 
re-orient the patient. 
Hallucinations 
If treatment is required for hallucinations, the drug of first 
choice is diazepam. If hallucinations do not respond to 
diazepam alone, add olanzapine. 
If olanzapine is required: 
! The patient should already be receiving diazepam 
(which will reduce risks of seizures or dystonic 
reactions). 
! The starting dose may be between 5 mg and 10 mg, 
orally or buccally (wafer).  
! If there is no response and no undue side effects, an 
additional dose may be administered. 
! Doses are ordered as required and should be under 
constant review. 
3.6.3 Management of withdrawal with 
intercurrent illness 
Alcohol withdrawal is more difficult to manage in the 
presence of intercurrent illness. In particular, 
decompensated liver disease and respiratory disease can 
make management of withdrawal very difficult.  
Loading doses should not be used in patients with severe 
chronic airflow limitation. Benzodiazepines need to be 
used with caution, and with close monitoring, and if a high 
dependency unit is available, an intravenous midazolam 
infusion is the best way to control withdrawal. 
Alternatively, a short acting benzodiazepine such as 
temazepam or oxazepam may be used cautiously, with 
close monitoring of respiration.  
Drug withdrawal regimens have to be modified when the 
patient has severe liver disease. Long-acting 
benzodiazepines should not be administered to patients 
who have jaundice, ascites or hepatic encephalopathy. In 
these instances, oxazepam (which is renally excreted) may 
be used with caution. 
3.7 Continuing care  
Successful withdrawal management should not be seen as 
an end in itself. All individuals should be encouraged to 
consider the range of relevant options that exist to assist 
them in maintaining their abstinence or a more controlled 
drinking pattern. 
For general information on continuing care, see section 2.8. 
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4 Benzodiazepines 
Chapter summary 
! Benzodiazepine users, in general, may be classified either as having “therapeutic dependence” or as 
being “polydrug users”. 
! Therapeutic dependence is best managed by very slow withdrawal supervised by the patient’s general 
practitioner.  
! Polydrug dependence should not generally be managed by general practitioners, but should be 
referred to specialist services for assessment.  
! Benzodiazepine withdrawal is usually mild.  
! Withdrawal onset occurs 2–5 days after stopping, reaching a maximum on days 7–10, and usually 
abating by the end of the second or third week. The half-life of the benzodiazepine involved 
determines onset of symptoms. 
! Abrupt withdrawal after benzodiazepine treatment may result in 2 or 3 days of “rebound” anxiety and 
insomnia. The symptoms are generally the same as those for which benzodiazepines were initially 
prescribed. 
! The major complications are the development of delirium and seizures. The aim of withdrawal 
management is safety — ceasing benzodiazepines without delirium or seizures, rather than providing 
patients with asymptomatic withdrawal. 
! Withdrawal is best managed by having clear program rules, effective patient communication, 
stabilisation and progressive withdrawal with a long-acting benzodiazepine, dispensed daily with 
supervision to minimise diversion. 
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4.1 Use and effects of 
benzodiazepines 
Benzodiazepines are effective anxiolytic medications. They 
are also effective amnestic agents, especially in high doses. 
People using high doses may be seeking a combination of 
these effects to provide “emotional blockade” against 
previous psychological trauma.  
Benzodiazepines, especially at high doses, may have a 
disinhibitory effect. “Benzo binges” are a common 
antecedent of shoplifting and other crime and may have 
devastating effects for the individual. Episodes of rage and 
violence are rare.  
Tolerance of the different effects of benzodiazepines 
develops at different rates. For example, rapidly developing 
tolerance of the anticonvulsant effects explains why these 
drugs are not used for prophylactic treatment. Tolerance of 
the sedative effects begins after 2 or 3 days and is 
significant by 2–3 weeks.  
Isolated intoxication with benzodiazepines presents with: 
! sedation from which the individual may be roused in 
response to stimulation, but with rapid relapse when 
not stimulated 
! slurred speech and drooling 
! loss of balance and coordination (ataxia) often 
associated with stumbling (gait disturbance) 
! disinhibition. 
 
Absorption rates, half-life, and equivalent daily doses of common benzodiazepines* 
Generic name Trade name 
Time to peak 
concentration Elimination half life† Equivalent dose‡ 
Diazepam Antenex 
Ducene 
Valium 
Valpam 
30–90 min Biphasic:  
rapid phase half-life, 3 hours; 
elimination half-life, 20–48 hours 
5 mg 
Alprazolam Alprax 
Xanax 
Kalma 
1 hour 6–25 hours 0.5–1.0 mg 
Bromazepam Lexotan 0.5–4 hours 20 hours 3–6 mg 
Clobazam Frisium 1 – 4 hours 17–49 hours 10 mg 
Clonazepam Paxam 
Rivotril 
2–3 hours 22–54 hours 0.5 mg 
Flunitrazepam Hypnodorm 1–2 hours 20–30 hours 1–2 mg 
Lorazepam Ativan 2 hours 12–16 hours 1 mg 
Nitrazepam Alodorm 
Mogadon 
2 hours 16–48 hours 2.5–5 mg 
Oxazepam Alepam 
Murelax 
Serepax 
2–3 hours 4–15 hours 15–30 mg 
Temazepam Euhypnos 
Normison 
Temaze 
Temtabs 
30–60 minutes after tablets, 
2 hours after capsules 
5–15 hours 10–20 mg 
Triazolam Halcion 1–3 hours Biphasic:  
rapid phase half-life, 2.5–3.5 hours; 
elimination half-life, 6–9 hours 
0.25 mg 
Zolpidem Stilnox 0.5–3 hours 2.5 hours Not known 
*Based on manufacturer’s product information.  
†Elimination half-life: time for the plasma drug concentration to decrease by 50%.  
‡Equivalent dose: approximate dose equivalent to diazepam 5 mg. 
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4.2 Assessment issues specific to 
benzodiazepine-dependent 
patients 
 
The patient may be intoxicated on presentation, and this 
may affect his/her ability to provide and receive 
information. 
See Appendix B for a guide to managing intoxication and 
overdose. 
Assessment of intoxicated individuals should be restricted 
to ensuring safety. It is never appropriate to provide 
prescriptions or medications to people while they are 
intoxicated. 
4.2.1 Patterns of use 
The critical issue at assessment is to attempt to classify 
patients according to whether they are dependent on 
therapeutic doses of benzodiazepines, or are intermittent 
or regular high-dose benzodiazepine users (usually in the 
context of dependence on, or use of, multiple drugs).  
Therapeutic dependence 
Many people take prescribed benzodiazepines for many 
years, without dose escalation, prescribed from a single 
doctor or practice, usually for management of anxiety or 
insomnia. Although they do not appear to have marked 
problems in relation to benzodiazepine use, such patients 
often have great difficulty stopping. Withdrawal avoidance, 
and the return of the initial presenting symptoms (eg, 
insomnia) are the major reinforcers of continued use in this 
group.  
The risks associated with therapeutic dependence are 
poorly defined, although there have been suggestions that 
long-term use of benzodiazepines in the elderly is 
associated with an increased rate of cognitive decline that 
may mimic dementia, and an increased risk of falls and 
fractures. 
In this group, withdrawal may produce more distress and 
problems than continuing on a long-term stable dose. The 
benefits of attempting withdrawal need to be set against 
the risks of continued prescribing. If doctor and patient 
agree that an attempt to withdraw should be made, it 
should be undertaken very slowly. During this time, 
support is essential, with regular monitoring and review, 
advice on strategies for optimising sleep, and ways of 
controlling anxiety.  
Problems with multiple drug use and multiple 
prescribers 
Benzodiazepines are sought-after drugs among a group of 
mainly young people who use multiple drugs. There is a 
brisk black market for benzodiazepines in this group, and 
people often obtain prescriptions from multiple doctors. 
Up to 35% of people in the NSW Opioid Treatment 
Program take benzodiazepines regularly or intermittently. 
Prescribing benzodiazepines to polydrug users poses 
serious risks. Patients are often highly skilled at obtaining 
prescriptions, and present a range of plausible and 
compelling reasons why they should receive 
benzodiazepines — of which the most common is that 
they are benzodiazepine-dependent, and at risk of seizures 
if not prescribed benzodiazepines.  
 
In seeking to manage these patients, there is an invidious 
trade-off between the risks of trying to stabilise the patient 
by prescribing benzodiazepines (thereby placing patients at 
risk of overdose, prolonging the problem, and adding to 
the pool of black market drugs), or not intervening and 
placing the patient at risk of major withdrawal. There are 
no easy answers to the problem; clinical judgement must 
prevail. Clinical reasoning should be documented clearly. 
Other paths to benzodiazepine dependence 
Some people, not polydrug users, are prescribed 
benzodiazepines but rapidly escalate their use of these 
drugs, often obtaining scripts from multiple doctors, and 
taking doses equivalent  to more than 40 mg diazepam per 
day. In general, these patients, although they may use only 
benzodiazepines, should be managed in the same way as 
polydrug users. 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
 Prescription Shopping Information Service 
Doctors who are registered with the Health 
Insurance Commission’s Prescription Shopping 
Information Service can phone the service 
(http://www.medicareaustralia.gov.au/providers/ 
programs_services/pbs/prescription_shop.htm;  
1800 631 181) to find out if a patient has been 
identified under the prescription shopping project’s 
criteria, and obtain information on the amount and 
type of PBS medicine recently supplied to that 
patient. This can help to identify polydrug users. 
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Some patients, often older people with alcohol 
dependence, become dependent on benzodiazepines, 
sometimes prescribed initially for withdrawal management, 
but then continued indefinitely, usually at therapeutic 
doses, from a single prescriber or practice. Such patients 
require careful assessment over time to determine whether 
prescribing benzodiazepines is more beneficial or harmful. 
Prescribing benzodiazepines does not consistently protect 
against relapse to alcohol dependence, and should be 
stopped if the patient regularly relapses while taking 
benzodiazepines.  
Some people with past histories of multiple drug 
dependence appear to “evolve” into therapeutic 
benzodiazepine dependence, taking a stable, therapeutic 
dose from a single prescriber.  
A good principle in prescribing long-term benzodiazepines, 
when there is a history of other drug dependence, is that 
patients should be reviewed periodically by a medical 
practitioner to provide a second opinion (specialist if 
possible). This is important because patients often form 
close, dependent relationships with their doctors, making it 
harder for doctors to review and change treatment. 
4.3  Withdrawal 
4.3.1 Incidence of benzodiazepine 
withdrawal  
Patients vary in the rate of developing dependence. Few 
users of prescribed benzodiazepines become dependent 
with less than 3 months of use. With between 3 and 12 
months of use, 10%–20% of patients become dependent, 
rising to 20%–45% after more than a year of use.  
If low-dose therapy is continued longer than 6 weeks, 
tolerance and symptoms of withdrawal will affect 15%–
50% of patients.  
Abrupt withdrawal from high dose use (> 50 mg diazepam 
or equivalent per day) without withdrawal symptoms has 
been observed, but the incidence is unknown. High-dose 
use is more likely to produce withdrawal with more severe 
symptoms. 
4.3.2 Onset and duration of benzodiazepine 
withdrawal 
Onset occurs between 2–5 days after stopping, reaching a 
maximum on days 7–10, and usually abating by the end of 
the second or third week. Withdrawal may occur earlier or 
later depending on the half-life of the benzodiazepine 
involved. 
 
 
 
Adapted from Frank L, Pead J. New concepts in drug withdrawal: a resource 
handbook. ©1995 State of Victoria. Reproduced with permission. 
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4.3.3 Signs and symptoms of benzodiazepine 
withdrawal  
Most patients discontinuing benzodiazepines experience a 
degree of “rebound” anxiety and insomnia. Specific 
withdrawal symptoms are subjective, with few observable 
signs (see table below). In diagnosing withdrawal, the 
sequence of the emergence of symptoms, and the 
presence of symptoms such as perceptual abnormalities 
(visual, auditory, tactile) helps to diagnose benzodiazepine 
withdrawal.  
4.4 Monitoring 
Benzodiazepine withdrawal scales offer a systematic 
measure of the severity of withdrawal, but there is little 
research on their validity, reliability and predictive value. If 
used, they should only be a guide to complement clinical 
assessment. 
 
 
 
 
 
4.5 Treatment 
Generally, therapeutic dependence should be managed by 
the patient’s general practitioner.  
However, it is not recommended that general practitioners 
attempt to manage benzodiazepine withdrawal in 
polydrug users, or prescribe benzodiazepines for this 
group, even as a temporary measure. 
The general principles governing benzodiazepine 
prescribing in primary care settings are: 
! Do not prescribe for patients not known to you. 
! Do not prescribe benzodiazepines for polydrug users  
(if concerned, these patients can be referred for 
specialist assessment). 
! Do not prescribe benzodiazepines for patients on 
methadone or buprenorphine (refer to their 
prescriber). 
! If in any doubt about patients thought to have 
therapeutic dependence, register with the Doctor 
Shopping Information Service 
(http://www.medicareaustralia.gov.au/providers/ 
programs_services/pbs/prescription_shop.htm) and 
check whether they are obtaining prescriptions from 
other doctors. 
It is not a matter of urgency to prescribe benzodiazepines 
to manage withdrawal, as the onset of withdrawal 
symptoms tends to be delayed. The onset of 
benzodiazepine withdrawal is earlier, and symptoms are 
more severe, in people taking short half-life 
benzodiazepines. With longer acting drugs, withdrawal 
symptoms may begin as late as 7–10 days after 
discontinuing use.  
Signs and symptoms of benzodiazepine withdrawal 
Common  Less common  Uncommon  
Anxiety 
Insomnia 
Restlessness 
Agitation 
Irritability 
Poor concentration 
Poor memory 
Depression 
Muscle tension, aches and twitching 
Nightmares, agoraphobia 
Feelings of unreality 
Depersonalisation 
Panic attacks 
Nausea, dry retching, decreased appetite, weight loss, sweating, 
lethargy 
Increased sensory perception, aches and pains, headaches, 
palpitations, tremor, blurred vision 
Increased temperature, ataxia 
Gastrointestinal unrest 
Menstrual changes 
Delusions 
Paranoia 
Hallucinations 
Seizures 
Persistent tinnitus 
Confusion 
   Good assessment and clinical judgement 
remain the gold standard for guiding 
management and clinicians should not rely on 
withdrawal scale scores alone. 
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4.5.1 Treatment setting for benzodiazepine 
withdrawal 
An ambulatory setting is preferred except when: 
! the safety of the patient would be at risk (eg, 
documented history of seizures, alcohol dependence, 
or significant mental illness) 
! the patient reports very high doses of benzodiazepine 
use  
! the likelihood of a successful outcome is poor in an 
ambulatory setting (repeated inability to complete 
outpatient reductions, other drug use, unstable social 
environment)  
! the patient will not consider withdrawal in an 
ambulatory setting. 
Ambulatory withdrawal is most suitable for low-dose users, 
except when repeated attempts at withdrawal have failed. 
Ambulatory withdrawal is also suitable for high-dose users 
who have been stabilised on a reduction regimen. 
Specialist residential withdrawal should be considered for 
stabilising high-dose users on a reduction regimen, and for 
patients who use benzodiazepines in combination with 
alcohol, elderly people and patients with other illnesses 
(especially psychiatric disorders). 
General hospital withdrawal is rarely necessary, unless 
specialist withdrawal facilities are unavailable (eg, in a rural 
setting). 
4.5.2 Withdrawal management 
Withdrawal is best managed by: 
! establishing a good therapeutic relationship with the 
patient 
! initial stabilisation of dose (preferably with a long-
acting benzodiazepine) 
! gradual dose reduction. 
Flexibility is essential. The risks associated with trying 
various approaches and being adaptable to the patient’s 
withdrawal needs are low, and the advantages of 
developing an individualised treatment regimen are great. 
Withdrawal attenuation is usually achieved by the careful, 
flexible, tapered withdrawal of the drug.  
Generally there is a trade off between rapid withdrawal, 
with intense, relatively short-duration symptoms and 
slower withdrawal, with protracted, less intense symptoms. 
4.5.3 Unplanned withdrawal 
Patients in hospital for other reasons may undergo 
benzodiazepine withdrawal from even low doses of 
regular, long-term benzodiazepine use. This can be a 
particular problem in elderly patients, who may develop 
delirium due to benzodiazepine withdrawal. For 
hospitalised patients: 
! Take a history of benzodiazepine use. 
! Do not abruptly discontinue benzodiazepines, even at 
low doses, because of the risk in the sick and the 
elderly of precipitating withdrawal. Generally, maintain 
benzodiazepine use at preadmission levels for 
therapeutic dependence. Hospitalisation and sickness 
make a very poor context for initiating elective 
withdrawal. 
! Patients taking high doses, or polydrug users, should 
be stabilised on a long-acting benzodiazepine 
(preferably, diazepam), at a dose about 40% of their 
regular intake before admission (or 80 mg/day, 
whichever is lower). Reduction and withdrawal should 
follow once their other medical condition has been 
dealt with. 
4.5.4 Managing benzodiazepine withdrawal 
in polydrug dependent patients 
It is important at assessment to obtain a detailed history of 
benzodiazepine use, accepting that it may not be accurate. 
Overestimation is common. In assessing tolerance, many 
users will report levels of use associated with intoxication 
and sedation. This is far in excess of what is required to 
avoid withdrawal.  
Endeavour to find corroborative evidence (eg, hospital 
admissions with seizures) rather than accepting the history, 
and maintain awareness that in managing benzodiazepine 
dependence in the setting of polydrug use, safety (not 
symptoms) is the key. For every polydrug-using patient 
requesting benzodiazepines, the clinician must judge 
whether it is safer to prescribe or not prescribe. The 
important issue is not to add to the pool of benzodiazepine 
use. 
If withdrawal management is to be offered, it should be on 
an ambulatory basis. Sometimes, a brief period of 
admission for stabilisation may be helpful.  
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It is important to provide clear information that the aim of 
treatment is to produce stabilisation and progressive dose 
reduction safely; this does not mean patients will feel 
comfortable or asymptomatic. Switching to a long-acting 
benzodiazepine (usually diazepam) and using only one 
benzodiazepine are important steps to minimise risks 
during withdrawal. Patients may be adamant that shorter-
acting preparations are the only ones acceptable or 
efficacious. Clinicians should not support the ongoing 
prescription of these drugs, which contribute to more 
severe withdrawal, and are more likely to be misused and 
diverted.  
The medication should be supplied as tablets to be taken 
under supervision daily, not to be taken away. 
If patients stabilise on a dose in the range 40–80 mg of 
diazepam daily, withdrawal should be at the rate of at least 
5 mg per week until the dose reaches 40 mg, then 
2.5 mg/week. At this rate, reducing from 80 mg diazepam 
will take nearly 6 months. A maximal rate of withdrawal 
would be to reduce the dose by 10 mg at weekly intervals 
until 40 mg, then by 5 mg at weekly intervals. This will 
take 12 weeks.  
During withdrawal, patients should be monitored with 
clinical reviews and by checking the Doctor Shopping 
Information Service.  
 
4.6 Continuing care 
See section 2.8 for general advice on continuing care after 
withdrawal. 
 The experience of most clinicians is that few 
patients comply with treatment, and most 
continue to seek and obtain additional 
benzodiazepines. In this situation, there is no 
point continuing with “withdrawal” treatment; 
the treatment simply becomes part of the 
source of benzodiazepines. 
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5 Opioids 
Chapter summary 
! The onset and duration of withdrawal from opioids depends on the half-life of the drug being taken. 
For heroin, the onset of subjective symptoms of withdrawal is usually 6–24 hours after the last dose, 
reaches a peak at 24–48 hours, and resolves after 5-10 days. For methadone, onset is usually 36–48 
hours after the last dose. The peak severity of withdrawal from methadone tends to be considerably 
lower than for heroin withdrawal, but withdrawal is more prolonged, with a debilitating low-grade 
withdrawal lasting 3–6 weeks. 
! Daily review may include monitoring symptoms with the use of a withdrawal scale such as the Clinical 
Opioid Withdrawal Scale.  
! Buprenorphine is the principal treatment option for managing opioid withdrawal. It is preferable to 
commence buprenorphine dosing after the onset of withdrawal symptoms. 
! Many services using buprenorphine blur the distinction between withdrawal and maintenance, 
initiating buprenorphine for management of withdrawal, but allowing patients to continue with 
buprenorphine maintenance treatment. This effectively engages them in maintenance treatment. 
! Planned naltrexone-assisted opioid withdrawal is a validated and valuable treatment option for some 
patients. It should be conducted only in highly supervised specialist environments. 
! During the first week of treatment, treatment options after withdrawal should be discussed with the 
patient. These include abstinence with or without naltrexone assistance or residential support, or 
continuing with buprenorphine treatment. 
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5.1 Use and effects of opioid drugs  
Opioids that bind to receptors and activate them are 
referred to as “agonist” drugs (such as morphine and 
methadone), and those that bind to receptors but do not 
activate them are called “antagonists” (such as naloxone 
and naltrexone). Partial agonists (buprenorphine) bind to 
the same receptors but have less of an activation effect. 
Opioid agonist drugs have a range of pharmacological 
actions: 
! analgesia (particularly for relieving the affective 
component of pain) 
! a sense of well being (euphoria) 
! sedation 
! central nervous system depression, particularly 
respiratory depression (in high doses) 
! pupil constriction 
! reduced pulse and blood pressure. 
Administering opioids may produce side effects:  
! nausea and vomiting  
! constipation 
! increased sweating 
! decreased sexual function (impotence).  
 
 
Opioid drugs, with details of approximately equivalent doses 
Generic name Trade name Approximate dose (mg) 
Duration of 
analgesia (hours) Half life (hours) 
Buprenorphine hydrochloride Subutex/ Suboxone 0.3 4-8 20-73  
Codeine phosphate 
 
Codeine, 
Panadeine forte 
30-60 3-4 2-4 
Diacetylmorphine Heroin (converts to morphine) 4–5 2 
Fentanyl citrate Fentanyl  0.1 1-1.5 3-4 
Methadone 4–5hydrochloride Biodone forte 
Methadone syrup 
Physeptone 
10 4-6 15-60 
Morphine sulfate Morphine 
Kapanol 
MS Contin 
10 
10 
4-5 
4-5 
2 
2-4 
Oxycodone hydrochloride OxyContin 
Endone 
4.5 3-4 6.5 
Sources: Katzung BG (2006) Basic and Clinical Pharmacology, 9th Edition, The McGraw-Hill Companies [CIAP]; MIMS on-line (2006) 
[CIAP].
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5.2 Assessment issues specific to 
opioid-dependent patients 
 
5.2.1 Assessing opioid dependence 
The presence of opioid dependence as defined by DSM-IV 
indicates the likelihood of opioid withdrawal developing. 
The patient’s prior experience of withdrawal can indicate 
how severe withdrawal is likely to be. Heroin users may 
exaggerate their drug use or withdrawal severity out of 
anxiety and in the hope of receiving sufficient medication 
to alleviate expected symptoms. Therefore, history should 
be supplemented with physical examination, and with 
regular monitoring and review during withdrawal 
management.  
Heroin dosage estimates are difficult because of wide 
variations in the concentration and purity of illicit heroin. 
Consumption may be recorded as: 
! the number of injections per day 
! the number of grams ingested 
! dollars spent. 
Note that “street” usage patterns alter frequently. 
Approximate guide to a patient’s level of heroin use 
Low end 
! one to two injections per day, or 
! 0.5 g or less per day 
High end 
! four or more injections per day, or 
! 1–2 g or more per day. 
The patient may be intoxicated on presentation, and this 
may affect his/her ability to provide and receive 
information. 
See Appendix B for a guide to managing intoxication and 
overdose. 
Assessment of intoxicated individuals may be difficult, and 
assessment findings should be reviewed after signs of 
intoxication have abated. 
5.2.2 Unplanned withdrawal 
Patients in hospital, prison, or other institutional care may 
undergo unplanned opioid withdrawal. 
Patients may not always reveal their use of opioids. 
Indicators of the possibility of unplanned opioid withdrawal 
include: 
! “track marks” in the typical venous access sites 
! repeated requests for analgesia or specifically for 
opioid drugs, in excess of what would be expected 
from the patient’s clinical circumstances.  
 
Methadone or buprenorphine treatment may be required 
to prevent withdrawal while other medical or psychiatric 
disorders are managed. If so, consult a drug and alcohol 
specialist with experience in methadone or buprenorphine 
prescribing. 
5.3 Withdrawal 
5.3.1 Onset and duration of withdrawal 
Heroin is a relatively short-acting drug. Symptoms of 
withdrawal usually commence 6–24 hours after the last 
dose, reach a peak at 24–48 hours, and resolve after 5-10 
days.  
Withdrawal from a long-acting opioid such as methadone 
usually commences 36–48 hours after the last dose. The 
peak severity of withdrawal tends to be lower than for 
heroin withdrawal, but withdrawal may be more 
prolonged, lasting 3–6 weeks.  
The symptoms and signs of withdrawal from 
buprenorphine are similar to those found in withdrawal 
from other opioids, but withdrawal from buprenorphine is 
generally milder than withdrawal from methadone or 
heroin because of its slow dissociation from the " receptor. 
Symptoms commence generally within 3–5 days of the last 
dose and can last for several weeks 
Following acute withdrawal, protracted, low-grade 
symptoms of discomfort (psychological and physical) may 
last many months.  
 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
 Patients who are opioid tolerant are likely to 
require higher than usual doses of analgesic 
drugs to achieve reasonable levels of pain 
relief. 
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5.3.2 Signs and symptoms of opioid 
withdrawal 
 
Signs Symptoms 
Restlessness 
Yawning 
Perspiration 
Rhinorrhoea 
Dilated pupils 
Piloerection 
Muscle twitching (particularly 
restless legs while lying 
down) 
Vomiting 
Diarrhoea  
Anorexia and nausea 
Abdominal pain 
Hot and cold flushes 
Bone, joint and muscle pain 
Insomnia and disturbed sleep 
Cramps 
Intense craving for opioids 
5.3.3 Monitoring 
Patients should be monitored regularly, and this may 
include use of a withdrawal scale. The frequency of 
observations should be determined by the severity of the 
withdrawal.  
Monitoring should be clinically based on observations, 
objective signs and subjective symptoms.  
 
5.3.4 Withdrawal scales 
The Clinical Opiate Withdrawal Scale (COWS) (see 
Appendix L) rates 11 items describing severity of 
symptoms from scores of 0 (not present) to >36 (severe). 
The COWS is considered a reliable and valid withdrawal 
scale. 
The Subjective Opiate Withdrawal Scale (SOWS) (see 
Appendix M) rates 16 items from 0 to 64 and is used in 
some clinical units.  
 
 Withdrawal scales do not diagnose withdrawal, 
but are merely guides to the severity of an 
already diagnosed withdrawal syndrome. 
Re-evaluate the patient regularly to ensure that it is 
opioid withdrawal and not another underlying 
medical condition that is being monitored, 
particularly if the patient is not responding well to 
treatment. 
 
 
 
Adapted from NSW Department of Health. NSW detoxification clinical 
practice guidelines. © 1999 NSW Department of Health. Reproduced with 
permission. 
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5.4 Treatment 
5.4.1 The regulatory context of treatment of 
addiction 
 
   In Australia, it is not legal to prescribe Schedule 
8 drugs (drugs of addiction such as morphine) 
to anyone who is a known addict for the 
purposes of treating addiction without an 
individual authority to prescribe from a state 
health department.  
 
In hospital settings, doctors may use methadone or 
buprenorphine as part of management of opioid-
dependent individuals hospitalised with medical problems. 
Outside hospital, methadone and buprenorphine may only 
be used in the treatment of opioid dependence by medical 
practitioners authorised to deliver this treatment. 
5.4.2 Treatment planning 
Treatment planning should: 
! address the patient’s reasons for seeking treatment, 
social setting, and expectations about withdrawal 
! identify short and long-term goals of treatment  
! establish a pattern of monitoring and review of 
progress 
! include regular review of the patient’s objectives, 
which may change during the course of withdrawal.  
5.4.3 Key elements of opioid withdrawal 
treatment 
Information 
People who use illicit drugs often possess a great deal of 
information about drug use, withdrawal and treatment. 
Much of this knowledge results from their own experience 
and deserves to be respected, but some reflects 
misinformation and misunderstanding. This misinformation 
may concern the nature and course of withdrawal, its 
severity, the effectiveness of treatments, and especially the 
response of health professionals to illicit drug users. These 
beliefs need to be elicited and responded to with objective 
information. 
Support 
An empathic, non-judgemental approach from healthcare 
providers and an encouraging and supportive attitude 
during withdrawal are essential. For details on supportive 
care, see section 2.6.3. 
Preventing dehydration 
In untreated or inadequately treated opioid withdrawal, 
there may be fluid loss due to sweating, vomiting and 
diarrhoea. In some cases dehydration may be serious and 
require aggressive fluid replacement. 
Medication 
Various pharmacological options can be used to treat  
opioid withdrawal. Medication is unlikely to entirely relieve 
the symptoms of withdrawal, but can be used to reduce 
the patient’s discomfort. Medications are detailed in the 
following sections. 
5.4.4 Buprenorphine 
Buprenorphine is the principal treatment option for 
managing opioid withdrawal. It relieves symptom severity 
in opioid withdrawal so that other symptomatic medication 
is not usually required.  
Buprenorphine can precipitate withdrawal in someone who 
has recently used heroin (in the previous 12 hours) or 
methadone (in the previous 48 hours). Give 4-6 mg of 
buprenorphine as the first dose. Review the patient 3–4 
hours after the first dose. If the patient is experiencing no 
increase in withdrawal severity and is still reporting 
withdrawal, give another 2–4 mg of buprenorphine. 
 
 If using a withdrawal scale as part of patient 
assessment:  
! treatment should not begin until a COWS score of 
at least 8 (representing the mid point of the scale, 
see Appendix L) or a SOWS score of 16–25 
(representing mild to more moderate withdrawal, 
see Appendix M). 
 
Combined use of other sedative substances (eg, 
benzodiazepines, opioids, alcohol, and tricyclic 
antidepressants) with buprenorphine can be extremely 
dangerous and may result in respiratory depression, coma 
and death.  
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If a patient is aged 16 or 17 years, a second opinion is 
required before authority to prescribe buprenorphine can 
be granted. A second opinion must be obtained from a 
drug and alcohol specialist in the local drug and alcohol 
service and be documented. Prescribing buprenorphine to 
patients less than 16 years of age requires an exemption to 
the provisions of the Children and Young Persons (Care 
and Protection) Act 1998. The request for an exemption 
should include a second opinion from a drug and alcohol 
medical specialist nominated by the Area Health Service 
and a written application must be made as per the 
protocol in New South Wales Opioid Treatment Program: 
clinical guidelines for methadone and buprenorphine 
treatment (NSW Department of Health GL2006_019 2006, 
page 22).  
Pain management and use of buprenorphine 
Buprenorphine binds strongly with opioid receptors and 
there is a theoretical risk that it may interfere with the 
effectiveness of other opioids prescribed for pain relief. See 
New South Wales Opioid Treatment Program: clinical 
guidelines for methadone and buprenorphine treatment 
(NSW Department of Health GL2006_019 2006) for further 
information. 
Outpatient management 
The recommended duration of buprenorphine treatment 
for heroin withdrawal is 4–8 days (see table below). If 
patients choose to continue buprenorphine, this should be 
done as maintenance treatment. 
Example buprenorphine regimen 
Suggested regimen 
Recommended  
lower and upper limits 
Day 1 6 mg 4–8 mg 
Day 2 8 mg 4–12 mg  
Day 3 10 mg  4–16 mg  
Day 4 8 mg 2–12 mg  
Day 5 4 mg 0–8 mg 
Day 6 0 0–4 mg 
Day 7 0 0–2 mg 
Day 8 0 0–1 mg 
 
Patients should be reviewed daily by an experienced health 
professional during the first few days of a withdrawal 
regimen. This is important for adjusting doses if necessary 
and to ensure provision of supportive care. 
Flexibility of dosing is recommended, and doses should be 
titrated to meet the severity of withdrawal symptoms. An 
initial dose of 4 mg or less will minimise precipitated 
withdrawal. Further doses can be administered after 4 
hours and should be guided by patient symptoms. 
Inpatient management 
Fixed regimens can be negotiated for inpatient areas where 
staff do not have experience in managing opioid 
withdrawal. More flexible regimens (with orders for 
additional doses as required) may be used where staff have 
suitable expertise. In both cases, multiple small doses (eg, 
2 mg) can be administered throughout the day (see table 
above for upper and lower dose limits). 
5.4.5 Symptomatic treatments 
Medication of symptoms and supportive care are often 
sufficient in treating mild withdrawal (see table of 
symptomatic treatments below). Adjunctive therapies (such 
as hot baths) are also helpful. 
Clonidine 
Clonidine may be prescribed for treatment of symptoms 
such as sweating and agitation.  
Before administering clonidine: 
! Take baseline blood pressure and heart rate 
measurements before first dose. 
! Do not use clonidine if: 
— patient is hypotensive (ie, blood pressure is less than 
systolic 90 mmHg or diastolic 50 mmHg) 
— heart rate is less than 50 per minute 
— there is clinical evidence of impaired circulation. 
Initial test dose: 
! Administer 75 µg test dose and monitor for 
hypotension after half an hour. Measure the patient’s 
blood pressure lying and standing. If hypotensive, 
clonidine is not recommended. 
! If no hypotension occurs, and dizziness or other side 
effects of clonidine are not a problem, give a second 
75 "g dose and continue treatment as shown in the 
table of symptomatic treatments. 
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5.4.6 Naltrexone  
Planned naltrexone-assisted opioid withdrawal is a 
validated and valuable treatment option for some patients. 
It should be conducted only in highly supervised specialist 
environments. 
A Code of professional conduct for rapid detoxification in 
an unlicensed setting has been approved by the NSW 
Minister for Health. The Code sets out the minimum 
standards of care to be observed by medical practitioners 
using opioid antagonists to accelerate withdrawal from 
opioid drugs in an unlicensed setting. The Code can be 
viewed at the NSW Medical Board’s website 
<www.nswmb.org.au>. 
5.5 Special issues 
5.5.1 Pregnancy and breastfeeding 
The preferred treatment of pregnant opioid users is 
methadone maintenance (withdrawal presents risks to the 
fetus and requires specialist management if it is to be 
attempted). Managing withdrawal in pregnancy is beyond 
the scope of these guidelines. If possible, specialist 
obstetric and drug and alcohol input should be sought. 
Patients (including those on methadone maintenance 
treatment) are encouraged to breastfeed in conjunction 
with appropriate postnatal support. 
5.6 Continuing care 
During the first week of treatment, post-withdrawal 
management options should be discussed with the patient. 
These include abstinence with or without naltrexone 
assistance or residential support, or continuation on 
buprenorphine treatment.  
5.6.1 Transfer to naltrexone 
Patients who have completed withdrawal can begin taking  
naltrexone 48 hours after ceasing buprenorphine. Some 
patients have a reasonably uneventful induction onto 
naltrexone; others experience considerable distress. It is 
best to warn prospective patients to expect symptoms. It 
may be useful to prescribe symptomatic medication for the 
24 hours after induction or in the event of precipitated 
withdrawal. 
If patients have used heroin during withdrawal before 
induction onto naltrexone, symptoms of withdrawal may 
be more severe. The history provided should be combined 
with the physical presentation of the patient (evidence of 
intoxication, recent use or withdrawal) to make a clinical 
judgement on the commencement of naltrexone. 
 
 Under circumstances where there is any doubt, 
a naloxone test before the first dose of 
naltrexone may be useful. 
 
The first dose of naltrexone should not exceed 12.5 mg. 
Patients should be observed for 3 hours, warned of 
possible delayed withdrawal, and reviewed on the next 
day. For the next 2 days, they should receive 25 mg per 
day, and thereafter 50 mg per day as tolerated. 
Symptomatic treatments 
Symptoms Suggested treatments 
Muscle 
aches/pains 
Paracetamol 1000 mg, every 4 hours as 
required (maximum 4000 mg in 24 hours) or 
Ibuprofen 400 mg every 6 hours as required (if 
no history of peptic ulcer or gastritis). 
Nausea Metoclopramide 10 mg, every 4–6 hours as 
required or 
Prochlorperazine 5 mg, every 4–6 hours as 
required. 
Second line treatment for severe 
nausea/vomiting: ondansetron 4–8 mg, every 
12 hours as required. 
Abdominal 
cramps 
Hyoscine 20 mg, every 6 hours as required. 
Second line treatment for continued severe 
gastrointestinal symptoms (for use in a 
hospital setting only): octreotide 0.05–0.1 mg, 
every 8–12 hours as required by subcutaneous 
injection.  
Diarrhoea Kaomagma or loperamide 2 mg as required. 
Sleeplessness Temazepam 10–20 mg at night. Cease the 
dose after 3–5 nights. 
Agitation or 
anxiety 
Diazepam 5 mg four times daily as needed. 
Restless legs Diazepam (as above) or baclofen 10–25 mg 
every 8 hours. 
Sweating, 
sedating 
agitation 
Clonidine 75 µg every 6 hours 
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The routine use of naltrexone implants has not been 
approved in Australia. Results from studies in this country 
are awaited.  
5.6.2 Post-withdrawal management 
Post-withdrawal management services include Narcotics 
Anonymous, outpatient programs, counselling and 
residential services. A variety of outpatient services may 
also be combined with naltrexone maintenance. 
It is important to link to these services in a timely manner, 
minimising the period from completing withdrawal to 
engaging in continuing treatment. In particular, organising 
direct transfer from a residential withdrawal setting to a 
longer term residential service is desirable for patients who 
have decided on continuing residential treatment. 
See section 2.8 for more information on continuing care. 
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6 Cannabis 
Chapter summary 
! Commonly reported symptoms of cannabis withdrawal are anger or aggression, decreased appetite, 
irritability, nervousness or anxiety, restlessness and sleep difficulties including strange dreams. Less 
common symptoms include chills, depressed mood, stomach pain, shakiness and sweating.  
! The general management approach for cannabis withdrawal should be supportive counselling, 
accurate information and appropriate planning. 
! No specific pharmacotherapies have proven utility in managing cannabis withdrawal.  
! Premorbid tendencies toward aggression and violence appear to predict particularly problematic and 
clinically significant exacerbation of symptoms.  
! Tobacco smoking predicts a poorer outcome for cannabis smokers. Concomitant treatment for 
nicotine withdrawal should assist. 
! Underlying psychiatric illnesses or symptoms may be unmasked during withdrawal, and particular 
attention should be paid to patients with comorbid disorders (especially bipolar illness), and patients 
with other severe mood and psychotic disorders. 
! Post-withdrawal interventions should be used, such as motivational enhancement, relapse prevention, 
cognitive behavioural therapies, other psychosocial interventions and self-help groups.  
New South Wales drug and alcohol withdrawal clinical practice guidelines PAGE 43 
6.1 Use and effects of cannabis 
Positive effects of cannabis include quiet euphoria, feeling 
“mellow” and content. There can be sensory 
intensification and occasionally illusions or distortion, 
although frank hallucinations are rare, occurring 
occasionally after very high doses or after the use of oral 
preparations or potent strains.  
Adverse effects include paranoia, anxiety, depression and 
sedation. Users may experience an increased appetite. 
Sedation occurs at higher doses and is used to aid sleep by 
many smokers. 
Cannabis may be smoked, often with tobacco, or taken 
orally. In NSW, the use of “bongs” (water pipes) is 
particularly common. The user packs the cannabis (with or 
without tobacco) into a cone-shaped metal bowl, hence 
the term “smoking a cone” (see section 2.3.5).  
One “joint” (cannabis cigarette) is equivalent in terms of 
tar to about 3–4 cigarettes. Cannabis contains as many 
carcinogens as tobacco, deposits a third more tar and is 
thought to be a risk factor for oropharyngeal and lung 
cancer as well as coronary heart disease.  
Because cannabis can affect physical coordination and 
reaction time and result in perceptual distortions, 
confusion and short-term memory loss, driving and other 
manual tasks may be impaired. 
6.2 Assessment issues specific to 
cannabis-dependent patients 
 
Cannabis  
Identify as accurately as possible: 
! the way in which the drug is consumed 
! the frequency of use 
! the amount spent per day on cannabis. 
Users will usually be able to report how many grams (10-
15 cones/gram, more if “mulled” or “spun” with tobacco) 
they smoke per day. Smoking marijuana cigarettes (rolled 
with or without tobacco) commonly known as “joints” or 
“spliffs” is another common mode of use. Heavy users can 
smoke more than 1 ounce / 28 grams) a week. 
The patient may be intoxicated on presentation, and this 
may affect his/her ability to provide and receive 
information. 
See Appendix B for a guide to managing intoxication and 
overdose. 
Assessment of intoxicated individuals is difficult but should 
be pursued as far as is possible. Assessment findings may 
be reviewed after signs of intoxication have abated. 
6.3 Withdrawal 
6.3.1 Onset and duration of cannabis 
withdrawal 
Most symptoms commence on day 1, peaking at day 2–3, 
returning to baseline after a week or two. However, there 
is temporal variation in the profile of specific symptoms, 
with the late onset of aggression (day 4) and anger (day 6) 
being particularly significant, with the former often 
peaking after 2 weeks of abstinence.  
6.3.2 Symptoms of cannabis withdrawal 
Clinical studies suggest that 50%–75% of dependent 
cannabis users will experience four or more symptoms, 
with sleep disturbance, reduced appetite, irritability, anger 
and aggressiveness occurring in at least 40%. 
 
Symptoms of cannabis withdrawal 
Common symptoms 
Less common 
symptoms/equivocal 
symptoms 
Anger or aggression 
Decreased appetite or weight loss 
Irritability 
Nervousness/anxiety 
Restlessness 
Sleep difficulties, including strange 
dreams 
Chills 
Depressed mood 
Stomach pain 
Shakiness 
Sweating 
 
 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
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6.3.3 Factors contributing to withdrawal 
severity 
Variables affecting withdrawal include: 
! psychiatric comorbidity 
! dose: amount and potency of preparation consumed 
! history of aggression or violence 
! setting: outpatient withdrawal is more severe than 
inpatient withdrawal 
! population: more severe in treatment seekers 
! duration of current use 
! rate of withdrawal 
! comorbid substance use 
! past or current substance use history. 
6.3.4 Monitoring withdrawal 
Assessment of withdrawal may be assisted by the use of a 
standardised withdrawal assessment scale or by direct 
questioning. The Clinician Cannabis Withdrawal Chart can 
be found in Appendix N. It is not a validated tool but can 
be useful for clinical practice. 
6.3.5 Urine drug screening 
Urine drug screening for the inactive cannabis metabolite 
(11-hydroxy-THC) can be supportive of cessation, and may 
be indicated as part of contingency management, positive 
feedback, or as a condition of a court diversion program.  
Creatinine/cannabis ratios fall rapidly with cessation and, 
although it may take up to 12 weeks of abstinence to 
attain clean urine in chronic smokers, reductions in urinary 
concentration may support self-report.  
6.4 Treatment 
 
When planning for cannabis withdrawal, therapists should 
take note of impending crises, current psychosocial 
stressors, likely triggers, paraphernalia, contact with 
users/dealers, and so on. The use of self-help booklets can 
be helpful, such as: 
! Mulling it over 
<http://www.adf.org.au/store/article.asp?ContentID=p
roduct_33212> 
 
 
 The default management approach for 
cannabis withdrawal should be supportive 
counselling, accurate information and 
appropriate planning. 
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! Quitting cannabis? Client booklet and clinician 
guidelines 
<http://ndarc.med.unsw.edu.au/ndarcweb.nsf/page/ 
resources#quitting> 
For individuals likely to receive medication, the dosing 
schedule, duration of treatment and possible side effects 
should be explained and written information should be 
provided.  
6.4.1 Indications for inpatient cannabis 
withdrawal 
When attempts at outpatient-supported withdrawal have 
been repeatedly unsuccessful, or where there are 
compelling psychosocial indications, admission for 1–2 
weeks of inpatient withdrawal may be warranted. Often 
this will be as much for removal of the patient from a 
source of the drug and psychosocial support as it is to 
monitor and medicate withdrawal.  
Inpatient withdrawal from cannabis may be indicated if: 
! Repeated outpatient attempts have proved 
unsuccessful. 
! The patient has significant mental health problems (eg, 
schizophrenia, bipolar disorder). If there is doubt over 
the existence of co-existing psychopathology, a period 
of confirmed abstinence with observation and 
monitoring within an inpatient unit may assist in 
assessment and diagnosis. 
! The patient has a history of severe premorbid 
aggression or violence, especially if previous 
withdrawal attempts have been associated with an 
exacerbation of such symptoms. This is particularly 
important if others sharing the user’s home (especially 
children) may be placed at risk during the withdrawal 
period. It may be appropriate with some patients to 
conduct a formal risk assessment to determine the 
most appropriate setting for management.  
! The patient has polydrug dependence, where 
complicated withdrawal may be expected. 
6.4.2 Pharmacotherapies 
There are no specific pharmacotherapies that have proven 
utility in managing cannabis withdrawal or maintaining 
abstinence. Although most clinical practice involves the use 
of benzodiazepines, there are no controlled studies 
assessing the efficacy of this practice.  
Users should refrain from caffeinated drinks during the 
withdrawal period, as they may increase restlessness, 
irritation and insomnia. 
Based on the limited literature available, the table below 
presents options that may be chosen on the basis of 
physician and patient preference, safety and supervision 
issues, contraindications and particular symptom profile.  
Medications to consider for different symptom 
clusters in cannabis withdrawal 
Symptom Medication 
Sleep problems benzodiazepines, zolpidem, zopiclone, 
promethazine  
Restlessness, 
anxiety, 
irritability 
diazepam  
Stomach pains hyoscine (Buscopan), atrobel 
Physical pain, 
headaches 
paracetamol, non-steroidal 
anti-inflammatory agents 
Nausea promethazine, metoclopramide 
6.4.3 Symptomatic relief by symptom cluster 
Given the wide interpersonal variability in the response to 
cannabis withdrawal, dosages and prescribing schedules 
for symptomatic relief will most effectively be decided 
upon only after thoroughly exploring the individual 
patient’s symptom profile and circumstances.  
Outpatient regimens might be: 
! 7 days of diazepam 5 mg four times daily, zopiclone 
7.5 mg at night, NSAIDs/buscopan as needed; or 
! 7 days of zolpidem 7.5 mg at night. 
Inpatient regimens should not use other medication types, 
but there may be a need to use higher doses of selected 
pharmacotherapies, administered for a longer period. 
Regular patient contact and monitoring, either via clinic 
visits or telephone, can be useful in adjusting drug 
selection and dose. Monitoring should continue when 
withdrawal is complete and medication ceases, to identify 
any psychiatric symptoms that were previously masked or 
latent. Routine outpatient follow-up during the first 2–4 
weeks should be offered.  
6.4.4 Psychosocial management, including 
dose tapering 
Many users will be able to stop smoking abruptly without 
experiencing significant withdrawal. Two specific cannabis 
reduction strategies are: 
! sudden cessation, with or without symptomatic relief 
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! gradual dose reduction through use of diaries and in 
combination with an evidence-based psychological 
intervention (the need for symptomatic relief may be 
reduced). 
Clinical experience suggests that, if the user is able to exert 
some control over the level of use (perhaps supported by a 
family member), a gradual tapering of consumption can 
significantly reduce the severity of withdrawal. It may be 
the only intervention required in some users, and may 
negate the need for psychotropic medication.  
With these complementary strategies in mind, it is possible 
to offer patients a choice of methods for getting through 
any withdrawal they might experience. Depending on 
precise patient characteristics and other clinical imperatives 
(eg, acute psychotic episode), the patient, clinician or carer 
may express a preference. Where pain is an issue, a more 
gradual reduction is advisable to ensure that adequate 
alternative analgesia is in place before cessation.  
 
Even if such approaches do not lead to abstinence, they 
support the user in reducing or controlling intake and are 
useful harm reduction interventions. 
Gradual reduction in daily use 
Suggestions to assist in the gradual taper of cannabis use 
may involve one or more of the following strategies:  
! Reducing the number of bongs or joints each day, to 
reduce total daily consumption of cannabis. 
! Gradually lengthening the time after waking to the 
first use of cannabis is a good way to develop a short-
term drop in tolerance. It also permits the opportunity 
for the user to take part in some non-drug reinforcing 
activity, preferably one incompatible with smoking or 
other substance use such as exercise (eg, walking, 
running).  
! Gradually reducing either cone size or cone strength, 
to reduce the amount consumed from each bong. 
! For joint smokers, alternative reduction techniques can 
be used, such as rolling smaller joints or weaker joints, 
or not smoking the whole joint at once.  
! Having an agreed dose reduction schedule (most users 
should aim to reduce to zero over 1–4 weeks) 
Family support 
The family or carers should be educated about the clinical 
picture of cannabis withdrawal, the purpose, side effects 
and doses of any prescribed medications, and advice on 
how to avoid exacerbating withdrawal. They may help in 
controlling access to cannabis (eg, rationing), although this 
is only likely to be effective if requested by the user. Safety 
is a key issue, especially among young men with a history 
of violence/aggression. In such cases, a risk assessment 
should be conducted. Cannabis withdrawal requires 
supportive management if young children or women may 
be at risk.  
Self-help booklets 
There is a wide range of excellent self-help books to assist 
in the management of cannabis use disorders.  
6.5 Special issues 
6.5.1 Premorbidly aggressive and prison 
populations 
In people with histories of aggression or severe withdrawal, 
closer monitoring and support should be provided, with 
particular attention to the withdrawal environment and 
individual’s circumstances. Inpatient admission may 
occasionally be appropriate.  
Cannabis withdrawal within gaols or young offenders’ 
institutions has anecdotally been associated with increased 
levels of aggression and violence. Health service providers 
to correctional facilities may wish to consider the potential 
effect of cannabis withdrawal on health and safety.  
6.5.2 Pregnancy 
Research findings on the effects of maternal cannabis 
consumption on fetal development, perinatal outcome and 
childhood development are inconsistent, but do not appear 
to suggest that use through pregnancy is a significant 
teratogen or cause of significant infant mortality.  
Cannabis use may be a marker for other more significant 
substance use, and if consumed with tobacco, carries the 
risks of intrauterine growth retardation and prematurity.  
Pregnant women should be strongly advised to stop and 
be supported using the minimum of medication.  
   Patients should be provided with a choice of 
intervention strategies and their preference 
should be strongly supported unless clinically 
contraindicated. 
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6.5.3 Pain 
Some people with chronic pain syndromes frequently use 
cannabis. Cannabis is an effective adjunctive analgesic with 
particular benefits for people with chronic pain or 
musculoskeletal/spasm/arthritic disorders such as multiple 
sclerosis. In these patients, careful consideration needs to 
be given to providing alternative analgesia before reducing 
cannabis use.  
6.5.4 Young people 
Dependent use of cannabis by people younger than 16 
years often exists as one of many problems experienced by 
the child. The absence of protective factors, co-existing 
family discord, poor school attainment, social exclusion, 
and childhood psychiatric disorder (eg, conduct disorder, 
post traumatic stress disorder, and attention deficit 
hyperactivity disorder) are likely to compound the problems 
associated with cannabis dependence and withdrawal.  
Non-confrontational approaches using motivational 
interviewing should be used, with family support where 
available and appropriate. Medication should be avoided. 
Admission to adult inpatient units should be avoided. 
Inpatient admission should be to a specialist adolescent 
unit within or supported by a drug and alcohol service. 
6.5.5 Comorbid psychiatric conditions 
Underlying psychiatric illnesses or symptoms may be 
unmasked during withdrawal, and particular attention 
should be paid to patients with comorbid disorders, 
especially bipolar illness (where sudden cessation can be 
associated with manic relapse), and in patients with other 
severe mood and psychotic disorders (where cessation can 
also lead to decompensation). In such instances, inpatient 
admission may be appropriate. Assessment after 
withdrawal may permit the accurate diagnosis and 
appropriate treatment of pre-existing psychiatric disorders. 
Frequent disorders reported in association with cannabis 
include depression, anxiety, paranoia and 
depersonalisation. 
Among patients receiving drug treatment for psychotic 
disorders, use of cannabis may be associated with 
antagonism of neuroleptic effect, reduced compliance and 
higher doses. These patients should be engaged in a 
planned intervention around their cannabis use. Key 
approaches include harm reduction advice, motivational 
interviewing and, particularly, compliance therapy, a 
variant on motivational enhancement therapy that has 
been shown to increase compliance and improve outcome 
among those prescribed antipsychotic medication.  
6.6 Continuing care  
There are no specific continuing care strategies for 
cannabis dependence once abstinence or a desired 
reduction in use has been attained. Standard interventions 
aimed at reducing relapses and sustaining motivation 
should be used.  
Supportive group programs may be useful for some.  
For general information on continuing care after 
withdrawal, see section 2.8. 
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7 Psychostimulants (amphetamines, cocaine and ecstasy) 
Chapter summary 
! Mental state symptoms such as paranoia, delusions or perceptual disturbances are common among 
stimulant users seeking treatment. Signs and symptoms can fluctuate with time. A formal mental state 
examination of all patients presenting with a history of stimulant use and a suicide risk assessment 
should be conducted (see section  2.3.12) 
! Withdrawal typically occurs in three phases. The crash phase commences as stimulants wear off, and 
can last for several days. Key features include fatigue, flat affect, increased sleep and reduced cravings. 
The withdrawal phase typically commences 2–4 days after last amphetamine use and 1–2 days after 
last cocaine use. Features are predominantly psychological, with fluctuating mood and energy levels, 
cravings, disturbed sleep, and poor concentration. Withdrawal features gradually subside during the 
extinction phase, which lasts from weeks to months.  
! Withdrawal from stimulant drugs is not medically dangerous, and no specific treatment has been 
shown to be effective. The usual objectives in treating stimulant withdrawal are to assist the patient to 
interrupt a period or pattern of compulsive use, to identify and manage comorbid conditions and to 
initiate relapse prevention treatment. 
! The role of medication in managing cocaine or amphetamine withdrawal is unclear. At present, there 
is no specific medication schedule recommended for treating this condition. 
! The protracted extinction phase of stimulant withdrawal requires integration between withdrawal 
services and post-withdrawal services. 
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7.1 Use and effects of 
psychostimulants 
Psychostimulants are a group of drugs including 
amphetamines, cocaine and ecstasy (MDMA). 
The term “amphetamine” includes the three types of 
amphetamines: amphetamine, dexamphetamine and 
methamphetamine. Most illicit drugs bought as speed or 
amphetamines are likely to be methamphetamine. 
Speed is a powder form of amphetamine or 
methamphetamine. It is produced in different colours and 
ranges in texture from fine granules to coarse crystals. It is 
the weakest form of illicit amphetamines and is usually 
injected, snorted or swallowed. 
Base is an oily, waxy, sticky form of methamphetamine 
coming in a moist paste or damp powder. There is also a 
liquid form called ‘ox blood’. It is high purity freebase and 
stronger in purity than speed and is normally swallowed or 
smoked. 
Ice is the strongest form of methamphetamine. It either 
comes as a crystalline powder or crystals and is white or 
translucent. It is the highest purity form of 
methamphetamine and is usually smoked or injected.  
Cocaine is a white crystalline powder and it is snorted, 
injected or swallowed. Crack cocaine, which is smoked, 
has been reported in Australia. Use of cocaine is relatively 
uncommon in Australia at present. 
Ecstasy (methylenedioxymethamphetamine) is readily 
available in NSW and is ingested generally in a tablet form. 
Tablets may contain a range of drugs often including 
methamphetamine. 
A range of psychostimulants are available for the treatment 
of various conditions. These may also be used non-
medically or illicitly. These include methylphenidate 
(tradename Ritalin), diethylphenidate (Tenuate), 
phentermine (Duramine), ephedrine and pseudoephedrine 
(Dimetapp, Sudafed, Benadryl and Sinutab). 
Psychosis in amphetamine users has increased over recent 
years reflecting increased use and availability of 
methamphetamine. To date, no pharmacological treatment 
managing this psychosis has been proven to be more 
effective than another. 
Stimulants are used by diverse groups in the community, 
including: 
! young people experimenting with illicit drugs 
! shift workers 
! people (often women) seeking to lose weight 
! individuals seeking to self medicate against depression, 
attention deficit hyperactivity disorder, or to counter 
the effects of sedating medication (eg, methadone, 
antipsychotics) 
! people in certain cultural groups where stimulant use 
is prevalent (eg, rave scenes). 
The pattern of stimulant use varies across these different 
groups. Amphetamines and cocaine can be injected, 
swallowed, snorted or smoked. Polydrug use is very 
common among people who use stimulants. A common 
pattern among dependent users is high-dose binges lasting 
for days, followed by exhaustion and withdrawal 
dysphoria. 
In general, stimulants increase alertness, the sense of well-
being, and the pleasurable reinforcement experienced with 
many activities. Some individuals move into a pattern of 
repeated use and higher doses, in an increasing search for 
intense euphoric sensations. 
Effects of psychostimulants 
Immediate effects Effects of higher doses 
Increased alertness 
Increased energy 
Increased confidence 
Euphoria 
Increased talkativeness 
Loss of appetite 
Insomnia 
Increased heart rate and 
breathing 
Nausea/vomiting 
Headaches 
Jaw clenching 
Hot and cold flushes 
Sweats 
Headaches 
Pale skin 
Restlessness 
Dizziness 
Rapid or irregular heartbeat 
Paranoia 
Anxiety 
Panic attacks 
Depression 
Confusion (feeling “scattered”) 
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7.2 Assessment issues specific for 
stimulant users 
 
Amphetamines are the most frequently used group of 
drugs in this category. 
Define the route of administration, the specific agents 
used, and the frequency and pattern of use. 
Many street products will not be pure, and urine drug 
screening is appropriate to document what has been 
consumed. 
Consumption may be recorded as frequency of 
administration or as dollars spent. 
The patient may be intoxicated on presentation, and this 
may affect his/her ability to provide and receive 
information. 
See Appendix B for a guide to managing intoxication and 
overdose. 
Assessment of intoxicated individuals is difficult but should 
be pursued as far as is possible. Assessment findings 
should be reviewed after signs of intoxication have abated. 
Patients may not consider their stimulant use to be a 
problem and therefore not disclose use unless a systematic 
enquiry of all drug classes is performed. Use of other drugs 
is common in association with (either during or after) 
stimulant use. 
7.2.1 Regular monitoring and repeated 
assessment over time 
Patients undergoing stimulant withdrawal require ongoing 
assessment and regular monitoring, particularly in the first 
2 weeks of abstinence (by which time peak symptoms will 
have appeared). 
Patients may appear calm, with few cravings and generally 
well, in the first few days without stimulant use (during the 
“crash” phase), but withdrawal or mental state problems 
may become apparent several days after the initial 
assessment. 
7.2.2 Assessment of potential complications 
of psychostimulant use 
 
Mental state symptoms such as paranoia, delusions or 
perceptual disturbances are common among stimulant 
users seeking treatment. Signs and symptoms can fluctuate 
with time. Repeated assessment is indicated — mental 
state problems may not surface until late in the first week 
of withdrawal, with features masked during the crash 
phase. 
If mental state problems are severe and/or persistent (eg, 
for longer than a week after last stimulant use), then 
specialist psychiatric assessment is necessary. 
The presence of significant mental state problems requires 
regular monitoring over a longer period (months) to 
differentiate the diagnosis. 
There are many potential complications associated with 
cocaine and amphetamine use, and every body system can 
be affected (see table below). 
A phenomenon associated with stimulant use is 
“kindling”: once an individual experiences certain 
complications from their stimulant use (eg, arrhythmias, 
seizures, psychosis), they are more susceptible to further 
episodes, even with low doses. Warn patients who have 
experienced stimulant-related complications against further 
stimulant use. 
 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
 All patients withdrawing from stimulants 
should undergo a medical and mental state 
assessment. 
 Specialist medical assessment is required for 
patients with medical complications. 
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Medical and psychiatric complications of stimulant use 
System Complication 
Cardiovascular Arrhythmias: tachycardia, bradycardia, ventricular tachycardia. 
Hypertension: may lead to cerebrovascular accidents. 
Spasm of arteries: leading to myocardial infarcts or cerebrovascular accidents (myocardial infarcts can occur 
during first weeks of withdrawal). 
Cardiomyopathy and congestive heart failure. 
Neurological Seizures: clonic convulsions. 
Cerebrovascular accident: including brain haemorrhages, infarcts and ischaemic episodes. 
Neuropsychological changes: deficits in attention, concentration, memory and new learning skills. 
Movement disorders: eg, tics, disturbed gait, stereotyped repetitive movements, choreoform movements. 
Psychiatric May mimic any psychiatric disorder. More commonly: 
Depression, with changes in mood and affect, sleep, activity.  
Paranoia, ranging from hypervigilance to paranoid psychosis. 
Anxiety and aggression, ranging from irritability and agitation to panic attacks or violence (more common in 
amphetamine users).  
Delirium, with clouding of consciousness, disorientation, confusion. 
Psychosis, characterised by paranoia and anxiety, impaired reality testing with loss of insight and delusions (eg, 
ideas of reference, persecutory delusions) and perceptual disturbances (including misperceptions and visual, 
auditory or tactile (formication) hallucinations).  
Respiratory Smoking of cocaine and amphetamines can result in chronic lung damage (including pneumonia, pulmonary 
oedema, bronchitis). 
Sexuality Short-term stimulant use is often associated with increased sexual drive and performance. However, chronic use 
can lead to difficulties achieving orgasm, altered menstruation (oligomenorrhea, amenorrhea) and galactorrhea 
in women, and reduced libido, impotence and gynaecomastia in men. 
Hyperpyrexia Extremely elevated body temperature, which can contribute to seizures, cardiac arrhythmias, and death. 
Rhabdomyolysis can also occur, resulting in acute renal and hepatic failure, disseminated intravascular 
coagulation, and death. 
Pregnancy Stimulant use during pregnancy is associated with higher rates of obstetric complications (spontaneous 
abortion, miscarriage and placental abruption), and harm to the fetus.  
Other Weight loss (chronic loss of appetite and increased metabolism).  
Skin lesions and abscesses, due to adulterants, particularly in injectors. 
7.2.3 Unplanned withdrawal 
Stimulant users come in contact with a variety of services, 
and may undergo withdrawal incidental to their primary 
presentation. Patients may conceal or under-report their 
stimulant use, as they may not consider it to be a problem. 
To detect stimulant use: 
! conduct a comprehensive and systematic assessment 
of all classes of drug use within recent weeks 
! be familiar with common patterns of use and 
withdrawal commonly associated with stimulant use 
! look for injection marks. Stimulant users who inject 
often do so multiple times during a session 
(particularly cocaine). Multiple recent injection marks 
are suggestive of stimulant injecting 
! individuals presenting to health services with 
complications of stimulant use should have a 
systematic assessment of their drug use.  
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7.3 Withdrawal  
7.3.1 Onset and duration 
Withdrawal typically occurs in three phases: 
Phase Time since last stimulant use Common signs and symptoms 
Crash Amphetamines: typically 
commences 12–24 hours after last 
amphetamine use, and subsides by 
days 2–4.  
Cocaine: occurs within hours of last 
use, with short duration (up to 48 
hours). Some individuals do not 
report a significant crash on 
stopping cocaine. 
Exhaustion, fatigue 
Sleep disturbances (typically increased sleep, although insomnia or restless 
sleep may occur) 
Mood disturbances — typically flat mood or dysphoria; may be associated 
with anxiety or agitation 
Low cravings 
Generalised aches and pains 
Withdrawal Amphetamines: typically 
commences 2–4 days after last use, 
peaks in severity over 7–10 days, 
and then subsides over 2–4 weeks.  
Cocaine: typically commences 1–2 
days after last use, peaking in 
severity over 4–7 days, then 
subsides over 1–2 weeks. 
Strong cravings 
Fluctuating mood and energy levels, alternating between: Irritability, 
restlessness, anxiety, and agitation  
Fatigue, lacking energy, anhedonia 
Disturbed sleep, including vivid dreams, insomnia 
General aches and pains, headaches 
Muscle tension 
Increased appetite 
Poor concentration and attention 
Disturbances of thought (eg, paranoid ideation, strange beliefs) and 
perception (misperceptions, hallucinations) can re-emerge during withdrawal 
phase after having been masked during crash. 
Extinction Weeks to months Gradual resumption of normal mood with episodic fluctuations in mood and 
energy levels, alternating between: irritability, restlessness, anxiety, agitation, 
fatigue, lacking energy and anhedonia 
Episodic cravings 
Disturbed sleep 
 
7.3.2 Factors affecting severity of withdrawal  
There is considerable variation in the severity of withdrawal 
upon ceasing regular and heavy psychostimulant use. The 
following factors appear to affect the severity of 
withdrawal: 
! intensity of psychostimulant use 
! type of psychostimulant (less potent psychostimulants 
[eg, ephedrine, duramine] are likely to produce less 
severe withdrawal) 
! dose, frequency and duration of use 
! mode of administration (injecting is often associated 
with greater amounts of stimulant use, higher 
incidence of psychopathology, higher severity of 
dependence, and perhaps more severe withdrawal) 
! other drug use 
! intercurrent illness 
! patient expectations 
! environment and psychosocial supports. 
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7.4 Monitoring 
Mood and energy levels fluctuate over time — a patient 
may present with low mood, flat affect and psychomotor 
retardation at one time, yet be quite restless and agitated 
later in the same day. 
Underlying mental state problems may be masked during 
the initial assessment or crash phase, and may surface later 
in the withdrawal.  
Withdrawal scales have not been routinely used in clinical 
practice.  
7.5 Treatment 
Withdrawal from stimulant drugs is not medically 
dangerous, and no specific treatment has been shown to 
be effective in reducing withdrawal symptoms.  
The primary aim of withdrawal management is to attend to 
complications and engage the patient in relapse 
prevention. 
7.5.1 Treatment planning 
Treatment planning needs to consider the specific 
characteristics of stimulant withdrawal. In particular, the 
onset of withdrawal discomfort may be delayed for several 
days after stopping stimulant use.  
Managing the prolonged withdrawal typical of 
psychostimulant dependence requires careful integration 
and coordination between withdrawal and post-
withdrawal services to provide ongoing support to the 
patient. Treatment should not be restricted to short term 
(1–2 week) episodes. 
To manage the high prevalence of complications 
(particularly mental state problems) in stimulant users, 
withdrawal services require adequate resources (eg, staff 
able to conduct mental state examinations, policies and 
procedures for dealing with aggressive patients) and 
coordination with relevant medical and psychiatric services. 
7.5.2 Treatment settings 
The usual treatment setting is ambulatory. People who are 
acutely psychotic may require management in a psychiatric 
unit. 
7.5.3 Supportive care 
The general principles of supportive care involve: 
! providing information  
! supportive counselling, aimed at helping the client 
cope with symptoms and cravings, and to maintain 
motivation 
! specific strategies for addressing agitation, anger, 
perceptual disturbances and sleep disturbances 
! frequent orientation, reassurance and explanation of 
procedures to patients with thought or perceptual 
disturbances, as they can easily misinterpret actions or 
events around them 
! crisis intervention, addressing accommodation, 
personal safety, or other urgent welfare issues. 
7.5.4 Pharmacotherapies 
The role of medication in managing cocaine or 
amphetamine withdrawal is unclear. Medications that have 
been tried fall into two categories: 
! those intended to counter the reduced dopaminergic, 
noradrenergic and/or serotonergic activity associated 
with stimulant withdrawal, including desipramine, 
bromocriptine, amantadine and various selective 
serotonin reuptake inhibitors (SSRIs; eg, fluoxetine) 
! mood stabilisers, such as lithium or carbamazepine. 
Symptomatic medications may be beneficial in ameliorating 
particular symptoms for individual patients during 
withdrawal. 
Antipsychotic medication should be considered for 
patients with features of psychosis (thought disorder, 
perceptual disturbances) which are distressing to the 
patient or others. Consult a psychiatrist if symptoms are 
severe or do not quickly resolve (within days). Medication 
should be continued for at least 1–2 weeks after symptoms 
resolve with careful monitoring for return of symptoms as 
the medication is withdrawn. 
Benzodiazepines are useful for anxiety and sleep 
disturbances, but should not be used for longer than 2 
weeks without review. Alternative approaches to 
managing anxiety and sleep problems should be 
encouraged, such as sleep hygiene, exercise, and relaxation 
techniques. 
Antidepressants are helpful for managing clients with 
persistent features of depression following stimulant 
withdrawal. Specialist assessment and a treatment plan 
combining counselling (eg, cognitive behavioural therapy) 
and antidepressants should be considered.  
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7.5.5 Addressing complications during 
withdrawal 
Specialist medical attention is required for patients with 
potential complications. Even if the complication is thought 
to be associated with stimulant use and to have resolved 
(eg, seizure), specialist referral and investigation for 
underlying predisposing conditions or alternative diagnoses 
(eg, epilepsy) are recommended for patients who have not 
previously been investigated. 
7.6 Continuing care  
Integration of withdrawal services and post-withdrawal 
services is required to manage the protracted nature of the 
extinction phase of stimulant withdrawal. 
Interventions such as relapse prevention and self-help 
groups should be encouraged for all patients. 
Specialist assessment should be considered for patients 
with medical or psychiatric complications (eg, persistent or 
severe features of psychosis or depression). 
Harm reduction interventions should be encouraged for 
patients who plan to resume stimulant use. 
For general information on continuing care after 
withdrawal, see section 2.8. 
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8 Nicotine 
Chapter summary 
! Symptoms of nicotine withdrawal include four or more of the following: depressed mood, insomnia, 
irritability, frustration or anger, anxiety, difficulty in concentration, restlessness, decreased heart rate 
and increased appetite or weight gain.  
! The general management approach for nicotine withdrawal should be supportive counselling, accurate 
information, pharmacotherapy options and appropriate planning. 
! Nicotine replacement therapy (NRT) is widely used to decrease withdrawal symptoms. Bupropion, 
clonidine and nortriptyline can also be used during withdrawal. These pharmacotherapies should be 
considered in a holistic approach to smoking cessation. 
! Cannabis smokers often mix tobacco for smoking. Concomitant treatment for cannabis withdrawal 
should be initiated if the person is stopping cannabis use (see Chapter 6). 
! Post-withdrawal interventions should be used, such as the Quitline (131 848), motivational 
enhancement, relapse prevention, cognitive behavioural therapies, other psychosocial interventions 
and self-help groups.  
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8.1 Use and effects of nicotine 
Nicotine is a psychoactive drug that affects mood and 
performance and is the source of addiction to tobacco. 
Nicotine facilitates the release of neurotransmitters 
including acetylcholine, norepinephrine, dopamine and 
serotonin. Behavioural rewards from nicotine and perhaps 
nicotine dependence as well are linked to dopamine 
release.  
In NSW in 2004, tobacco smoking was the cause of 18% 
of all male and 10% of all female deaths. In 2004–2005, it 
is estimated that smoking caused 55 591 hospitalisations 
(4% of all male and 2% of all female hospital admissions). 
Adverse effects include acute effects on the central 
nervous, gastrointestinal and musculoskeletal systems, and 
longer-term effects on the cardiovascular system and 
respiratory system. Tobacco use contributes to 
complications related to pregnancy, degenerative disease 
and injuries. It is a major cause of malignancy in the lung 
and elsewhere. Environmental tobacco smoke causes 
disease in non-smokers.  
Tobacco is generally smoked using cigarettes, cigars or 
pipes. Tobacco can also be chewed. “Chop-Chop” is 
tobacco that has been made and sold illegally. Because of 
the lack of quality control in its production, it may contain 
a range of substances, including mould and fungus, that 
can cause additional health problems.  
8.2 Assessment issues specific for 
nicotine-dependent patients 
 
The Fagerstrom test for nicotine dependence should be 
used to gauge the dependence of a tobacco smoker and 
their risk of nicotine withdrawal (see Appendix O). A 
two-question version of this test can be used. 
 
 
 
 
 
 
Two question version of Fagerstrom test for nicotine 
dependence 
Question Answer Score 
How soon after waking up 
do you smoke you first 
cigarette? 
Within 5 minutes 3 
6–30 minutes 2 
   
How many cigarettes a 
day do you smoke? 
10 or less 0 
11–20 1 
21–30 2 
31 or more 3 
Score  0–2 very low 
3 low 
4 moderate 
5 high 
6 very high 
8.3 Withdrawal 
8.3.1 Onset and duration of nicotine 
withdrawal 
Withdrawal symptoms commence within a few hours of 
the last cigarette, peaking in the first 24-72 hours and 
resolve in about 2-4 weeks. The DSM-IV states that four or 
more of the symptoms below within the first 24 hours of 
nicotine reduction or cessation indicate nicotine 
withdrawal. 
Signs and symptoms of nicotine withdrawal: 
! depressed mood 
! insomnia 
! irritability, frustration or anger 
! anxiety 
! difficulty in concentration 
! restlessness 
! decreased heart rate 
! increased appetite or weight gain. 
   Note: general assessment for withdrawal is 
detailed in section 2.3. 
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8.3.2 Factors contributing to withdrawal 
severity 
Variables affecting withdrawal may include: 
! psychiatric comorbidity 
! duration of current use 
! past or current substance use history or withdrawal.  
 
In planning for nicotine withdrawal, health care workers 
should take note of impending crises, current psychosocial 
stressors as likely triggers. Health care professionals such as 
General Practitioners and Pharmacists can provide support 
and advice. 
Patients should be given information to assist them in 
reaching an informed choice of which pharmacotherapy (if 
any) they would wish to use. 
For individuals likely to receive a pharmacotherapy, 
explanation and information concerning the dosing 
schedule, duration of treatment and possible side effects 
should be provided.  
8.4 Treatment 
8.4.1 Indication for inpatient nicotine 
withdrawal 
There is generally no indication for admission into an 
inpatient facility for management of nicotine withdrawal. 
However, many patients will be admitted to hospital and 
experience withdrawal from nicotine consequently. 
Patients should be informed of the NSW Department of 
Health Smoke Free Workplace Policy (1999) and offered 
support to stop; nicotine replacement therapy (NRT) should 
be used when not contraindicated. Information on offsite / 
outdoor designated smoking areas should be provided, if 
available, if patients wish to continue to smoke. 
Assessment, information, education, support, NRT and 
referral should be offered to all patients in this situation 
whether they intend to continue smoking on discharge 
not. If they intend to stop, a referral to the Quitline and a 
general practitioner or pharmacist should be provided. 
Supportive counselling, accurate information, 
pharmacotherapy options and appropriate planning should 
be used during the withdrawal period. A range of 
resources are available including fact sheets, self help 
booklets and the Quitline for use during and after the 
withdrawal period. Counselling is also provided by some 
services. The guidelines for coping skills in Appendix I can 
help in dealing with cravings and anxiety. 
 
8.4.2 Pharmacotherapies 
A holistic approach to smoking cessation is important and a 
pharmacotherapy should be seen as one part of this approach. 
Pharmacotherapies include: 
! Nicotine replacement therapy (NRT) 
! Buproprion  
! Other options such as clonidine, and nortriptyline. 
  
Nicotine replacement therapies 
NRT provides lower nicotine levels than those achieved by 
smoking, but can relieve the physiological withdrawal 
symptoms of smoking, reducing the urge to smoke 
cigarettes. NRT options are gum, patches and an inhaler. 
Combining a patch with another self administered form of 
NRT may be more efficacious than one form alone.  
Because NRTs are available without prescription at 
pharmacies, pharmacists can play an important role in 
providing information to people wanting to use this 
option. In general, issues such as the type of NRT, previous 
withdrawal symptoms and patterns, the need for a 
combination of agents and regular review should be 
explored in all settings. Not smoking while using NRT 
should be strongly encouraged.  
Buproprion (Zyban) 
Bupropion is an alternative to NRT and smokers should 
start 7 days before they plan to stop smoking. It should be 
taken for 7 weeks. 
Clonidine and nortriptyline 
Clonidine and nortriptyline should be considered if NRT and 
buproprion are contraindicated, but may have more severe 
side effects.  
   The default management approach for nicotine 
withdrawal should be supportive counselling, 
accurate information, pharmacotherapy and 
appropriate planning. 
 Quitline 131 848.  
The National Tobacco Campaign 
<http://www.quitnow.info.au/> 
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8.5  Special issues 
8.5.1 Pregnancy 
There are great benefits in stopping smoking before and 
during pregnancy and all women and their partners should 
be offered information and support. NRT is contraindicated 
in pregnancy although it may be considered if the 
woman’s smoking is considered a greater risk. 
8.5.2 Comorbidity 
Some smokers report that smoking helps relieve depression 
and some smokers become severely depressed after 
stopping smoking. The neurochemical effects of smoking 
may resemble effects of some antidepressant medication 
(Degenhardt and Hall 2001). 
8.6  Continuing care  
Post-withdrawal interventions should be used, such as the 
Quitline, motivational enhancement, relapse prevention, 
cognitive behavioural therapies and other psychosocial 
interventions and self-help groups. Referrals to general 
practitioners or pharmacists are also encouraged for the 
patient’s ongoing support and advice on 
pharmacotherapies. Acupuncture, hypnosis and relaxation 
therapy also may be offered or requested for smoking 
cessation, but they have not proven to be effective in 
randomised control trials. There is a range of information 
on the internet concerning tobacco and quitting smoking; 
many links are available at <www.quitnow.info.au>. 
For general information on continuing care after 
withdrawal, see section 2.8. 
Dosage for nicotine replacement therapy 
Type 
NRT dose matched to dependency 
Side effects Contraindications 
Less than 10 
cigarettes per day 
10–20 cigarettes 
per day 
More than 20 
cigarettes per day 
Patches None Nicabate 4 mg 
Nicorette 10 mg 
Nicabate 21 mg 
Nicorette 15 mg 
Transient skin irritation, 
itching, dreams, sleep 
disturbance, indigestion, 
diarrhoea  
Relative: 
Ischaemic heart disease 
Absolute: 
Recent myocardial 
infarction 
Serious arrhythmias 
Unstable angina 
pregnancy 
Gum None 2 mg, 8-12 per 
day 
4 mg, 8-12 per day Jaw discomfort, nausea, 
indigestion, hiccups, excess 
saliva, sore throat 
Inhaler None Nicorette 6-12 
cartridges per day 
Not recommended Mouth and throat irritation, 
cough, nausea and 
indigestion 
Dosage for buproprion replacement therapy 
Buproprion dose  
(for all patients) Side effects Contraindications 
150 mg for 3 days then  
150 mg twice a day for 7 weeks 
Headaches, dry mouth, impaired sleep, 
seizures, nausea, constipation, anxiety, and 
dizziness 
Seizure disorders or significant risk of seizure 
Bulimia 
Anorexia nervosa 
Bipolar disorders 
New South Wales drug and alcohol withdrawal clinical practice guidelines PAGE 59 
References and suggested readings list 
American Psychiatric Association. The diagnostic and statistical 
manual of mental disorders, 4th edition (DSM-IV). Washington: 
American Psychiatric Press, 2004. 
Australian Government Department of Health and Ageing; 
Clinical guidelines and procedures for the use of naltrexone in 
the management of opioid dependence. Canberra, 2003. 
Australian National Council on AIDS, Hepatitis C and related 
diseases. National hepatitis C testing policy. Canberra: 
ANCAHRD, 2003. 
<http://www.hepatitisc.org.au/resources/documents/hepctesting
.pdf> 
Black E, Degenhardt L, Stafford J. New South Wales drug trends 
2005: findings from the Illict Drug Reporting System (IDRS). 
Sydney: National Drug and Alcohol Centre, 2006. 
<http://ndarc.med.unsw.edu.au> 
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the 
validity and significance of cannabis withdrawal syndrome. Am J 
Psychiatry 2004: 161: 1967–1977. 
Burns TL, Ineck JR. Cannabinoid analgesia as a potential new 
therapeutic option in the treatment of chronic pain [Review] [81 
refs]. Ann Pharmacother 2006; 40(2): 251-260. 
Centre for Substance Abuse Treatment. Detoxification and 
substance abuse treatment. Treatment Improvement Protocol 
(TIP) Series 45. DHHS Publication No (SMA) 06-4131. Rockville, 
MD: Substance Abuse and Mental Health Services 
Administration, 2006. 
Commonwealth Government of Australia. National Clinical 
Guidelines for the management of drug use during pregnancy, 
birth and the early development years of the newborn. NSW 
Department of Health, 2006. 
<http://www.health.nsw.gov.au/pubs/2006/pdf/ 
ncg_druguse.pdf> 
Degenhardt L, Hall W. The relationship between tobacco use, 
substance-use disorders and mental health: results from the 
National Survey of Mental Health and Well-being. Nicotine 
Tobacco Res 2001; 3: 225-234. 
Dunn M, Degenhardt L, Stafford J. NSW trends in ecstasy and 
related drug markets 2005: findings from the Party Drugs 
Initiative (PDI). Sydney: National Drug and Alcohol Research 
Centre, 2006. <http://ndarc.med.unsw.edu.au> 
Gowing L, Ali R, White J. Buprenorphine for the management of 
opioid withdrawal (Review). The Cochrane Collaboration, John 
Wiley and Sons, 2006. 
Gowing L, Ali R, White J. Opioid antagonists under heavy 
sedation or anaesthesia for opioid withdrawal (Review). The 
Cochrane Collaboration, John Wiley and Sons, 2006. 
Gowing L, Proudfoot H, Henry-Edwards S, Teesson M. Evidence 
supporting treatment: the effectiveness of interventions for illicit 
drug use. Canberra: Australian National Council on Drugs, 2001. 
Hamilton M, King T, Ritter A, editors. Drug use in Australia: 
preventing harm. Melbourne: Oxford University Press, 2004. 
Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating 
scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13 
(3): 293-308. 
Hepatitis C, a management guide for general practitioners 
(RACGP) 1999, updated 2003. <http://www.racgp.org.au> 
Australian National Council on AIDS, Hepatitis C and related 
diseases. A model of care for the management of hepatitis C 
infection in adults. Canberra: ANCAHRD, 2003. 
<http://www.hepatitisc.org.au/resources/documents/ 
modelofcare.pdf>  
Jarvis T, Tebbutt J, Mattick RP, Shand F. Treatment approaches 
for alcohol and drug dependence — an introductory guide. 2nd 
ed. Sussex, England: John Wiley & Sons, 2005. 
Jenner L, Saunders JB. Psychostimulant withdrawal and 
detoxification. In: Baker A, Lee NK, Jenner L, editors. Models of 
intervention and care for psychostimulant users, 2nd ed. 
National Drug Strategy Monograph Series No. 51. Canberra: 
Australian Government Department of Health and Aging, 2004. 
<http://www.nationaldrugstrategy.gov.au> 
Katzung BG. Basic and clinical pharmacology, 9th ed. McGraw-
Hill Companies, 2006. [CIAP] 
MIMS on-line. (2006) [CIAP].  
Mayo-Smith MF. Pharmacological management of alcohol 
withdrawal: a meta-analysis and evidence-based practice 
guideline. JAMA 1997: 278: 144-151. 
Murray P,  Linterzeris N, Gijsbers A, Dunlop A. Prescribing for 
drug withdrawal. Clinical treatment guidelines for alcohol and 
drug clinicians, No. 9. Fitzroy, Victoria: Turning Point Alcohol 
and Drug Centre Inc, 2002.  
Naranjo C, Sellers E. Clinical assessment and pharmacotherapy 
of alcohol withdrawal syndrome. In: Galanter M, editor. Recent 
developments in alcoholism. New York: Plenum Press, 1986: 
265–281 
National Drug Strategy. National clinical guidelines and 
procedures for the use of buprenorphine in the treatment of 
heroin dependence. Canberra: Department of Health and Aged 
Care, 2001. <http://www.nationaldrugstrategy.gov.au> 
National Health and Medical Research Council. Guidelines for 
the prevention and management of benzodiazepine 
dependence. Canberra: AGPS, 1991. 
NCETA Consortium. Alcohol and other drug problems. A 
handbook for health professionals. Australian Government 
Department of Health and Ageing, 2004. 
<http://www.aodgp.gov.au/internet/aodgp/publishing.nsf/Conte
nt/handbook> 
Novak H, editor. Nurse education and nursing management of 
alcohol and other drugs. Sydney: CEIDA, 1989. 
NSW Children and Young Persons (Care and Protection) Act 
1998. 
NSW Department of Health. NSW Health Circular 98/31. Policy 
guidelines for the management of patients with possible suicidal 
behaviour for NSW Health staff and staff in private hospital 
facilities. 2004. [See also: NSW Department of Health 
PD2005_121.]  
NSW Department of Health. NSW detoxification clinical practice 
guidelines. State Health Publication Number (DTPU) 990049. 
Sydney: NSW Department of Health, 1999.  
NSW Department of Health. Smoke free workplace. 1999. 
NSW Department of Health. Alcohol and other drugs policy for 
nursing practice in NSW: clinical guidelines 2000–2003. State 
Health Publication Number: (DA) 000031. Sydney: NSW 
Department of Health, 2000. 
PAGE 60 New South Wales drug and alcohol withdrawal clinical practice guidelines 
NSW Health frontline procedures for the protection of children 
and young people. 2000. 
<http://www.health.nsw.gov.au/policy/hsp/child-
protection/procedures/frontlineprocedures.pdf> 
NSW Department of Health. Guide for the management of 
nicotine dependent inpatients: A summary of evidence. 2002. 
<http://www.health.nsw.gov.au/pubs/g/pdf/nicotine_sum.pdf> 
NSW Department of Health. Policy for identifying and 
responding to domestic violence. 2003. 
<http://www.health.nsw.gov.au/pubs/p/pdf/policy_dom_violence
.pdf>  
NSW Department of Health. Framework for suicide risk 
assessment and management. 2004. 
<http://www.health.nsw.gov.au/pubs/2005/pdf/risk_assessment.
pdf> 
NSW Department of Health. Amphetamine, cocaine and ecstasy 
– prevention and treatment plan 2005–2009. Sydney: NSW 
Department of Health, 2005.  
NSW Department of Health Policy Directive PD2005_048. 
Counselling associated with HIV antibody testing — guidelines. 
<http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_0
48.pdf>  
NSW Department of Health Policy Directive PD2005_049. 
Management of opioid dependent persons admitted to public 
hospitals in NSW. 
<http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_0
49.pdf>  
NSW Department of Health Policy Directive PD2005_121. Policy 
guidelines for the management of patients with possible suicidal 
behaviour for NSW Health staff and staff in private hospital 
facilities. 
<http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_1
21.pdf> 
NSW Department of Health Policy Directive PD2005_299. 
Protecting children and young people. 
<http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_2
99.pdf> 
NSW Department of Health Policy Directive PD2005_413. 
Identifying and responding to domestic violence. 
<http://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_4
13.pdf> 
NSW Department of Health Policy Directive PD2006_084. 
Domestic violence — identifying and responding. 
<http://www.health.nsw.gov.au/policies/PD/2006/pdf/PD2006_0
84.pdf> 
NSW Department of Health. Psychostimulant users – clinical 
guidelines for assessment and management. Sydney: NSW 
Department of Health, 2006. 
NSW Department of Health. Tobacco. 
<http://www.health.nsw.gov.au/public-health/health-
promotion/tobacco/quitting/index.html> 
NSW Medical Board. Code of professional conduct. Rapid 
detoxification in an unlicensed setting. 
<http://www.nswmb.org.au/system/files/f1/o39//Naltrexone_App
roved_Code.pdf> 
O’Brien S. Treatment options for heroin and other opioid 
dependence: a guide for frontline workers. Canberra: Australian 
Government Department of Health and Ageing, 2004. 
<www.nationaldrugstrategy.gov.au>  
QLD Health. Psychostimulants information for health workers. 
Queensland. 2004. 
Ritter A, Linterzeris N. Specialist interventions in treating clients 
with alcohol and drug problems. In: Hamilton M, King T, Ritter 
A, editors. Drug use in Australia: preventing harm. Melbourne: 
Oxford University Press, 2004. 
Rog DJ. Nurmikko TJ. Friede T. Young CA. Randomized, 
controlled trial of cannabis-based medicine in central pain in 
multiple sclerosis. [Journal Article. Randomized Controlled Trial] 
Neurology 2005; 65(6): 812-819. 
Routine screening for domestic violence in NSW Health: an 
implementation package. 
<http://internal.health.nsw.gov.au/policy/hsp/domesticviolence/p
df/routine_screening.pdf>  
Shand F, Gates J, Fawcett J, Mattick R. Guidelines for the 
treatment of alcohol problems. Canberra: National Alcohol 
Strategy, Australian Government Department of Health and 
Aging, 2003. <http://www.nationaldrugstrategy.gov.au> 
Shand F, Gates J. Treating alcohol problems: guidelines for 
hospital staff. Canberra: National Alcohol Strategy, Australian 
Government Department of Health and Aging, 2004. 
<http://www.nationaldrugstrategy.gov.au> 
Sullivan J, Sykora M, Schneiderman J, et al. Assessment of 
alcohol withdrawal: the revised Clinical Institute withdrawal for 
alcohol scale (CIWA-AR). Br J Addict 1989; 84: 1353–1357. 
Tucker T, Ritter A, Maher C, Jackson H. Naltrexone maintenance 
for heroin dependence: uptake, attrition and retention. Drug 
Alcohol Rev 2004; 23: 299-309.  
Maccallum F, Blaszczynski A, Barker G, et al. Working out 
gambling — assessment & case formulation — a practical skills 
training manual. 2003.  
World Health Organization. International statistical classification 
of diseases and related health problems, 10th revision. Geneva: 
WHO, 1992. 
New South Wales drug and alcohol withdrawal clinical practice guidelines PAGE 61 
Selected web sites and information lines 
Alcohol and Other Drugs Council of Australia (ADCA) 
www.adca.org.au 
Alcoholics Anonymous 
www.alcoholicsanonymous.org.au 
Australian Drug Foundation 
Provides drug facts sheets and resources regarding drug 
and alcohol use 
www.adf.org.au 
Australian Drug Information Network (ADIN) 
Provides drug and alcohol information via websites and 
data bases  
www.adin.com.au 
Australian Drug Foundation.  
Mulling it over [booklet available for purchase]  
www.adf.org.au/store  
Counselling online, Turning Point Alcohol and Drug 
Centre 
This service is for anyone seeking help about their own 
drug use or the drug use of a family member, relative or 
friend.The service is free and available 24-hours a day, 7-
days a week, across Australia. 
www.counsellingonline.org.au 
NSW Department of Health  
Clinical guidelines, fact sheets and information 
www.health.nsw.gov.au 
Drug & Alcohol Multicultural Education Centre 
(DAMEC)  
DAMEC helps bridge service gaps by assisting alcohol and 
other drugs service providers improve access for non-
English-speaking-background (NESB) clients. DAMEC also 
works with NESB Communities to develop resources and 
information on alcohol and other drugs. 
www.damec.org.au 
Austroads. Assessing fitness to drive. 
www.austroads.com.au/aftd/index.html 
Family drug support 
Provides information and support for people affected by 
someone’s illicit drug use 
www.fds.org.au 
Al-anon, Alateen Family support 
Helps families and friends of alcoholics recover from the 
effects of living with the problem drinking of someone 
close.  
www.al-anon.alateen.org/australia/ 
Nar-anon family groups 
Self-help support groups for families and friends of drug 
users. 
www.naranon.com.au/ 
G-Line: 1800 633 635 
NSW Office of Liquor, Gaming and Racing 
G-line (NSW) is a telephone helpline offering crisis 
counselling for people affected by gambling problems and 
is available to professional and patients. 
www.dgr.nsw.gov.au/gaming_hfpg_gline.asp 
Hepatitis C Council of NSW 
Provides information to people affected by Hepatitis C and 
the community 
www.hepatitisc.org.au 
Health Insurance Commission. Prescription shopping 
project and Prescription shopping information service 
www.medicareaustralia.gov.au/providers/programs_ 
services/pbs/prescription_shop.shtml 
Narcotics Anonymous 
na.org.au/community/index.php 
National Drug and Alcohol Research Centre: 
For drug facts sheets, drug and alcohol research and 
related information. 
ndarc.med.unsw.edu.au 
NSW Users and Aids Association (NUAA) 
Provides a range of information and advocacy for injecting 
drug users. 
www.nuaa.org.au/nuaa/about/index.html 
NSW Multicultural Health Communication Service 
(Multicultural Communication)  
Provides information and services to assist health 
professionals to communicate with non-English-speaking 
communities throughout New South Wales. 
www.mhcs.health.nsw.gov.au 
SMART Recovery 
SMART Recovery offers free face-to-face and online mutual 
help groups. It aims to help people recover from all types 
of addictive behaviors, including: alcoholism, drug abuse, 
substance abuse, drug addiction, alcohol abuse, gambling 
addiction, cocaine addiction, and addiction to other 
substances and activities. 
www.smartrecovery.org 
Turning Point Alcohol and Drug Centre 
To promote and maximise the health and wellbeing  
of individuals and communities living with and affected by 
alcohol and other drug-related harms. 
www.turningpoint.org.au 
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Glossary 
A wide range of terms has been listed to assist those who 
are not expert in the assessment of patients for 
withdrawal. 
This list has been adapted from Ordinary people: 
integrating alcohol and other drug management into 
nursing practice, produced by Western Sydney Area Health 
Service in 1996. 
Note: quotation marks denote that the expression is slang 
or jargon. 
Alcohol related brain damage (ARBD) 
A generic term that encompasses chronic impairment of 
memory and higher mental functions associated with the 
frontal lobe and limbic system. 
Ambulatory detoxification 
Managed withdrawal from a drug undertaken with the 
patient visiting the medical practitioner from home or 
travelling to and from a day care facility. 
Amphetamine 
A synthetic central nervous system stimulant. The term 
includes the three types of amphetamines: amphetamine, 
dexamphetamine and methamphetamine. Amphetamines 
have medical uses (such as in the treatment of attention 
deficit disorder), but most are manufactured and sold 
illegally.  
Antidepressant 
One of a group of psychoactive drugs prescribed for the 
treatment of depressive disorders. Also used for other 
conditions such as panic disorder. 
“Bad trip” 
Substance users’ jargon for an adverse effect of drug use, 
consisting of any mixture of the following feelings: losing 
control, distortions of body image, bizarre and frightening 
hallucinations, fears of insanity or death, despair, suicidal 
thoughts and strong negative mood. Physical symptoms 
may include sweating, palpitations, nausea and 
paraesthesia. A “bad trip” usually refers to the effect of a 
hallucinogen, but can also refer to amphetamines and 
other stimulants, antihistamines and sedatives/hypnotics. 
Barbiturate 
One of the sedative–hypnotic groups of drugs that are now 
rarely seen in Australia. With increasing dosage they 
produce progressive CNS depression, ranging from mild 
sedation to anaesthesia and death from respiratory 
depression. They are strongly dependence-inducing. 
Benzodiazepine 
One of the sedative-hypnotic groups of drugs. Introduced 
as safer alternatives to barbiturates, they have a general 
depressant effect that increases with the dose, from 
sedation to hypnosis to stupor. Benzodiazepines have 
significant potential for dependence. These are also 
referred to as minor tranquillisers. 
Binge drinking 
An episodic pattern of heavy drinking with periods of lesser 
alcohol consumption. 
Blood alcohol level 
The concentration of alcohol (ethanol) present in blood. 
The legal blood alcohol limit for driving in New South 
Wales is 0.05 g/100 mL 
Brief intervention 
A treatment strategy in which a short structured therapy is 
offered (between five minutes and two hours) and typically 
on a single occasion. Aimed at helping a person to reduce 
or stop substance use. 
Buprenorphine 
A partial opioid agonist drug used in the treatment of 
opioid withdrawal and as a maintenance treatment for 
opioid dependence.  
Cannabis 
The generic name given to the psychoactive substances 
found in the marijuana plant Cannabis sativa. The main 
active constituent is delta 9- tetrahydrocannabinol (THC). 
Cap 
A small amount of heroin, wrapped in foil. 
Cocaine 
A central nervous system stimulant derived from the coca 
plant, used non-medically to produce euphoria or 
wakefulness. Often sold as white translucent, crystalline 
flakes or powder. 
Continuing care 
In the context of withdrawal managment, continuing care 
means managing the transition to life after withdrawal, 
when patients are likely to have continuing issues arising 
from their drug dependence. Continuing care includes 
referral to counselling, maintenance treatment, self-help 
groups and family services.  
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Controlled drinking 
Drinking that is moderated to avoid intoxication or 
hazardous use of alcohol. 
Craving 
A very strong desire for a substance, or for the intoxicating 
effects of that substance. 
Delirium tremens 
An acute confusional state occurring during withdrawal 
from alcohol, characterised by rapid pulse, clouding of 
consciousness, dehydration, delirium, elevated body 
temperature, sweating, extreme fear, hypertension, 
tachycardia, tremor and hallucinations. 
Dependence (criteria for substance dependence) 
Dependence, as defined by DSM-IV (Diagnostic and 
statistical manual of mental disorders, 4th ed), is a 
maladaptive pattern of substance use, leading to clinically 
significant impairment or distress, as manifested by three 
(or more) of the following, occurring at any time in the 
same 12-month period: 
—Tolerance, as defined by either of the following: 
a) a need for markedly increased amounts of the 
substance to achieve intoxication or desired effect 
b) markedly diminished effect with continued use of the 
same amount of the substance. 
—Withdrawal, as manifested by either of the following: 
a) the characteristic withdrawal syndrome for the 
substance 
b) the same (or a closely related) substance is taken to 
relieve or avoid withdrawal symptoms. 
—The substance is often taken in larger amounts or over a 
longer period than was intended. 
—There is a persistent desire or unsuccessful efforts to cut 
down or control substance use. 
—A great deal of time is spent in activities necessary to 
obtain the substance (eg, visiting multiple doctors or 
driving long distances), use the substance (eg, chain-
smoking), or recover from its effects. 
—Important social, occupational, or recreational activities 
are given up or reduced because of substance use. 
—The substance use is continued, despite knowledge of 
having a persistent or recurrent physical or physiological 
problem that is likely to have been caused or 
exacerbated by the substance (eg, current cocaine use 
despite recognition or cocaine induced depression, or 
continued drinking despite recognition than an ulcer 
was made worse by alcohol consumption. 
Depressant 
Any substance that suppresses, inhibits or decreases some 
aspects of CNS activity. The main classes of CNS 
depressants are sedatives/hypnotics, opioids and 
neuroleptics. 
Detoxification  
Now outmoded term for managed withdrawal from a drug 
of dependence, the process by which a person is 
withdrawn from a psychoactive substance on which they 
are dependent.  
“Drop” 
To overdose. 
Ecstasy  
(MDMA, 3,4-methylenedioxy-N-methylamphetamine) 
A synthetic drug with stimulant effects on the central 
nervous system. 
Comorbidity 
In the context of withdrawal management, refers to a 
person who has coexisting substance use and mental 
health problems. 
“Fit” 
A needle and syringe used for injecting drugs. 
Fetal alcohol syndrome 
A pattern of retarded growth and development, both 
mental and physical, caused to a child in utero by excessive 
alcohol consumption when the mother is pregnant. 
“Flashbacks” 
A perception disorder that can occur after a period (from 
months or years) following hallucinogen use. Flashbacks 
are a spontaneous recurrence of the feelings that occurred 
when the person was intoxicated with hallucinogens. 
These feelings include visual distortions, physical 
symptoms, loss of ego boundaries, or intense emotions, 
and the flashbacks can last from a few seconds to a few 
hours. 
GHB (gamma-hydroxybutyrate) 
A central nervous system depressant, sometimes used 
illegally as an alternative to ecstasy, usually in liquid form.  
Glue sniffing 
Inhaling fumes from glue, petrol, or other volatile 
substances including petrol (also called inhalants, solvents) 
for their psychic effect. 
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GHB (gamma-hydroxybutyrate) 
A central nervous system depressant, sometimes used 
illegally as an alternative to ecstasy, usually in liquid form.  
Glue sniffing 
Inhaling fumes from glue, petrol, or other volatile 
substances including petrol (also called inhalants, solvents) 
for their psychic effect. 
Hallucinogen 
A substance that alters perception, typically by inducing 
illusions or even hallucinations. Hallucinogens can include 
naturally occurring compounds (eg, magic mushrooms) 
and synthetic chemicals. They are usually taken orally. 
“Half-weight” 
Half a street gram of heroin. 
“Hanging out” 
Withdrawing from opioids. 
“Hangover” 
A state that follows excessive consumption of alcohol. 
Physical features may include fatigue, headache, thirst, 
vertigo, gastric disorders, nausea, vomiting, insomnia, fine 
tremors of the hands, and raised or lowered blood 
pressure. Psychological symptoms include anxiety, guilt, 
depression, irritability and extreme sensitivity. Usually lasts 
not more than 36 hours after alcohol has been cleared 
from the body. 
Harm minimisation/harm reduction 
A drug strategy based on a harm minimisation approach 
has the following primary objectives: 
! To minimise the harm and the social problems to the 
individual and the community resulting from the use 
of drugs 
! To reduce the prevalence of hazardous levels and 
patterns of drug use in the community 
! To prevent the initiation into harmful or hazardous 
drug use, especially by young people. 
Harmful use 
A pattern of substance use that is causing damage to 
health–either physical (eg, hepatitis following injecting of 
drugs) or mental (eg, depressive episodes after heavy 
alcohol intake). Harmful use commonly has adverse social 
consequences. 
Hashish 
A concentrated form of cannabis. 
Hazardous use 
A pattern of substance use that increases the risk of 
harmful consequences for the user. 
Heroin 
Heroin is the most common illicit opioid drug of 
dependence. It is usually intravenously injected, but it can 
also be smoked. 
Ice 
The strongest form of methamphetamine. It either comes 
as a crystalline powder or crystals and is white or 
translucent. It is the highest purity form of 
methamphetamine and is usually smoked or injected. 
Illicit drug 
A substance obtained and used illegally for its psychoactive 
or physical effect. 
Inhalant 
One of a group of gases and highly volatile compounds, or 
mixtures of compounds, that are inhaled for their 
intoxicating effects. Inhalants are also called solvents or 
volatile substances. 
Intoxication 
The condition resulting from use of a psychoactive 
substance that produces behavioural and/ or physical 
changes. 
Ketamine 
A dissociative general anesthetic used legally for human 
and veterinary use, and traded illegally as a recreational 
drug.  
LSD (lysergic acid diethylamide) 
A hallucinogenic substance. 
Maintenance therapy 
A form of treatment of substance dependence by 
prescribing a substitute drug (eg, methadone for the 
treatment of heroin). 
Marijuana 
See cannabis. 
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Methadone 
A long acting synthetic opioid drug used in maintenance 
therapy for those who are dependent on opioids 
(prescribed in oral doses). 
Methamphetamine 
The most common illicit amphetamine, available in 
powder, base or ice form.  
Morphine 
An opioid drug. 
Naloxone 
An opioid receptor blocker that reverses the features of 
opioid intoxication. It is sometimes prescribed for the 
treatment of opioid overdose. 
Naltrexone 
A specific opioid antagonist similar to naloxone, but more 
potent and long-acting. 
Narcotic 
A chemical agent that induces stupor, coma, or insensibility 
to pain. The term usually refers to opioids, which are called 
narcotic analgesics. In general use, this term is often used 
incorrectly to refer to illicit drugs. 
Narcotics Anonymous 
A self-help group based on the 12-step philosophy of 
Alcoholics Anonymous, in which participants support each 
other in recovering or maintaining recovery from opioid 
dependence. 
Narrowing of repertoire 
A feature of dependence: the tendency of substance use to 
become progressively stereotyped around a self-imposed 
routine of custom and ritual. Characterised by reduced 
variation of dose and type of substance taken and of time, 
place and manner of self-administration. 
Neuroadaptation 
Physical dependence on a psychoactive substance. This 
means that a person has developed tolerance to the 
substance. If the drug is withdrawn, the person is likely to 
experience withdrawal symptoms. 
Neuroleptic 
One of a class of drugs used for treating acute and chronic 
psychoses. Also known as major tranquillisers and 
antipsychotics. 
Nicotine 
The major psychoactive substance in tobacco, which has 
both stimulant and relaxant effects. Considerable tolerance 
and dependence develop to nicotine. 
Opiate 
One of a group of substances derived from the opium 
poppy with the ability to induce analgesia, euphoria and, in 
higher doses, stupor, coma, and respiratory depression. 
This term excludes synthetic opioids. 
Opioids 
The generic term applied to alkaloids from the opium 
poppy, their synthetic analogues, and similar compounds 
synthesised within the body. 
Overdose 
The use of any drugs in such an amount that acute adverse 
physical or mental effects are produced. A dose that 
exceeds the individual’s tolerance. Overdose may produce 
transient or lasting effects, or death. 
PCP (phencyclidine, phenylcyclohexylpiperidine) 
A dissociative drug formerly used as an anaesthetic agent, 
with hallucinogenic and neurotoxic effects. 
Pharmacotherapy 
Drug treatment: in the context of withdrawal 
management, drug treatment for the symptoms and signs 
of withdrawal from a drug of dependence. 
Polydrug use 
Where a person uses more than one drug, often at the 
same time or following one another, and usually with the 
intention of enhancing, potentiating, or counteracting the 
effects of another substance. 
Psychoactive substance 
A substance that, when ingested, affects mental processes. 
Psychostimulants 
A class of drug with stimulatory effects on the central 
nervous system. The psychostimulants most commonly 
used illicitly in Australia today are amphetamines, ecstasy  
and cocaine. 
Psychotropic 
In the most general sense, a term with the same meaning 
as “psychoactive” (ie, affecting the mind or mental 
processes). 
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“Rave” 
A dance party, often involving the use of psychoactive 
substances, especially amphetamines and hallucinogens. 
Recreational use 
Use of a drug, usually an illicit substance, in social 
circumstances. This term implies that the user is not 
dependent on the substance; it has the same connotations 
as “social drinking”. 
Rehabilitation 
The process by which a person recovers from a substance 
use disorder to achieve an optimal state of health, 
psychological functioning, and well being. 
Relapse 
A return to substance use after a period of abstinence. 
“Rush” 
An immediate, intense, pleasurable effect that follows 
injection of certain substances (eg, heroin, amphetamine, 
cocaine). 
Sedative/hypnotic 
Any of a group of central nervous system depressants that 
can relieve anxiety and induce calmness and sleep. 
Selective withdrawal  
Managed withdrawal of one drug of dependence from a 
person with multiple drug dependencies.  
Solvent 
See inhalant. 
“Speed” 
See amphetamine. 
“Speedball” 
A combination of a stimulant and an opioid (eg, cocaine 
and heroin, amphetamine and heroin). 
Steroid 
One of a group of naturally occurring or synthetic 
hormones that affect chemical processes in the body, 
growth, and sexual and other physiological functions. 
Steroids can be taken orally or injected. 
Stimulant 
Any agent that activates, enhances, or increases neural 
activity of the central nervous system. Stimulants include 
the amphetamines, cocaine, caffeine and nicotine. 
THC 
Tetrahydrocannabinol, the main active constituent in 
cannabis. 
Therapeutic community 
A structured environment in which people with drug use 
problems live in order to achieve rehabilitation. Such 
communities are often specifically designed for drug 
dependent people. 
Tolerance 
A decrease in response to a drug dose that occurs with 
continued use. Increased doses of the drug are required to 
achieve the effect originally produced by lower doses. 
Tranquilliser 
General term for several classes of drugs employed to 
manage symptoms of various mental disorders. The 
tranquillisers have a quieting or dampening effect on 
psychomotor processes without — except at high doses — 
interfering with consciousness and thinking. In this way 
they differ from the sedatives/hypnotics, which are used, 
among other things, to induce sleep. The term tranquilliser 
is often used to refer to any drug that is used for treating 
anxiety disorders. 
Volatile substance 
See inhalant. 
Wernicke’s encephalopathy 
An acute, life threatening, neurological syndrome 
consisting of confusion, apathy, dullness, a dreamy 
delirium, palsies of the ocular muscles and of gaze, 
nystagmus and disturbances in equilibrium, and ataxia. Its 
most common cause is thiamine deficiency associated with 
long term excessive use of alcohol. If not treated 
immediately with thiamine, the patient is likely to progress 
to an amnestic syndrome. In some cases fatality can occur. 
Withdrawal syndrome 
A series of symptoms that occur when a person who has 
developed tolerance to a drug (after long and/or high dose 
use) stops or reduces use of the drug. 
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Appendix A  Withdrawal services in New South Wales 
There is a range of inpatient/outpatient, medicated/non medicated, government/non-
government/private withdrawal services (also known as detoxification services) in NSW. 
Services change over time, so it is important to check first with the service and or ADIS. 
 
Name  Type Location  
Phone 
number 
Greater Southern Area Health Service 
NGO/Private, southern NSW 
O’Connor House Inpatient, medicated Wagga Wagga 6925 4744 
Greater Western Area Health Service  
NGO/Private, western NSW 
Lyndon Withdrawal 
Unit 
Inpatient, medicated Orange 6362 5444 
Hunter / New England Area Health Service 
Lakeview Detox Unit Inpatient/outpatient, 
medicated 
Belmont (Lake 
Macquarie) 
4923 2060 
Lorna House Outpatient, medicated Mater Hospital 
Newcastle 
4921 1825 
Calvary Mater Hospital 
Newcastle 
Inpatient, medicated Newcastle 4921 1825 
North Coast Area Health Service 
Riverlands Drug and 
Alcohol Centre 
Inpatient, medicated Lismore 6620 7600 
NGO/Private, north coast NSW 
Sherwood Cliffs Inpatient, non medicated Glenreach(near Coffs 
Harbour) 
6649 2139 
Northern Sydney / Central Coast Area Health Service 
Herbert Street Inpatient, medicated Royal North Shore 
Hospital 
9906 7083 
Maruma-Li Centre Inpatient, medicated Wyong Hospital 4394 4880 
Private, northern Sydney 
Northside Clinic Inpatient and outpatient, 
medicated 
Greenwich 9433 3555  
New South Wales drug and alcohol withdrawal clinical practice guidelines PAGE 69 
Name  Type Location  
Phone 
number 
South Eastern Sydney / Illawarra Area Health Service 
Drug and Alcohol 
Community Adult Team 
Outpatient and home, 
medicated 
Port Kembla Hospital 1300 652 226 
Gorman House Inpatient, non-medicated Darlinghurst 9361 8080 
Jarrah House (for 
women with children) 
Inpatient, medicated Little Bay 9661 6555 
Langton Centre Outpatient, medicated Surry Hills 9332 8777 
Orana House  Inpatient, medicated Port Kembla Hospital 1300 652 226 
St George Alcohol and 
Drug Service 
Outpatient medicated St George Hospital 9350 2944 
Wollongong Crisis 
Centre 
Inpatient, non-medicated Berkeley 4272 3000 
Private, southern Sydney 
The Sydney Clinic Inpatient, medicated Bronte 9389 8888 
Wandene Private Inpatient, medicated Kogarah 9587 5077 
Sydney South West Area Health Service 
Canterbury Drug and 
Alcohol Service  
Outpatient, medicated Canterbury Hospital 9787 0272 
Corella Drug Treatment 
Services 
Inpatient, medicated Fairfield 9616 8586 
McKinnon Unit Inpatient, medicated Rozelle Hospital 9556 9241 
NGO/Private, south-western Sydney 
Odyssey House Inpatient, medicated Campbelltown 9281 5144 
St John of God Inpatient, medicated Burwood  9747 5611 
Wesley Private Hospital Inpatient, medicated Croydon 9716 1400 
Sydney West Area Health Service 
Wentworth Centre for 
Drug and Alcohol 
Inpatient and outpatient, 
medicated 
Penrith 4734 1333 
Private, western Sydney 
Northside West Inpatient, medicated Wentworthville 8833 2222 
St John of God Inpatient, medicated North Richmond 4588 5088 
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Appendix B  Assessment of intoxication and overdose 
Patients who use drugs or alcohol often present 
intoxicated, or having overdosed. The correct management 
of these conditions is an essential part of practice. 
Intoxication occurs when a person’s intake of a substance 
exceeds his or her tolerance and produces behavioural 
and/or physical abnormalities. It complicates the 
assessment and management of patients because: 
! psychoactive drugs affect mood, cognition, behaviour 
and physiological functioning 
! intoxication can have a major impact on informed 
consent to treatment and the validity of all further 
information reported by the patient 
! intoxication can mimic or mask serious illness and 
injury 
! patients who are aggressive or disruptive because they 
are intoxicated can risk their own safety or the safety 
of others 
! severe intoxication can be life threatening by altering 
physical and mental functions leading to inappropriate 
actions or central nervous system depression and 
death. 
Identifying intoxication and overdose 
In withdrawal settings, always assess the possibility that the 
patient is intoxicated. Some serious medical conditions can 
mimic intoxication. Objective observations should be given 
more weight than the patient’s report. 
Managing intoxication 
Assessment is urgent if intoxication is pronounced, and 
medical assessment is required if intoxication is worsening 
or affecting breathing, blood pressure or level of 
consciousness. 
Identify the most recent drug type, dose and time 
consumed. 
Consider the possibility that underlying illness (eg, 
concussion, subdural haematoma, infections, diabetes, or 
electrolyte disturbances) may be the cause of apparent 
intoxication. 
Check for possible head injury if the patient is incoherent, 
disoriented or drowsy. 
Monitor the airway if breathing is affected or 
consciousness is impaired, as death may occur from 
respiratory depression or aspiration pneumonia. 
 
 
 Indications of intoxication 
Maladaptive behaviour 
Evidence of intoxication by history and physical 
examination 
Blood alcohol level by breath analysis. Saliva, urine 
or blood testing for alcohol and other drugs 
Behavioural and physical signs: 
Alcohol: loss of control of voluntary movements, 
slurred speech, disinhibition, low blood pressure, 
smells of alcohol 
Benzodiazepines: slurred speech, loss of control of 
voluntary movements, sedation, nystagmus 
(repetitive eye movement), low blood pressure, 
drooling, disinhibition 
Opioids: pinpoint pupils, sedation, low blood 
pressure, slowed pulse, itching and scratching 
GHB: rapid onset of drowsiness, disinhibition, 
dizziness, nausea, muscle spasms, movement and 
speech impairment 
Cannabis: increased pulse, confusion, restlessness, 
excitement, hallucinations, anxious or panicky, 
disconnected from reality, paranoia, violent or 
suicidal behaviour 
Psychostimulants (amphetamines, cocaine and 
ecstasy): Increased confidence, excitement, 
euphoria, anxiety, agitation, speech, hypervigilance, 
increased body temperature and blood pressure, dry 
mouth, paranoia, psychotic features 
LSD: anxiety, fear, frightening hallucinations, panic, 
feeling of loss of control, going mad, paranoia, 
violent or suicidal behaviour  
Magic mushrooms (psilocybin): Similar to LSD 
PCP: similar to LSD, with euphoria, numbness, 
psychosis, aggression 
Ketamine: thought disorder, hallucinations, 
perceptual distortion, anxiety, agitation, 
tachycardia, hypertension, analgesia and sensory 
dissociation 
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Keep intoxicated patients under observation until their 
intoxication diminishes and they are considered safe. If the 
intoxication does not diminish, assess the patient for other 
possible causes of the condition. 
Managing suspected overdose 
Monitor signs of intoxication to identify possible overdose 
(ie, intoxication to the point of loss of consciousness) on 
the patient’s arrival and then as frequently as the patient’s 
state requires (usually 1–4 hourly). The Glasgow Coma 
Scale plus vital signs provide the best method of 
assessment. 
 
 
 
 Indications of overdose 
In order of progressive impairment: 
! increasing agitation 
! cold and clammy skin 
! pinpoint pupils (opioids) 
! changing mental state (hallucinations, panic or 
deep depression) 
! changes to heart rate (eg, irregular, below 
60/min, or above 120/min) 
! lowered body temperature 
! slow and noisy respiration 
! muscle twitching 
! cyanosis 
! pulmonary oedema 
! stupor 
! convulsions 
! coma. 
People with decreased levels of consciousness 
require: 
! urgent medical assessment 
! management in a medical setting 
! monitoring of vital signs and neurological 
function 
! examination and support of airway, breathing 
and circulation. 
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Appendix C  Area Health Service drug and alcohol intake lines 
 
Area Health Service  Central intake number 
Greater Southern Area Health Service  
Greater Murray 1800 800 944 / 02 9425 3923  
Southern 1800 809 423 
Greater Western Area Health Service  
Far West 1800 665 066 / 08 8080 1556  
Macquarie 1800 092 881 / 02 6841 2360 
Mid Western 1300 887 000 
Hunter / New England Area Health Service  
Hunter 02 4923 2060 
New England 1300 660 059 
North Coast Area Health Service 1300 662 263 
Mid North Coast 02 6588 2882 
Northern Rivers 02 6620 7612 
Northern Sydney / Central Coast Area Health Service  
North Sydney 1300 889 788 
Central Coast 4394 4880 
South Eastern Sydney / Illawarra Area Health Service  
South East Sydney 02 9113 4444 
Illawarra 1300 652 226 
Sydney South West Area Health Service  
South West Sydney 02 9616 8586 
Central Sydney 02 9515 6311 
Sydney West Area Health Service  
Wentworth 02 4734 1333 
Western Sydney 02 9840 3355 
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Appendix D One week consumption calendar 
Drug type Sun Mon Tue Wed Thur Fri Sat Total 
A L 100g L 20g L 200g L10g L150g L 150g L 150g L 780g 
T H 40 
cigs/day 
Nicotine = 
40x8 =  
320 mg 
H 
320 mg 
H 
240 mg 
H     
         
         
         
         
         
 
Coding of drug types 
Drug type Route Amount 
A = alcohol L = oral g = grams 
B = benzodiazepines N = anal mg = milligrams 
O = opioids I = injecting $ = amount spent 
M = amphetamines H = inhalation F = number of injections 
T = tobacco S = subcutaneous  
 
Source: Frank L, Pead J. New concepts in drug withdrawal: a resource handbook. © 1995 State of Victoria. Reproduced 
with permission. 
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Appendix E  Suicide risk assessment: immediate management and referral 
Immediate management 
The safety of the person being assessed is of primary 
concern throughout the assessment process. The level of 
observation/supervision before and after the assessment 
while waiting for referral is an important issue. Is the 
person medically fit enough to participate in the interview 
and or do they require a medical assessment? 
Suicide risk ratings and actions for community based 
services (see flow chart below) 
Guidelines have been developed for the management of 
patients with possible suicidal behaviour in general 
community setting (specifically drug and alcohol services), 
emergency departments, general hospital wards, mental 
health inpatient facilities, community mental health 
services and corrections health services (Justice Health) (see 
NSW Department of Health PD2005_121  and Framework 
for suicide risk assessment and management [NSW 
Department of Health 2004] for further information). 
 
 
Referral to mental health services / follow up 
arrangements / care planning 
Referral to mental health service should be via local 
processes, which need to be developed, well known and 
maintained. A preliminary assessment, by drug and 
alcohol staff, needs to be conducted before this 
referral is made. Negotiations then need to occur 
regarding referral to the mental health service. If you are 
unable to provide support yourself, you must contact an 
appropriate service and formally transfer ongoing 
responsibility for the patient. The key staff member 
managing the assessment must be identified to the patient 
and relevant supports. The follow-up appointment times 
and place, what 24-hour supports are available and 
contingency plans need to be communicated to the patient 
and supports. A management plan should be negotiated. 
Any further contact or information regarding drug and 
alcohol services, including withdrawal services, should be 
arranged at an appropriate time in the process. 
 
   For general community health settings, 
including drug and alcohol services: 
! If there is any immediate risk of harm to the 
patient, staff or others, follow local 
protocols.  
! If there is high or intermediate risk of suicide, 
the clinician ensures the person is in a safe 
and secure environment and that they are 
assessed by mental health services within 24 
hours. The clinician ensures contingency 
plans are in place for re-assessment if distress 
or symptoms escalate. 
! Low risk – an appointment is made with 
mental health services within 24–48 hours. 
The clinician ensures that contingency plans 
are in place for re-assessment if distress or 
symptoms escalate. 
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Flow Chart for General Community Health Services
      
 Patient with possible suicidal behaviour makes 
contact with general health service staff 
Staff recognise warning signs and determine 
the following: 
    * Is the patient in distress? 
    * Does the patient need to see a Doctor for  
       a physical assessment? 
Staff conduct preliminary suicide 
risk assessment, for eg.: 
           * Risk of suicide  
           * Suicide plans 
           * Previous attempts 
           * Loss of hope 
           * Drug and alcohol 
           * History of mental illness 
           * Social situation 
           * Suicide of friend or family
Ensure patients safety
Ensure follow-up
        
Consultation 
protocol*
Risk 
assessment 
guidelines*
If patient is thought to be at intermediate to high risk of 
suicide, the patient must have an assessment by Mental 
Health Staff within 24 hours. Otherwise an appointment 
must be made within 24 to 48 hours.
*Development of model protocols will be facilitated by the Department of Health and will be available
from the Centre for Mental Health as they are developed.
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Appendix F  Routine screening for domestic violence 
Routine screening for domestic violence is a key element of the NSW Department of Health 
policy and procedures for identifying and responding to domestic violence. 
 
Further information 
NSW Department of Health Routine for Domestic Violence Program Snapshot Report: November 2003. 
<http://www.health.nsw.gov.au/pubs/2004/routinescreen.html>  
NSW Department of Health. Policy for identifying and responding to domestic violence. 2003. 
<http://www.health.nsw.gov.au/pubs/p/pdf/policy_dom_violence.pdf>  
NSW Department of Health Policy Directive PD2006_084. Domestic violence — identifying and responding. 
<http://www.health.nsw.gov.au/policies/PD/2006/pdf/PD2006_084.pdf> 
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Appendix G Patient assessment summary 
Name: ..................................................................................................... . Sex: M / F 
Date of birth: ............................................................................................ Age: ....... 
Date of interview: .....................................................................................  
Name of practitioner: ................................................................................  
Major problems (including comment): 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
Summary of assessment: 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
Treatment plan:  
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
.............................................................................................................................................. 
Signature of health professional: ........................................................................................... 
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Appendix H Supportive care protocol 
To be undertaken and recorded in addition to physical observations (ie, at least every 4 
hours). 
 
Check withdrawal severity  
(with withdrawal scale) 
 
Offer fluids  
 
Check general health 
 1  Consciousness 
 2  Blood pressure 
 3  Self report 
 
Check physical comfort 
 1  Pillows 
 2  Blankets 
 3  Hot packs 
 
Orientate 
 1  Time 
 2  Place 
 3  Person 
Check environment 
 1  Calm 
 2  Quiet 
 3  Low lighting 
 4  Privacy 
 5  Safety 
 6  Self report 
 7  Supportive person (s)  
 
Reassure 
 1  Allay concerns and fears 
 2  Give positive encouragement 
 3  Offer information 
 
 
Source: Naranjo C, Sellers E. Clinical assessment and pharmacotherapy of alcohol 
withdrawal syndrome. In: Galanter M, editor. Recent developments in alcoholism. New York: 
Plenum Press, 1986: 265–281. 
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Appendix I  Guidelines for coping skills 
Adapted from: National Health and Medical Research Council. 
Guidelines for the prevention and management of 
benzodiazepine dependence. Canberra: AGPS, 1991. 
Relaxation 
Preparation 
1. Sit in a comfortable chair or lie down somewhere 
comfortable in a quiet, airy room where you will not 
be interrupted. 
2. If you are sitting, take off your shoes, uncross your 
legs, and rest your arms on the arms of a chair. 
3. If you are lying down, lie on your back with your arms 
at your sides and cover yourself with a blanket. 
4. Close your eyes, notice how you are breathing and 
where the muscle tensions are. 
Breathing 
1. Start to breath slowly and deeply, expanding your 
abdomen as you breathe in, then raising your rib cage 
to let more air in, until your lungs are filled right to the 
top. 
2. Hold your breath for a couple of seconds and then 
breathe out slowly, allowing your rib cage and 
stomach to relax and empty your lungs completely. 
3. Keep this slow, deep, rhythmic breathing going 
throughout your relaxation session. 
Relaxing 
After you have your breathing pattern established, start the 
following sequence: tense each part of the body on the 
inbreath, hold your breath while you keep your muscles 
tense, then relax and breathe out at the same time. 
1. Curl your toes hard and press your feet down—then 
relax. 
2. Press your heels down and bend your feet up—then 
relax. 
3. Tense your calf muscles—then relax. 
4. Tense your thigh muscles, straighten your knees, 
making your legs stiff—then relax. 
5. Make your buttocks tight—then relax. 
6. Tense your stomach—then relax. 
7. Bend your elbows and tense the muscles of your 
arms—then relax. 
8. Hunch your shoulders and press your head back—then 
relax. 
9. Clench your jaw, frown and screw up your eyes really 
tight—then relax. 
10. Tense all your muscles together—then relax. 
Remember to breathe deeply and be aware when you relax 
of the feeling of physical well being and heaviness 
spreading through your body. 
11. After you have done the whole sequence and you are 
still breathing slowly and deeply, imagine something 
pleasant, eg, a beautiful country scene. Try to “see” 
whatever you have chosen as clearly as possible, 
concentrating your attention on it for 30 seconds. Do 
not hold your breathing during this time. Continue to 
breathe as you have been doing. After this, go on to 
visualise another peaceful object of your choice in a 
similar fashion. 
12. Lastly, give yourself the instruction that when you 
open your eyes you will be perfectly relaxed but alert. 
The six second breath 
Controlling your rate of breathing is one of the most 
important things you can do to stop your anxiety from 
getting out of control. 
If you keep your breathing to one breath every six seconds 
this will help: breathe in over three seconds and out over 
the next three seconds. This can be in stages (eg, in–in–in, 
out–out–out). 
The six second breath can be used anywhere and any time 
when you feel anxious. It does pay, however, to practise 
this technique a few times per day so that you will have it 
rehearsed for when you really need it. 
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Sleep 
Disturbed sleep is one of the features of withdrawal. It is 
not uncommon to experience difficulty falling asleep, have 
disturbing dreams or nightmares, night sweats, wake up in 
the middle of the night, or wake up early in the mornings. 
It can take a number of weeks before your sleep pattern 
returns to normal. It is important to remember that 
disturbed sleep is a normal part of withdrawal and that it is 
not permanent. 
Hints for better sleep 
1. Have a comfortable sleeping environment. 
2. Do not exercise before bedtime. Exercise earlier in the 
day to increase physical tiredness. 
3. Lie down to go to sleep only when you are actually 
sleepy. 
4. Do not use your bed for activities other than sleeping 
(sex is the only exception to this rule). 
5. If you do not fall asleep within about 30 minutes after 
turning out the light, get up, go to another room, and 
do something that is not too arousing (eg, watch TV). 
6. If you return to bed and still cannot sleep, repeat step 
5. Do this as often as necessary until you fall asleep 
within 30 minutes of going to bed. 
7. If you wake up in the middle of the night and cannot 
go back to sleep, follow steps 5 and 6. 
8. Get up at the same time every morning, regardless of 
how long you have slept. This will help your body to 
develop a regular sleep rhythm. 
9. Do not nap during the day. 
10. Do some form of relaxation before sleeping. 
11. Most of the thinking and worrying that we do in bed 
needs to be done—it just does not need to be done in 
bed. Take time earlier in the day for thinking and 
worrying. 
12. Avoid stimulants such as caffeine or cigarettes late at 
night and cut down on your caffeine consumption 
during the day. Alcohol can make you sleepy, but it 
also has a waking effect after several hours sleep, so 
that it often results in a poor night’s sleep overall. Hot 
drinks such as chamomile or valerian tea, or warm milk 
(with nutmeg) late at night can help put you to sleep. 
Diet 
1. Drink lots of fluids: at least two litres a day. Water 
with a dash of lemon juice, fruit juices, cordial mixed 
with water and non fizzy mineral water are very good. 
Also, try to keep the fluids going in throughout the 
day, taking small sips all the time. 
2. Take nourishing meals in a relaxed environment. Avoid 
large meals. Try to eat small meals and snacks 
throughout the day rather than one big meal a day, 
and chew your food well. 
3. Avoid greasy, fried, fatty foods, or large amounts of 
fatty meat if you have indigestion. 
Craving 
1. Cravings are usually only very severe for short periods 
(usually less than 1 hour), then the severity of the 
craving reduces to a level which is easier to deal with. 
The goal is to see through this severe period. 
2. Delay the decision for 1 hour as to whether you will 
use. 
3. Distract yourself with some activity during this hour. 
4. After an hour, ask yourself “Why don’t I want to 
use?” and “What have I got to lose?” 
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Appendix J  CIWA-AR, withdrawal assessment for alcohol* 
Patient: ............................................................................ Date: ....................................... Time: ...............................  
Pulse or heart rate, taken for one minute: ...............................................................................  
Blood pressure: ……/……     Rater’s initials: ......................... 
 
See below for key to scoring. 
Nausea and vomiting (0–7)  
Withdrawal severity: 
<10 Mild 
10–20 Moderate 
>20 Severe 
 
 
 
 
Tremor (0–7)  
Paroxysmal sweats (0–7)  
Anxiety (0–7)  
Agitation (0–7)  
Tactile disturbances (0–7)  
Auditory disturbances (0–7)  
Visual disturbances (0–7)  
Headaches, fullness in head (0–7)  
Orientation and clouding of sensorium (0–4)  
Total (maximum possible is 67)  
*Source: Sullivan J, Sykora M, Schneiderman J, et al. Assessment 
of alcohol withdrawal: the revised Clinical Institute withdrawal for 
alcohol scale (CIWA-AR). Br J Addict 1989; 84: 1353-1357. 
 
Nausea and vomiting 
Ask “Do you feel sick to your stomach? Have you vomited?” and 
observe. 
0  No nausea and no vomiting 
1  Mild nausea with no vomiting 
2 
3 
4  Intermittent nausea with dry heaves 
5 
6 
7  Constant nausea, frequent dry heaves and vomiting 
 
 
 
Tremor 
Observe patient’s arms extended and fingers spread apart. 
 
0  No tremor 
1  Not visible, but can be felt fingertip to fingertip 
2 
3 
4  Moderate, with patient’s arms extended 
5 
6 
7  Severe, even with arms not extended 
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Paroxysmal sweats 
0  No sweat visible 
1  Barely perceptible sweating, palms moist 
2 
3 
4  Beads of sweat obvious on forehead 
5 
6 
7  Drenching sweats 
Anxiety 
Observe, and ask “Do you feel nervous?” 
0  No anxiety, at ease 
1  Mildly anxious 
2 
3 
4  Moderately anxious, or guarded, so anxiety is inferred 
5 
6 
7  Equivalent to acute panic states as seen in severe delirium  
or acute schizophrenic reactions 
Agitation 
0  Normal activity 
1  Somewhat more than normal activity 
2 
3 
4  Moderately fidgety and restless 
5 
6 
7  Paces back and forth during most of the interview, or  
constantly thrashes about 
Tactile disturbances 
Ask “Have you any itching, pins and needles sensations, any 
burning, any numbness or do you feel bugs crawling on or 
under your skin?” 
0  None 
1  Very mild itching, pins and needles, burning or numbness 
2  Mild itching, pins and needles, burning or numbness 
3  Moderate itching, pins and needles, burning or numbness 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
Auditory disturbances 
Ask “Are you more aware of sounds around you? Are they 
harsh? Do they frighten you? Are you hearing anything that is 
disturbing to you? Are you hearing things you know are not 
there?”, and observe. 
0  Not present 
1  Very mild harshness or ability to frighten 
2  Mild harshness or ability to frighten 
3  Moderate harshness or ability to frighten 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
Visual disturbances 
Ask “Does the light appear to be too bright? Is its colour 
different? Does it hurt your eyes? Are you seeing anything that 
is disturbing to you? Are you seeing things you know are not 
there?”, and observe. 
0  Not present 
1  Very mild sensitivity 
2  Mild sensitivity 
3  Moderate sensitivity 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
Headaches, fullness in head 
Ask “Does your head feel different? Does it feel like there is a 
band around your head?” Do not rate for dizziness or 
lightheadedness. Otherwise, rate severity. 
0  Not present 
1  Very mild 
2  Mild 
3  Moderate 
4  Moderately severe 
5  Severe 
6  Very severe 
7  Extremely severe 
Orientation and clouding of sensorium 
Ask “What day is this? Where are you? Who am I?” 
0  Orientated and can do serial additions 
1  Cannot do serial additions or is uncertain about date 
2  Disorientated for date by no more than 2 calendar days 
3  Disorientated for date by more than 2 calendar days 
4  Disorientated for place and/or person 
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Appendix K  Alcohol withdrawal scale (AWS)* 
Patient: ............................................................................ Date: ....................................... Time: ...............................  
Pulse or heart rate, taken for one minute: ...............................................................................  
Blood pressure: ……/……     Rater’s initials: ......................... 
 
See below for key to scoring. 
Perspiration (0–4)  
Withdrawal severity: 
<4 Mild 
5–14 Moderate 
>15 Severe 
 
 
 
 
Tremor (0–3)  
Anxiety (0–4)  
Agitation (0–4)  
Axilla temperature (0–4)  
Hallucinations (0–4)  
Orientation (0–4)  
Total (maximum possible is 27)  
*A widely used scale in New South Wales. Novak H, editor. Nurse 
education and nursing management of alcohol and other drugs. 
Sydney: CEIDA, 1989. 
Perspiration 
0 No abnormal sweating 
1 Moist skin 
2 Localised beads of sweat, eg, on face, chest 
3 Whole body wet from perspiration 
4 Profuse maximal sweating—clothes, linen are wet 
Tremor 
0 No tremor 
1 Slight tremor 
2 Constant slight tremor of upper extremities 
3 Constant marked tremor of extremities 
Anxiety 
0 No apprehension or anxiety 
1 Slight apprehension 
2 Apprehension or understandable fear (eg, of withdrawal  
symptoms) 
3 Anxiety occasionally accentuated to a state of panic 
4 Constant panic like anxiety 
Agitation 
0 Rests normally during day, no signs of agitation 
1 Slight restlessness, cannot sit or lie still Awake when others 
asleep 
2 Moves constantly, looks tense Wants to get out of bed but 
obeys requests to stay in bed 
3 Constantly restless Gets out of bed for no obvious reason 
4 Maximally restless, aggressive Ignores requests to stay in bed 
Axilla temperature 
0 Temperature of 37.0°C 
1 Temperature of 37.1°C 
2 Temperature of 37.6–38.0°C 
3 Temperature of 38.1–38.5°C 
4 Temperature above 38.5°C 
 
 
 
 
 
New South Wales drug and alcohol withdrawal clinical practice guidelines PAGE 85 
Hallucinations (sight, sound, taste or touch) 
0 No evidence of hallucinations 
1 Distortions of real objects, aware that these are not real if  
this is pointed out 
2 Appearance of totally new objects or perceptions, aware  
that these are not real if this is pointed out 
3 Believes the hallucinations are real but still orientated in  
place and person 
4 Believes himself to be in a totally non existent environment,  
preoccupied and cannot be diverted or reassured 
Orientation 
0 The patient is fully orientated in time, place and person 
1 The patient is fully orientated in person but is not sure  
where he is or what time it is 
2 Orientated in person but disorientated in time and place 
3 Doubtful personal orientation, disorientated in time and  
place; there may be short periods of lucidity 
4 Disorientated in time, place and person; no meaningful  
contact can be obtained. 
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Appendix L  Clinical opiate withdrawal scale (COWS) 
  
For each item, circle the number that best describes the patient’s signs or symptom. Rate on just the apparent 
relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior 
to assessment, the increased pulse rate would not add to the score.
Patient’s Name:_____________________Date and Time: ____/_____/____:__________
Reason for this assessment:___________________________________________________________
Resting Pulse Rate: ________beats/minute
Measured after patient is sitting or lying for one minute 
0 pulse rate 80 or below
1 pulse rate 81–100
2 pulse rate 101–120
4 pulse rate greater than 120
GI upset: over last ½ hour
0 no GI symptoms
1 stomach cramps
2 nausea or loose stool
3 vomiting or diarrhoea
5 multiple episodes of diarrhoea or vomiting
Sweating: over past ½ hour not accounted for by room 
temperature or patient activity.
0 no report of chills or flushing
1 subjective report of chills or flushing
2 flushed or observable moistness on face
3 beads of sweat on brow or face
4 sweat streaming off face
Tremor. Observation of outstretched hands
0 no tremor
1 tremor can be felt, but not observed
2 slight tremor observable
4 gross tremor or muscle twitching
Restlessness. Observation during assessment
0 able to sit still
1 reports difficulty sitting still, but is able to do so
3 frequent shifting or extraneous movements of legs/
arms
5 unable to sit still for more than a few seconds
Yawning. Observation during assessment
0 no yawning
1 yawning once or twice during assessment
2 yawning three or more times during 
assessment
4 yawning several times/minute
Pupil size
0 pupils pinned or normal size for room light
1 pupils possibly larger than normal for room light
2 pupils moderately dilated
5 pupils so dilated that only the rim of the iris is visible
Anxiety or irritability
0 none
1 patient reports increasing irritability or 
anxiousness
2 patient obviously irritable anxious
4 patient so irritable or anxious that 
participation in the assessment is difficult
Bone or joint aches. If patient was having pain 
previously, only the additional component attributed to 
opiates withdrawal is scored
0 not present
1 mild diffuse discomfort
2 patient reports severe diffuse aching of joints/ muscles
4 patient is rubbing joints or muscles and is unable to sit 
still because of discomfort
Gooseflesh skin
0 skin is smooth
3 piloerection of skin can be felt or hairs 
standing up on arms
5 prominent piloerection
Runny nose or tearing not accounted for by cold 
symptoms or allergies
0 not present
1 nasal stuffiness or unusually moist eyes
2 nose running or tearing
4 nose constantly running or tears streaming down cheeks 
Total score ________
The total score is the sum of all 11 items
Initials of person
completing assessment: _____________
Score: 5–12 = mild; 13–24 = moderate; 25–36 = moderately severe; more than 36 = severe withdrawal.
Source: Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35: 253-259.
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Appendix M Subjective opiate withdrawal scale (SOWS) 
Date Time Please score each of the 16 items below according to
how you feel NOW (circle one number)
Symptom
Not 
at all A little Moderately
Quite 
a bit Extremely
1 I feel anxious 0 1 2 3 4
2 I feel like yawning 0 1 2 3 4
3 I am perspiring 0 1 2 3 4
4 My eyes are teary 0 1 2 3 4
5 My nose is running 0 1 2 3 4
6 I have goosebumps 0 1 2 3 4
7 I am shaking 0 1 2 3 4
8 I have hot flushes 0 1 2 3 4
9 I have cold flushes 0 1 2 3 4
10 My bones and muscles ache 0 1 2 3 4
11 I feel restless 0 1 2 3 4
12 I feel nauseous 0 1 2 3 4
13 I feel like vomiting 0 1 2 3 4
14 My muscles twitch 0 1 2 3 4
15 I have stomach cramps 0 1 2 3 4
16 I feel like using now 0 1 2 3 4
Range 0–64. 
Source: Handelsman L, Cochrane, K J, Aronson M J, et al. Two new rating scales for opiate withdrawal. Am J Alcohol Abuse 
1987; 13: 293-308.
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Appendix N Cannabis withdrawal chart 
 Patient MRN label here:     
 
DATE:             
TIME:             
SCORES: 0 — not at all, 1 — mild, 2 — moderate, 3 — severe 
SYMPTOM             
Craving for marijuana             
Decreased appetite             
Sleep difficulty             
Increased aggression             
Increased anger             
Irritability             
Strange dreams             
Restlessness             
Chills             
Feverish feeling             
Stuffy nose             
Nausea             
Diarrhoea             
Hot flashes             
Dizziness             
Sweating             
Hiccups             
Yawning             
Headaches             
Shakiness             
Muscle spasms             
Stomach pains             
Fatigue             
Depressed mood             
Difficulty concentrating             
Nervousness             
Violent outbursts             
TOTAL SCORE             
Person completing 
assessment (INITIAL) 
            
 
Source:  Budney A, et al. Archives of General Psychiatry 2001; 58 (10): 917-924. 
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Appendix O Fagerstrom test for nicotine dependence 
Question  Answer  Score 
1. How soon after waking up do you smoke your first cigarette?  Within 5 minutes  
6-30 minutes  
31-60 minutes  
3 
2 
1 
2. Do you find it difficult to abstain from smoking in places where it is forbidden?  Yes  
No  
1 
0 
3. Which cigarette would you hate to give up?  The first one in the morning  
Any other  
1 
0 
4. How many cigarettes a day do you smoke?  10 or less  
11-20  
21-30  
31 or more  
0 
1 
2 
3 
5. Do you smoke more frequently in the morning than in the rest of the day?  Yes  
No  
1 
0 
6. Do you smoke even though you are sick in bed for most of the day?  Yes  
No  
1 
0 
 Total   
Score  0-2  
3-4  
5  
very low dependence  
low dependence  
medium dependence  
6-7 
8+  
high dependence  
very high dependence  
 
Source: Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose and Throat Journal 1990; 89(11): 
763-765. 
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